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Abstract 
Macrophages are immune cells known to have a diverse array of functions dependant 
on the local tissue environment. This thesis aimed to investigate the role of macrophages in the 
skin. The first aim was to study if targeting inflammatory cytokines and cellular pathways was 
able to improve the rate of wound closure in acute and/or chronic wounds. These inflammato ry 
pathways included the IL-17/IL-23 axis, the IL-33/ST2 pathway and the NLRP3 
inflammasome. The next aim was to identify the role of macrophages in UV irradiation, 
specifically neonatal UV and the long-term effects in the skin and on local immune 
suppression. Finally, we aimed to identify the long-term effects of inflammation in the skin on 
the resident macrophage populations, studying the kinetics of their self-renewal. 
 
Macrophages play a vital role in wound healing, with either excessive or insufficient 
infiltration both able to induce impaired healing responses. Current therapies for chronic 
wounds have poor prognosis and outcomes, and as such the development of alternat ive 
treatments are required. We found IL-17 and IL-23 inhibition improved wound closure in 
obese, diabetic mice by switching the macrophage phenotype from pro-inflammatory to pro-
healing. IL-17 secreted from gamma delta T-cells significantly impaired wound closure, and 
the inhibition of IL-17 and its upstream regulator IL-23 by blocking antibodies was able to 
significantly improve chronic wound healing by increasing the percentage of alternative ly 
activated, pro-healing macrophages.  
IL-33 is a molecule that can function as an alarmin through its receptor, ST2. We used 
ST2-/- mice to assess the action of IL-33 during wound healing. We found ST2-/- mice had 
impaired wound closure, reduced angiogenesis and altered collagen deposition/remodelling 
compared to BALB/C controls. There was increased neutrophilic infiltrate and altered 
macrophage polarisation in ST2-/- mice wounds. These results indicate that ST2 signalling is 
important for macrophage differentiation, which may improve wound closure, increase 
angiogenesis and delay or prevent scarring.  
The NLRP3 inflammasome has been implicated in a variety of inflammatory diseases . 
We used MCC950, a water-soluble small molecule inhibitor of NLRP3 in a chronic wound 
healing mouse model in an attempt to improve wound healing. We failed to identify any 
significant differences in the rate of wound healing, or angiogenesis in MCC950-treated mice 
compared to controls. Our results indicated that the NLRP3 inflammasome is not significantly 
involved in chronic wound healing.  
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UVR has been repeatedly reported to induce immune suppression, one of the driving 
factors for tumour formation. Delayed-type contact hypersensitivity (CHS) is the leading 
mechanism for testing UVR-mediated immune suppression. Previous studies in the 
Khosrotehrani lab identified that clodronate depletion was able to inhibit neonatal development 
of melanoma in transgenic mice. I therefore aimed to investigate the changes in the immune 
environment which were causing the inhibition of melanoma formation. We found the 
depletion of macrophages in neonates using clodronate liposomes during the period of a single 
burning dose of UVR was able to prevent a long-term local immune suppression, mediated by 
CD4+ regulatory T-cells. We also defined the changing resident myeloid cells in the skin as a 
response to UV exposure, and opened up new avenues of research to follow on from this work. 
 
Langerhans cells are a well-studied resident immune cell in the epidermis, with 
hundreds of publications identifying their origin, from the yolk-sac/foetal liver and their 
method of self-renewal under homeostatic conditions, and their ability to be renewed by 
monocytes with the presence of chronic inflammation. A lesser studied resident macrophage 
population in the skin involves the resident dermal macrophages, which have been implica ted 
in conditions such as wound healing and hair follicle cycling. We aimed to use a multicolour, 
fluorescent lineage-tracing model to investigate the mechanism of renewal of dermal 
macrophages in homeostasis, and inflammation. Unfortunately, the model chosen for this 
project was insufficient for this particular study and we were unable to gather any useful 
information from this project. 
 
This thesis has identified a list of molecules and cytokines that are either important or 
not for macrophage polarisation and the effects on wound healing in both chronic and acute 
wound healing scenarios. These molecules could be applied in a clinical setting for the possible 
treatment of chronic wounds, and the IL-17 therapy has already been approved for Phase I 
clinical trials.  I have also identified a link between phagocytic myeloid cells and UV-induced 
immunosuppression and subsequent hapten-controlled inflammation in contact-
hypersensitivity. Finally, a shift in long-term resident macrophages has also been identified 
following UV-irradiation, which may play a role in immune suppression and contact 
hypersensitivity. This can information can be used as a base point for possible sunburn-rela ted 
therapies in the future, pending further investigations. 
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Chapter 1 – Introduction 
 
Introduction 
The skin is the largest organ of the body, with a vital role as a first-line barrier of 
defence against pathogens, dehydration and trauma. A plethora of diseases ranging from 
autoimmune conditions, UV-induced damage, wound injury and infection, all revolve around 
the ability of the skin to mount a correct immune response. Without a sufficient balance of pro- 
and anti-inflammatory effects, the skin will not adequately function as the first-line barrier. 
The skin consists of 3 major layers; the epidermis, dermis and hypodermis (subcutaneous) and 
dispersed throughout the skin are appendages including hair follicles, sweat glands and 
sebaceous glands. Each layer also has a specific immune environment, with the epidermal 
immune cells vastly different in form and function to the dermal immune cells. In mice, the 
resident epidermal immune cells primarily consist of Langerhans Cells (LC) and Dendrit ic 
Epidermal T-Cells (DETC). These two cell types have a primary role in immune surveillance, 
to help mount both an inflammatory reaction in the presence of pathogenic microbes or in 
sensitisation in the presence of commensal microflora (Seneschal, Clark et al. 2012, MacLeod, 
Hemmers et al. 2013). Langerhans cells have also been described to have a significant effect 
following exposure to UV irradiation, where they migrate to the lymph nodes and create an 
anti-inflammatory environment (Taguchi, Fukunaga et al. 2013). However, their exact role in 
UV-induced immunosuppression is controversial (Wang, Jameson et al. 2009, Schwarz, 
Noordegraaf et al. 2010).  
The dermis has a multitude of immune cells, with differing functions, albeit working in 
synergy with one another. These consist of mast cells, multiple T-cell populations, dermal 
dendritic cells and macrophages (Wang, McGovern et al. 2014, Tong, Roediger et al. 2015). 
Macrophages play a broad role in the dermis; in homeostatic skin they are essential as 
scavenger cells for clearance of dead cells and killing of microorganisms. Macrophages are 
also implicated in the activation of hair follicle stem cells, where the apoptosis and secretion 
of TNF induce hair growth (Castellana, Paus et al. 2014). Macrophages play an even bigger 
role in damaged skin, as they are essential for wound healing as both an inflammato ry 
scavenger cell during the early stages of wound healing, and later function as a pro-angiogenic, 
growth-factor secreting cell in the later stage of proliferation in wound healing (Koh and 
DiPietro 2011). Macrophages also play significant roles in the following disease models of 
ultraviolet (UV) irradiation, dermatitis, contact hypersensitivity (CHS) and cancer prognosis , 
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all of which will be discussed in further detail throughout this chapter. (McCormick, Stevens 
et al. 2000, Shimizu, Abe et al. 2003, Tuckermann, Kleiman et al. 2007, Cela, Friedrich et al. 
2015, Tavori, Su et al. 2015)(Kim, Lee et al. 2017, Suzuki, Meguro et al. 2017, Muliaditan, 
Caron et al. 2018).  
Due to the heterogeneity of macrophages, the regulation of their desired and undesired 
effects during pathogenic models has been difficult to understand. As mediators of 
inflammation, they tend to have the undesired effect of sustaining or prolonging inflammation, 
which can be commonly found in chronic wounds, psoriasis, atopic dermatitis and chronic 
contact dermatitis (McCormick, Stevens et al. 2000). It is therefore essential to understand the 
mechanisms by which this inflammatory ‘switch’ can be turned on or off. 
This thesis will further elucidate the mechanism of action of skin resident immune 
populations, but specifically focusing on macrophages in homeostasis, wound healing, UV 
irradiation and CHS. I will describe how different macrophage populations are affected long-
term after UV damage and full-thickness wounding. I will also describe how I attempted to 
identify how macrophage repopulation occurs in the skin occurs during both homeostasis and 
in pathologic conditions, using multicolour lineage tracing.  
 
Literature Review: 
This review will focus on the presence, distribution and potential role of immune cells 
in the skin, during homeostasis but also in physiological and pathological situations where they 
might have a role. More especially, after briefly describing each of these situatio ns, we will 
focus on macrophage populations that are present in the skin and highlight their activity in hair 
follicle cycling, wound healing, their response to UV and contact hypersensitivity. Although 
macrophages have long been described to participate in tumour progression, this particula r 
topic is beyond the aims of my work and will not be covered. 
 
Skin resident immune cells; The Epidermis 
The outermost layer of the skin; the epidermis is comprised of multiple layers of 
keratinocytes, interlaced with melanocytes, Merkel cells and immune cells. One of these 
immune cells are Langerhans cells (LC), which are a yolk-sac derived dendritic cell. LC are a 
strange dendritic cell, due to their origin which rises from fetal liver monocytes and the yolk-
sac during development, which differs to most other dendritic cells which are bone-marrow 
derived (Hoeffel, Wang et al. 2012). Another key feature of LC is their ability to self-renew 
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for maintenance, rather than derive from differentiated presursors, a model which has been 
tested using congenic mice (Merad, Manz et al. 2002). LC are believed to self-renew under 
non-pathological conditions (Merad, Manz et al. 2002), however further studies have identified 
the ability for LC to repopulate via Gr-1hi monocyte precursors in vivo (Ginhoux, Tacke et al. 
2006). Their primary function is projecting their dendrites through tight junctions in the 
epithelium to sample external antigens (Merad, Sathe et al. 2013). They are indispensable for 
both protection against pathogenic organisms and tolerance against commensal microflo ra 
naturally found on the skin surface (Seneschal, Clark et al. 2012). LCs are believed to play a 
stronger role in immune suppression and tolerance, as they preferentially induce Th2-type 
responses over Th1 (Klechevsky, Morita et al. 2008). Indeed, in genetically modified mice 
which have an attenuated form of diptheria toxin under control of a bacterial artific ia l 
chromosome containing human langerin which is specifically expressed in Langerhans cells , 
these mice had an enhanced response to contact hypersensitivity (CHS) testing (Kaplan, 
Jenison et al. 2005) Their model used is of particular interest because the found the mice lacked 
LC specifically, without modification to other dermal dendritic cells, implicating the 
importance of LC in the regulation of contact hypersensitivity. LC’s have also been found to 
work in conjunction with surrounding skin-resident, memory T-cells in order to suppress an 
immune reaction to maintain homeostasis, or activate and induce proliferation in effector 
memory T-cells in the presence of commensal or pathogenic bacteria, based on antigen 
presentation without the need to migrate to the lymph nodes (Seneschal, Clark et al. 2012).  
Another type of resident immune cell found in mice but not humans, is the dendritic 
epidermal T-cell (DETC). DETCs are a type of gamma-delta T-cell, specifically localised in 
the epidermis. Interestingly, DETC are not present in human skin, although humans have 
another type of γδ T-cell residing in the epidermis instead (Bergstresser, Cruz et al. 1993). 
DETCs have recently been implicated in a variety of immune roles such as wound healing 
responses (Jameson, Ugarte et al. 2002) and induced contact hypersensitivity (Nielsen, Lovato 
et al. 2014). DETCs serve multiple roles, the first in antimicrobial function, where they are able 
to secrete antimicrobial peptides and proteins (AMP) (MacLeod, Hemmers et al. 2013). The 
second is in wound repair, where genetic manipulation of Tcrd-/- mice, which lack γδ T-cells 
including DETCs display a significantly reduced wound healing capacity (Jameson, Ugarte et 
al. 2002). The final function DETCs play a role in is CHS, where secretion of IL-17 from 
DETC is a leading contributor to swelling and hapten-driven inflammation (Gray, Suzuki et al. 
2011, Nielsen, Dyring-Andersen et al. 2015). In human skin,  T-cells are present in both 
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epidermis and dermis, at a density of 300-fold less than classic   T-cells in the skin 
(Suwanpradid, Holcomb et al. 2017). The remaining T-cell repertoire consists of CD4 and CD8 
resident-memory T-cells (TRMs) which also both differ between mice and humans depending 
on their compartmentalisation. Some of these differences have been highlighted in Figure 1, 
directly adapted from Suwanpradid et al. (2017). 
Figure 1. The heterogeneity between resident T-cell populations found in mice vs. humans. 
Note. Reprinted from “Emerging Skin T-Cell Functions in Response to Environmenta l 
Insults,” by J Suwanpradid; Z.E Holcomb; A.S Macleod, 2017, J Invest Dermatol, 137:2, 289. 
Copyright 2017 by Elsevier 
 
Skin resident immune cells; The Dermis 
The dermal layer of the skin houses the majority of the skin-resident immune cells, 
comprised of mast cells, multiple dendritic cell types, macrophages and T-cells.   
 
Dermal Mast Cells 
Mast cells widely vary in their functions, with differential cytokine secretion able to 
induce a multitude of effects on the resident leukocyte populations in the skin. Most commonly 
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associated with allergy and inflammation, upon activation of their IgE specific Fc receptors, 
mast cells degranulate leading to a release of histamine, cytokines and growth factors (Galli 
and Tsai 2012). Mast cells can also induce DC activation and maturation, which then induce 
direct effects on T-cell migration, proliferation, polarization and activation (Dudeck, Suender 
et al. 2011). The effects of mast cells on immune function are incredibly diverse, being able to 
induce proinflammatory Th1 and Th17 responses, or mediate inflammation through the 
secretion of Th2 cytokines to down-regulate antigen-specific immune responses (Depinay, 
Hacini et al. 2006). Dermal mast cells are also able to secrete proteases such as tryptase and 
chymase which have vital roles in skin inflammation, whereby  (Harvima, Naukkarinen et al. 
1993).  Mast cells have vital functions in mediating immune responses via the secretion of 
cytokines such as IL-10 during severe CHS (Gaudenzio, Marichal et al. 2018). Indeed, the role 
of mast cells during CHS has proven to be of great interest, as the absence of mast cells in 
genetically modified mice suppresses CHS and delayed-type hypersensitivity (DTH) responses 
(Hart, Grimbaldeston et al. 1998). Further papers studying the roles of mast cells in UV-
mediated immune responses such as PUVA have demonstrated how essential the presence of 
mast cells is to mount systemic immunosuppression through the serotonin signalling pathway 
(Wolf, Byrne et al. 2016). While this list does not cover the vast function of immune responses 
from dermal mast cells, it aims to demonstrate the significance of mast cells among a vast 
resident immune network located in the dermis, and their roles in affecting downstream targets 
such as the elicitation of an immunosuppressive T-cell response in CHS. 
 
Dermal T-Cells 
Dermal T-cells have multiple phenotypes, and consist of CD8+ resident memory T-
cells (TRMs), FoxP3+ regulatory T-cells (Tregs), CD4+ TRMs and  T-cells. The pro-
inflammatory T-helper 17 (Th17) and  T-cells are essential for the protection against 
pathogenic organisms such as bacterial and viral infection, but have also been implicated with 
excessive inflammation in multiple inflammatory skin conditions including but not limited to; 
skin wound healing, psoriasis, atopic dermatitis and CHS (Cai, Shen et al. 2011). The CD4+ 
Treg T-cell population also provides immunomodulatory capabilities, which are associated 
with tumour growth and UV-induced immunosuppression (Baumgartner, Wilson et al. 2007, 
Hori, Kuribayashi et al. 2015). Natural killer (NK) T-cell inhibition has been reported to 
improve skin wound healing via the reduction of inflammation in the early stages of wound 
healing in mice (Schneider, Palmer et al. 2011). γδ T-cells are also associated with continuous 
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immunosurveillance, with a prominent ability to self-renew. These γδ T-cells are known to 
secrete IL-17 in response to mycobacterial infection (Sumaria, Roediger et al. 2011), but also 
in excessive immune reactions as well, such as psoriasis (Cai, Shen et al. 2011). However, 
inhibition of T-cell function would be far from ideal, as it would alter homeostatic function, as 
well as the ability for dermal γδ T-cells to induce hair follicle neogenesis after wounding (Gay, 
Kwon et al. 2013). This ability would offset their excess inflammatory reaction at the initiat ion 
of wounding, as regeneration of the skin, as opposed to scarring repair is the best possible 
outcome following wounding. Further studies will elucidate how effective the T-cells ability 
to induce neogenesis is, and if there are possible therapeutic outcomes available. 
 
Dermal Myeloid Cells 
Macrophages and dendritic cells comprise the majority of the immune cells in mouse 
dermis (Tong, Roediger et al. 2015). The role of macrophages in skin is diverse, as they have 
been implicated in multiple tissue specific functions such as hair follicle cycling (Castellana, 
Paus et al. 2014) and immune surveillance, as well as cell-specific functions such as the 
clearing of cell debris and pathogens. Dermal macrophages have been described as a 
heterogeneous population, expressing both classically-activated ‘inflammatory’ (M1) and 
alternatively activated (M2) cell surface markers in homeostatic skin (Castellana, Paus et al. 
2014). The heterogeneity of these macrophages allows for the rapid ability to respond to stimuli 
during pathological conditions such as wounding and skin infections. However, because of the 
overlapping phenotypes between macrophages and dendritic cells, it has been difficult to 
distinguish one from the other (Hashimoto, Miller et al. 2011). A study by Tamoutounour, 
Guilliams et al. (2013) distinguished macrophages and dendritic cells in mouse dermis using a 
combination of flow cytometry markers, namely CCR2, CD64, MerTK, Ly6c and MHCII. I 
will cover the specific detail of this paper later on in this thesis, as it was a paper which chapter 
6 bases its description of the different myeloid populations off. This allowed them to 
distinguish functional differences between these two populations, where in non-pathologica l 
skin, dermal dendritic cells were primarily the antigen-presenting cells, whereas macrophages 
functioned as the scavenger cells, with a major role in clearing of macromolecules and 
microbes. However, that is not the only function of dermal macrophages, as their unique profile 
allows them to secrete growth factors essential for wound healing and hair follicle cycling.  
Another important function of macrophages is their ability to recognise pathogen-associa ted 
molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs) and then to 
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execute an appropriate response. Part of this response involves activation of a protein complex 
called the inflammasome. The inflammasome is a complex of proteins One inflammasome in 
particular, the NOD-like receptor protein 3 (NLRP3) is involved in caspase-1 activation, a 
protease which cleaves pro-Interleukin-1 Beta (IL-1) and pro-IL-18 into their active forms, 
IL-1  and IL-18 (Malik and Kanneganti 2017). Caspase-1 can also activate pyroptosis, a 
mechanism of inflammatory programmed cell death, important for control of microbia l 
infection (Miao, Rajan et al. 2011). While the inflammasome is a key player in the control of 
microbial infection, overactivity and unregulated inflammation through excessive caspase-1 
activation has been associated with multiple autoimmune diseases (Coll, Robertson et al. 
2015). Adverse effects due to inflammasome activation will be addressed later in this chapter.  
 
The different types of Macrophages  
Proinflammatory macrophages (M1) 
Proinflammatory macrophages are most well known for their effects in driving 
antibacterial immunity, with their ability to phagocytose bacteria and other foreign particles. 
The in vitro polarisation of M1 macrophages from bone-marrow derived monocytes is through 
the presence of macrophage colony stimulating factor (M-CSF) and the presence of 
lipopolysaccharide (LPS) and IFN, which are both expressed with the presence of bacteria. 
Other methods of M1 characterisation are the classicly high expression of induced nitric oxide 
synthase (iNOS) and low expression of arginase 1. Upon polarisation and activation, M1 
macrophages express tumor necrosis factor (TNF), IL-6, IL-12, iNOS, CCR7 and transcribe 
Socs2 and STAT1 (Gensel, Kopper et al. 2017). The induction of a local inflammato ry 
response is useful for fighting pathogens, however can be detrimental in absence of any 
pathogens, where excessive inflammation can drive chronic diseases including, but not limited 
to; asthma, atopic dermatitis, atherosclerosis and diabetes (Parisi, Gini et al. 2018).  
Alternatively activated macrophages (M2) 
Alternatively-activated macrophages (AAM) are any macrophage subtype which 
doesn’t fit the category of M1, proinflammatory macrophages. The characterisation of 
macrophages in vitro reveals a vast number of AAM subtypes, such as M2a which is induced 
by IL-4 and IL-13, and is commonly associated with fungal and helminth infections, M2b 
which is induced by IL-1R and/or the immune complex (IC). M2c are polarised by IL-10 and 
transforming growth factor beta (TGF-), both associated with anti-inflammatory properties, 
and are believed to represent the tissue-repair and remodelling population of M2 macrophages. 
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This population is of particular interest in vivo as they are also commonly identified in tumours 
and are thus labelled tumour-associated macrophages (TAMs). The presence of CD163, a 
common marker for M2 macrophages present in melanoma samples from human biopsies has 
been associated as a prognostic marker for increased incidence of death (Rowe, Tang et al. 
2016). However M2 macrophages are also useful in tissue repair, as these same macrophages 
assist in wound closure and angiogenesis. The difference between M1 and M2 macrophages 
have been summarised in Figure 2. 
 
 
Figure 2. The differentiation of monocytes into M1 vs M2 macrophage populations, and their 
differences 
  
Origins of skin-resident macrophages 
Skin resident macrophages are derived from three different progenitor pathways. 
Firstly, there are yolk-sac derived macrophages which are formed during early embryogenes is. 
These migrate to the embryo proper, and then differentiate to LC in the epidermis. Following 
this initial seeding, foetal liver haematopoiesis creates precursors which add to and replace the 
YS-derived macrophages during late embryogenesis (Hoeffel, Wang et al. 2012). As such, LCs 
were one of the first macrophage cell types identified to have dual origins in homeostatic skin. 
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Haematopoietic stem cell (HSC)-derived macrophages comprise the remaining population 
found in the skin. 
It is widely accepted that the yolk-sac/foetal liver macrophages and LC repopulate in 
the skin via self-renewal and independently of any HSC differentiation (Collin and Milne 
2016). Congenic studies using CD45.1 mice transplanted with bone marrow from mice 
expressing the CD45.2 antigen have shown that around 3 months after transplant, as many as 
50% of dermal macrophages can be donor derived, but no Langerhans cells are under steady 
state conditions (Merad, Manz et al. 2002). However, in non-homeostatic skin, such as in 
conditions of induced inflammation, Ly6chi monocytes are able to differentiate into LC 
precursors, and then further differentiate into LC (Merad, Manz et al. 2002, Ginhoux, Tacke et 
al. 2006).  
The HSC-derived population of resident macrophages repopulates via bone marrow 
monocyte differentiation in situ under homeostatic conditions. Monocytes can differentiate into 
different cell types, namely macrophages and dendritic cells in the skin, although research 
suggests they are also able to maintain their own properties and functions without the need to 
differentiate (Jakubzick, Randolph et al. 2017). The differentiation of monocytes into tissue 
macrophages is dependent on colony stimulating factor-1 receptor (CSF-1R), which was tested 
using an antibody against CSF1-R (MacDonald, Palmer et al. 2010). Investigations are still 
underway to determine what functional differences there are between HSC-derived 
macrophages in the skin compared to the self-renewing Yolk-Sac (YS) derived macrophages, 
although monocyte-derived macrophages may be the driving force behind tumor progression 
through the differentiation of tumor associated macrophages (TAMs) as opposed to the tissue 
resident, yolk-sac derived macrophages, at least in some cancers such as hepatic and lung 
cancer (Kang, Yevsa et al. 2011, Cortez-Retamozo, Etzrodt et al. 2013). Further studies are 
required to identify the purpose of resident macrophages in the skin compared to monocyte 
derived under conditions of cancer, autoimmune disorders such as psoriasis and wound healing.  
It is also unknown which progenitor repopulates the continuous turnover of macrophages found 
throughout different time points in the hair follicle cycle. One aim of this thesis was to use a 
lineage tracing model, a brainbow 1.0 construct specific for bone marrow-derived macrophages 
to identify the repopulation of macrophages in the skin following wounding. This is discussed 
in much more detail in chapter 7. The origins of different myeloid cells in the skin has been 
presented in figure 3. 
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Figure 3. The origins of myeloid cells and their location of residence within the compartments 
of the skin. Green arrows indicate the origin of dermal macrophages and Langerhans cells 
normally from fetal development, the orange arrows indicate the origin of dermal macrophages 
from the bone marrow under both homeostasis and inflammation, and the red arrow indicates 
the development of Langerhans Cells from Ly6chi monocytes due to inflammation. 
 
Skin wound healing 
Wound healing is a process involving four stages, haemostasis, inflammation, 
proliferation and remodelling. The rate of wound healing can be impacted by multiple factors 
such as the severity of the wound, presence of infection, the type of dressing used and even 
genetics. Differences between any of these conditions can be the difference between a small 
scar, a hypertrophic scar or even complete failure of closure. It is therefore important to 
understand the mechanisms involved in each phase, and how we can attempt to regulate these 
mechanisms.  
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Acute wound healing 
When a healthy individual experiences a graze or cut, their skin instantly progresses 
toward the first stage of healing, which is hemostasis, i.e. the bleeding and clotting of the new 
wound. From here, wound healing undergoes a further three consecutive overlapping phases 
of inflammation, proliferation and remodelling. In a 6mm model of full-thickness wound 
healing in murine skin, the first haemostatic phase takes minutes, rapidly followed by the 
inflammatory phase which predominates from the initiation of wounding until 3-4 days post-
wounding (Rodero and Khosrotehrani 2010). This stage consists of the infiltration of 
neutrophils and monocyte-derived macrophages, in order to rapidly clear the wound of debris 
and prevent colonisation of bacteria. Neutrophils and macrophages are also important for the 
release of cytokines for growth and repair. The next stage of healing is proliferation, occurring 
from 4-7 days post-wounding, where there is increased angiogenesis, proliferation of 
keratinocytes, fibroblasts and extracellular matrix and keratinocyte migration for epithelia l 
closure. Macrophages are also known to switch from a proinflammatory phenotype into a pro-
wound healing phenotype, secreting growth factors. The final phase of wound healing is 
remodelling, whereby matrix metalloproteinases such as MMP1 remodel collagen fibres for 
optimal scar formation, and there is regression of vasculature formed during the proliferat ive 
phase through apoptosis (Xie, Bian et al. 2008). This phase can last up to one-year post-
wounding, after which the scar can still persist. 
Haemostasis 
 Haemostasis is often left out as a phase of wound healing, due to how rapidly it occurs 
and how quickly inflammation takes over. It is the phase which the blood begins to clot and 
prevent further blood loss and prevents the entrance of pathogens found on the skin surface. It 
does this by the constriction of blood vessels in the subcutaneous layers, the deposition of fibrin 
strands which appear within a minute, the recruitment of platelets and the secretion of 
coagulants and prothrombin (Golebiewska and Poole 2015). It creates a cytokine-rich plug to 
signal the immune system to begin the next phase of inflammation. 
Inflammation 
In adults, inflammation occurs rapidly and robustly, with maximum neutrophil 
recruitment within 24 hours post-wounding, and an influx of inflammatory, monocyte-derived 
macrophages from 1 day to 3 days post-wounding. These cells are recruited in order to clear 
cellular debris, and control bacterial colonization. In order for this rapid response to occur, 
immediately upon wounding there is a release of RNA, inflammatory cytokines, growth factors 
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and cell-signalling molecules from damaged keratinocytes, DETCs, LCs, platelets and 
endothelial cells. The essential mediators for this inflammatory phase are transforming growth 
factor-beta (TGF-β), tumour necrosis factor alpha (TNFα), interferon-gamma (IFNγ), 
interleukin (IL-) 1α, IL-1β, IL-6, macrophage inflammatory protein (MIP-) 1α, MIP-2 and 
chemokine ligand-2 (CCL-2, also known as MCP-1) (Murray and Wynn 2011, Vannella and 
Wynn 2017)(DiPietro, Burdick et al. 1998). The majority of these cytokines and chemokines 
are released from resident macrophages, in order to recruit further macrophages which are 
monocyte-derived. These macrophages serve a role in the progression from inflammation to 
proliferation, by secreting growth factors such as transforming growth factor beta (TGF), 
platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and 
anti-inflammatory cytokines including IL-10 and arginase. (Krzyszczyk, Schloss et al. 
2018)(Rodero and Khosrotehrani 2010). 
Neutrophils are used as a first-line mechanism of defence for the prevention of 
microbial colonisation in the wound. However, they are not necessary for successful wound 
healing in an acute setting (Dovi, He et al. 2003, Martin, D'Souza et al. 2003). The loss of 
neutrophils through the use of an anti-Gr1 antibody induced rapid wound healing, without 
affecting macrophage populations, collagen synthesis or final wound strength (Dovi, He et al. 
2003). The caveat to the loss of Neutrophils in clinical settings is that unlike in laboratory 
settings where mice are stored in specific pathogen free facilities, humans face constant 
microbial challenge, and the removal of neutrophils may result in infection. 
Unlike neutrophils, macrophages are essential for wound closure, depending on the 
wound environment. In an acute wound healing scenario, the depletion of macrophages has 
been reported to significantly delay wound closure (Mirza, DiPietro et al. 2009). Another study 
by Lucas, Waisman et al. (2010) used a diphtheria toxin time-point specific depletion of 
macrophages during early wound healing using transgenic mice with LysMcre-inducib le 
diptheria toxin receptor (iDTR). This effect caused defective healing if depletion occurred at 
D0, although by D14 the wound site was comparable to untreated mice and had reduced 
scarring. However, LysM-Cre mice are not specific to macrophages. This is a topic which will 
be covered in great detail in chapter 7 of this thesis. 
Proliferation 
Macrophages also play a major role in the proliferative phase of wound healing. The 
proliferative phase is characterised by an increase in fibroblasts, endothelial cells and M2 
macrophages. As mentioned in the previous section on inflammation, when inflammato ry 
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macrophage transition to pro-healing macrophages, they begin to secrete VEGF, which 
increases angiogenesis. This allows for proper vascularisation of the granulation tissue, where 
a large number of cells are migrating and proliferating. Macrophages are also able to assist in 
the recruitment of fibroblasts, through TGF-β and PDGF (Vannella and Wynn 2017). 
Fibroblasts are able to proliferate and differentiate into myofibroblasts, which enable wound 
contraction and therefore wound closure. Myofibroblasts deposit vast amounts of collagen in 
the wound, which then initiates the start of the final stage of healing, remodelling. 
Remodelling 
Remodelling occurs via the apoptosis of unnecessary fibroblasts and myofibroblasts, 
and the regression of vasculature formed during angiogenesis. Recent studies have identified a 
method of fibrosis caused by endothelial-to-mesenchymal transition (EndMT), where the 
excess blood vessels formed through angiogenesis progress to a mesenchymal cell-type during 
wound healing. (Patel, Baz et al. 2018). Macrophages also play a key role in remodelling, 
whereby they secrete matrix metalloproteinases, essential for the breakdown and remodelling 
of collagen in the wound, including MMP2, MMP9, MMP12 and MMP13 (Krzyszczyk, 
Schloss et al. 2018). Indeed, a study looking at macrophage depletion at specific phases during 
wound healing indicated that depletion of macrophages using a CD11b-DTR transgenic mouse 
model just before fibrosis impaired extracellular matrix degradation (Duffield, Forbes et al. 
2005). Remodelling is most likely important for the prevention of hypertrophic or keloid scars, 
but current mechanisms causing these scars remain unknown, with genetic differences within 
individuals, for example those expressing mendelian disorders, rubinstein taybi syndrome 
patients and UCMD patients which all express mutations in their collagen genes playing the 
largest factor in keloid formation (Halim, Emami et al. 2012).  
These events of the stages of wound healing have been summarised in Figure 4. 
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Figure 4. The phases of wound healing 
 
Foetal vs. adult wound healing 
Foetal wound healing is a well-described phenomenon, whereby foetal wounds heal 
using a mechanism of regeneration rather than repair. This allows for perfect skin to replace 
the area of damage, unlike in an adult wound of a similar nature, a scar would form. There are 
many hypotheses to explain this phenomenon, such as a minimal-to-non-existent inflammato ry 
phase, altered extracellular matrix composition and gene expression profiles. Although these 
differences are vast, the key regulator of scar formation is believed to be driven by 
inflammation. Artificially- induced inflammation by the addition of bacteria, PDGF or mast 
cell lysates, in foetal wounds creates a similar phenotype to an adult wound, with scar formation 
as an end result (Frantz, Bettinger et al. 1993, Haynes, Johnson et al. 1994, Wulff, Parent et al. 
2012). These results support studies from Martin, D'Souza et al. (2003), in identifying that an 
inflammatory response during skin wound healing results in scar formation. Foetal 
reepithelialisation of wounds also differs from adult wounds, whereby foetal epidermal cells 
migrate via an actin cable which pulls the two edges together, rather than by lamellipod ia l 
crawling in adult wounds (Martin and Lewis 1992). Cell signalling is also different in foetal 
and adult wounds, where foetal wounds secrete growth factors including: sonic hedgehog 
(Shh), BMP-2, and fibroblast growth factor-4 (FGF-4). The adult wound dermis does not 
receive these signals (Nohno, Kawakami et al. 1995, Zhou, Byrne et al. 1995). The 
investigation into methods to replicate scarless, ‘foetal-like’ wound healing in adults still 
remains elusive. 
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Chronic wounds 
The economic burden of these wounds is massive, with $286 million in bed days alone 
for pressure ulcers in Australia. The cost of hospitalizations for diabetic foot ulcers and 
complications was over $100 million between 2008-09 (Australia 2014). There are several 
mechanisms where chronic wounds can form, with the most common underlying factors of 
obesity and/or diabetes or age related chronic venous ulcers. Diabetic foot ulcers are the most 
common form of chronic wound, with up to 25% of diabetic patients developing a chronic 
wound (Singh, Armstrong et al. 2005). Up to 12% of these result in amputation of the limb due 
to further complications such as gangrene and limb ischemia, and following amputation, the 5-
year survival rate is 50% (Lyon 2008, Sen, Gordillo et al. 2009). There is no singula r 
underlying cause; the most common are peripheral neuropathy caused by diabetes, or venous 
insufficiency. Peripheral neuropathy prevents the initial trauma to be felt, and continuous use 
of the limb only exacerbates the wound. Venous insufficiency is the next contributing factor, 
with the ability to generate spontaneous wounds, or prevent a current wound from healing. 
Spontaneous wounds form by the extravasation of red blood cells at a particular site. This 
induces the recruitment of scavenger macrophages which express the cell-surface marker 
CD163, which have an unrestrained pro-inflammatory effect (Sindrilaru, Peters et al. 2011). 
For wounds to heal, it is important for macrophages to switch from a pro-inflammatory to a 
non-inflammatory state. Most chronic wounds are characterised by excessive inflammation. 
These macrophages associated with venous insufficiency become iron overloaded due to the 
extravasation of red blood cells and fail to switch from their pro-inflammatory phenotype into 
the pro-angiogenic, pro-healing phenotype like in acute wounds (Zhou, Que et al. 2018) 
(Sindrilaru, Peters et al. 2011). They achieve this by releasing toxic reactive oxygen species 
(ROS) including H2O2 and OH radicals into the wound, generating an ulcer. Without the 
transition from a pro-inflammatory phase into the proliferative phase of wound healing, chronic 
wounds fail to close (Crawford, Lal et al. 2017). Future therapies are investigating methods for 
the reduction of inflammation driven by inflammatory macrophages, thus inducing a switch 
into producing pro-angiogenic and pro-healing macrophages instead.  
 
Current therapy for the treatment of chronic wounds 
 The current therapies for chronic wounds depend entirely on the stage and severity of 
the wound. Management of the underlying disease such as maintenance of blood glucose levels 
or attempting to reduce the weight of obese patients is the first critical step for treatment, and 
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the prevention of any further chronic wounds. The treatment from here greatly varies, and 
mostly relies on a trial and error basis, testing multiple avenues of various therapies. These 
start with simple wound care such as debridement of the wound and changing dressings every 
few days. The use of different dressings can aide with healing. Gauze is a cheap and convenient 
dressing but can lead to damage and reopening of the wound when changing the dressing. 
Occlusive films retain moisture in the wound which can be good for inflammatory processes 
but are less beneficial when the wound is exudative. Hydrocolloids, hydrogels, foams, algina te 
and hydrofibres are all alternatives between absorbent and occlusive dressings, each with their 
individual benefits and applied on a case-by-case basis (Frykberg and Banks 2015, Han and 
Ceilley 2017). The risk of infection in chronic wounds is significant, and appropriate treatment 
is required to prevent the build-up of bacterial biofilms on the wound surface. Silver-coated, 
iodine and even honey or any other antimicrobial material can be integrated into certain 
dressings to reduce the build-up of biofilms (Sarheed et al., 2016). After dressings, ‘advanced’ 
treatments can be applied in severe cases such as the use of hyperbaric oxygen therapy, 
negative pressure wound therapy and even bioengineered tissue although some of these have 
controversial efficacy (Wu, Marston et al. 2010).  
Emerging technology such as the use of stem cell therapy, continuous monitor ing 
electrical dressings and antibody therapies are becoming the forefront of chronic wound 
research. Although a ‘one size fits all’ treatment approach is a far cry away, current research 
aims at targeting specific elements of the wound healing phase such as inflammation. They 
attempt to do this using anti-inflammatory cytokines such as IL-17, IL-23, IL-1  and TNF 
without affecting key cytokine production such as IL-6 (Gallucci, Simeonova et al. 2000, 
Matias, Saunus et al. 2011, Rodero, Hodgson et al. 2013, Mirza, Fang et al. 2014, Takagi, 
Kawakami et al. 2016). IL-17 has been previously identified as a possible therapeutic target 
for the treatment of chronic wounds, where (Rodero, Hodgson et al. 2013) demonstrated 
increased IL-17A expression in wounds from obese mice.  
 
Interventions investigated for the treatment of chronic wounds in this thesis  
IL-17A, or more commonly referred to as just ‘IL-17’ is a proinflammatory cytokine 
from the IL-17 family consisting of IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (IL-25), and IL-
17F. IL-17F is most similar to IL-17A, and can also bind to IL-17RA, although at a much lower 
binding affinity (Brembilla, Senra et al. 2018).  IL-17 production by CD4+ T-helper cells 
(Th17) involves the activation of naïve T-cells by IL-6, although different stimuli are required 
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for the generation of Th17 cells with a combination of TGF- , IL-23 and IL-1  permitt ing 
expression of STAT3 and RORt transcription factors which are essential for Th17 lineage 
development (Bhaumik and Basu 2017, Kuwabara, Ishikawa et al. 2017). While IL-17 is 
important for its roles in reducing microbial infections, it has also been associated with 
autoimmune inflammatory conditions such as psoriasis, rheumatoid arthritis (RA), multip le 
sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE), the corresponding 
mouse model for MS (Mony, Khorooshi et al. 2014, Kolbinger, Huppertz et al. 2016, Balato, 
Scala et al. 2017). Excessive inflammation driven by the production of IL-17 is currently a 
topic of interest, especially with the efficacy of anti-IL-17 antibodies used for the treatment of 
psoriasis. This has led to further investigations on the inflammatory properties of IL-17 in other 
skin conditions, and in the model studied in this thesis we look at wound healing. 
IL-23 is an upstream regulator of IL-17 in most Th17 populations (Iwakura and 
Ishigame 2006, Gaffen, Jain et al. 2014). IL-23 is derived of two subunits, a unique IL-23p19 
and a subunit shared with IL-12; IL-12/23p40 subunit. IL-23 has been implemented as an 
upstream target for IL-17-mediated autoimmune diseases with the first antibodies used for 
therapy against the chronic autoimmune disease psoriasis. The first human antibody; 
ustekinumab targeted the combined IL-12/23p40 subunit to treat moderate-to-severe plaque 
psoriasis with great clinical efficacy (Papp, Langley et al. 2008, Papp, Griffiths et al. 2013). 
However, alternative antibodies were needed so that IL-12 was still able to function while still 
inhibiting IL-23, due to associated risks found with another antibody labelled Briakinumab, 
which found adverse cardiac side effects (Traczewski and Rudnicka 2012). Therefore 
monoclonal antibodies such as guselkumab and tildrakizumab were developed which 
specifically target the IL-23p19 subunit (Blauvelt, Papp et al. 2017, Reich, Papp et al. 2017). 
While the association with chronic autoimmune diseases is well established, what isn’t known 
is whether there is a link between excessive inflammation driven by the IL-23/IL-17 axis and 
the excessive inflammation found in chronic wounds. In chapter 4 of this thesis, I will present 
data based on our experiments using genetically modified mice, a mouse model of chronic 
wounds, and antibodies against mouse IL-17 and IL-23 to investigate the efficacy of inhibit ing 
inflammation driven by IL-17 and/or IL-23. 
On the topic of inflammation and cytokines, a protein of interest is the unique IL-33. 
IL-33 is a nuclear cytokine, which is constitutively expressed in endothelial and epithelial cells 
of barrier tissues such as skin, lungs and gut, where it functions as an alarmin, a protein that is 
released upon cell necrosis or damage to alert neighbouring cells of possible danger and rapidly 
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prime an immune response (Cayrol and Girard 2018). IL-33 was first described as a cytokine 
from the IL-1 superfamily of cytokines, with a prominent role in T-helper 2 (Th2) 
inflammation. It was therefore associated with asthma and other allergic diseases due to this 
Th2-biased inflammation (Liew, Pitman et al. 2010). The receptor for IL-33 is known as ST2, 
but also as T1, IL1RL1, IL-1R4 or IL-33R. IL-33 signals by binding to its full- length, 
transmembrane receptor ST2L, which then recruits its associated IL-1 receptor-associated 
protein (IL1-RAcP) to induce signalling via various signalling complexes in which all 
pathways end with the activation of nuclear factor kappa-light-chain-enhancer of activated B-
cells (NF-B) and mitogen-activated protein kinase (MAPK) . ST2 can also exist in a soluble 
form known as soluble ST2 (sST2). sST2 is believed to act as a decoy receptor, which lacks 
the transmembrane and cytoplasmic domains of ST2L. sST2 reportedly binds free IL-33 to 
control and moderate IL-33-induced signalling and inflammation (Bandara, Beaven et al. 2015, 
Braun, Afonina et al. 2018). ST2L is found on a wide variety of immune cells including mast 
cells, macrophages, T-cells innate lymphoid cells (ILC) eosinophils and basophils (Oboki, 
Ohno et al. 2010). When IL-33 binds and activates ST2L, this promotes type-2 immune 
responses such as IL-5 and IL-13 secretion by ILC2 cells (Lund, Walford et al. 2013), polarises 
macrophages towards an alternatively activated phenotype which secretes arginase, CCL24 
and CCL17 (Kurowska-Stolarska, Stolarski et al. 2009), and activation of mast cells, basophils 
and eosinophils (Saluja, Khan et al. 2015). However, one paper published identified that IL-33 
can also act independently of ST2. They believe IL-33 can function as a nuclear transcript ion 
factor, where it inhibits NF-B gene transcription (Ali, Mohs et al. 2011). However, more 
recent research used siRNA to knock out IL-33 transcription and found no differences in the 
endothelial proteome indicating that IL-33 may act as a cytokine, but not as a nuclear 
transcription factor (Gautier, Cayrol et al. 2016). This was not known at the time when chapter 
5 was published, and thus we decided to investigate whether the effects from IL-33 in wound 
healing were due to the signalling through its receptor ST2, or through nuclear transcript ion 
modifications.  
The final inflammatory mechanism to be studied in this thesis is the inflammasome. 
There are multiple inflammasomes; the Nod-like receptor (NLR)-subsets are NLRP1, NLRP3 
and NLRC4, there is also the absent in melanoma 2 (AIM2) and apoptosis-associated speck-
like protein (ASC) inflammasomes.  For brevity, I will only be focusing on the NLRP3 
inflammasome in this segment. The Nod-, LLR- and pyrin domain-containing 3 (NLRP3) 
inflammasome is widely regarded as the most clinically relevant inflammasomes due to the 
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wide variety of stimuli which it responds to (Abderrazak, Syrovets et al. 2015, He, Hara et al. 
2016, Mangan, Olhava et al. 2018). The function of the NLRP3 inflammasome is to mediate 
host immune responses to the presence of microbes or cell damage. It does this via the 
activation of Caspase-1, which cleaves pro-IL-1  and pro-IL-18 into functional length, 
inflammatory IL-1  and IL-18. It is also able to induce a type of inflammatory cell death, 
known as pyroptosis. This inflammatory event is well-described in macrophages, and as 
inflammatory macrophages are a key regulator in the process of wound healing, we decided to 
find a model to investigate the inhibition of the NLRP3 inflammasome in wounds. 
The inhibition of the NLRP3 inflammasome can be achieved with a synthetic molecule 
developed in the Institute of Molecular Biology, The University of Queensland (Coll, 
Robertson et al. 2015). While previous therapies to treat inflammasome disorders have 
included biologics targeting IL-1, such as IL-1R antagonists, IL-1 neutralising antibodies and 
even artificial decoy receptors. However, biological antibodies all have relatively short half-
lives, are not stable at room temperature and are very expensive. MCC950 is able to be stored 
as a lyophilized powder, stable at room temperature for months on end and cheap to produce.  
We therefore decided to test MCC950 as a therapy for the treatment of chronic inflammato ry 
wounds in an obese mouse model in chapter 6. 
 
UV irradiation and contact hypersensitivity 
The first process in the skin upon excessive UV irradiation is erythema, where the 
keratinocytes secrete inflammatory danger signals such as the IL-1 family of cytokines (Nasti 
and Timares 2012). This process induces the extravasation of immune cells and fluids from 
leaky blood vessels which gives the characteristic hot, red flushing of the skin. Depending on 
the severity of the UV exposure, extensive keratinocyte death can induce large sheets of 
keratinocytes peeling from the stratum corneum. The signalling induced by keratinocytes 
recruit neutrophils in the first 24 hours, followed by macrophages in a process not too different 
from wound healing (Rodero, Handoko et al. 2014). It has been well described that exposure 
to the sun and ultraviolet B irradiation is directly correlated to the risk of skin cancer. Multip le 
mechanisms of action have been proposed in order to describe the changes that occur in the 
skin in order for normal, healthy cells to progress into a hyperproliferative, mutated state. The 
first method describes an increase in mutations due to UV-induced damage (Becker and Wang 
1989). UV damage, specifically UVB, is able to induce molecular changes in DNA, causing 
interactions or loss of interactions between adjacent DNA bases or DNA and proteins.  
Common UV signatures found in DNA include a C to T or CC to TT transition, known as the 
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formation of cyclobutane pyrimidine dimers (CPDs) commonly found in the p53 tumor 
suppressor gene, the formation of 6-4 photoproducts (6-4PPs) and DNA double strand breaks 
(DSBs) (Cleaver and Crowley 2002)(Brash and Haseltine 1982, Benjamin, Ullrich et al. 2008, 
Rastogi, Richa et al. 2010). Aside from the direct loss of function of p53 acting as a tumor 
suppressor gene, CPD have been reported to cause immunosuppression as the repair of 
damaged CPD was able to prevent an observable immunosuppression (Kripke, Cox et al. 
1992). UV is also able to alter urocanic acid (UCA), which in its natural form is found in a 
trans-UCA isomer, however when exposed to UV is convered into its cis-UCA isomer. The 
resulting confirmation change is also able to induce immunosuppression, through impaired 
antigen presentation from splenic dendritic cells (Noonan, De Fabo et al. 1988). One paper 
described the mechanism of action of cis-UCA-induced immune suppression by the binding of 
Cis-UCA to the serotonin receptor, 5-HT and activating it (Walterscheid, Nghiem et al. 2006).  
The first study to find immunosuppression as an effect of UV irradiation by Kripke, M 
(1974) identified UV-induced antigenicity in skin cancers due to the fact transplanted tumours 
from UV radiated mice into mice which hadn’t been exposed to UV, were able to successfully 
prevent tumour growth. Further research identified that immunosuppression was systemic, by 
using parabiotic mice (Fisher and Kripke 1977). This study paved way for further immunologic 
research into UVR and immune suppression. More recent studies have looked at immunologic 
tolerance to contact allergens, with and without UV exposure. They identified that not only 
was the UV-irradiated area of skin immunologically suppressed, but areas that were not 
exposed showed identical levels of immunosuppression (Noonan and Fabo 1990). One of the 
most well-described mechanisms via which this immune suppression occurs has been 
demonstrated as a Regulatory T-cell (Treg) response due to incorrect antigen presentation by 
APCs (Greene, Sy et al. 1979, Schwarz and Beissert 2013). Studies have explored the 
expansion of Tregs can increase by 50-60% following UV irradiation, a significant number 
considering regulatory T-cells secrete large amounts of IL-10 to suppress the inflammation and 
restore the skin to an apparent homeostasis, which results in a systemic immunosuppress ion 
(Yamazaki, Nishioka et al. 2014). Langerhans cells have highly debated functions with their 
role in UV-mediated immunosuppression. Immediately following UV, Langerhans cells 
migrate to the lymphs nodes, where they are believed to activate Tregs and play a critical role 
in immunoregulation (Beissert, Ruhlemann et al. 2001, Fukunaga, Khaskhely et al. 2010, 
Taguchi, Fukunaga et al. 2013). This was debated with an article published in 2009, which 
demonstrated that LC were NOT required for UV-mediated immunosuppression, through the 
use of langerin-DTR mice and the finding of a langerin+ dermal dendritic cell population which 
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were not Langerhans cells (Wang, Jameson et al. 2009). The addition of IL-12 to mice 
following UV has been demonstrated to prevent the systemic immunosuppression, possibly by 
countering the effects of cis-UCA (Beissert, Ruhlemann et al. 2001), its DNA repair ability 
(Schwarz, Maeda et al. 2005) or by its cytokine suppressive abilities (Schmitt, Walterscheid et 
al. 2000).  
Mast cells are a key player in systemic immune suppression, as mast cell migration due 
to CXCR4 to CXCL12 expressing B-cells in the lymph nodes upon UV irradiation was found 
to be essential for systemic immune suppression (Byrne, Limon-Flores et al. 2008). Mast-cell 
derived IL-10 was also important for mediating anti-inflammatory properties in allergic contact 
dermatitis (Grimbaldeston, Nakae et al. 2007). However, mast cells are not involved in local 
immune suppression induced by UV with studies using mast-cell deficient mice still able to 
suppress hapten-mediated inflammation (Hart, Grimbaldeston et al. 1998). 
There have been only a few reports of macrophages modifying T-cell responses. This 
is likely due to the fact that the most common myeloid population to induce T-cell responses 
are dendritic cells (Dasgupta and Dasgupta 2017, Macri, Pang et al. 2017). However, 
macrophages themselves have been identified to play a role in UV-mediated immune 
suppression. In 2000, one group showed DC and/or Macrophages polarised in vitro after UV 
exposure expressed a IL-12p40 homodimer, a natural antagonist for bioactive IL-12 which as 
previously mentioned, is important for the prevention of immunosuppression (Schmitt and 
Ullrich 2000). In 2008, another group demonstrated that skin infiltrat ing 
monocytes/DC/macrophages were able to migrate to the lymph nodes and produce IL-10 
following contact sensitization exposure to UV-irradiated skin (Toichi, Lu et al. 2008). 
 
Previous research performed by members of our lab used a genetically modified mouse 
model termed the Cdk4R24C/R24C::Tyr-NRASQ61K for the study of melanoma and melanocytic 
lesions (Rodero, Handoko et al. 2014). They found that these mice were predisposed to 
melanoma formation over time, and that when neonates with these genetic mutations were 
exposed to a single burning dose of UV, they formed melanomas much sooner than those which 
were not exposed at all. They also found that adults which were UV exposed did not develop 
melanomas faster than those that were not. This implied that there was something specific 
about the neonatal skin, which was lost as an adult. Other experiments utilized clodronate 
liposomes to study melanocyte proliferation and found that inflammatory CCR2+ cells in 
neonates were responsible for the proliferation of melanocytic lesions, whereas the depletion 
of CD11c+ DC populations, using CD11c-diptheria toxin receptor (DTR) mice were not. 
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We therefore decided to investigate the effects of clodronate depletion in neonates and 
exposure to UV, in order to investigate if macrophages have any role in the long-term 
immunosuppression found due to UV irradiation. This work was performed using wild-type, 
C57Bl/6 mice instead of the genetically modified melanoma strains, as we did not want to add 
melanocyte proliferation and other factors into account. 
 
Aims and Hypotheses: 
Macrophages and their heterogeneous functions in the skin have been implicated in 
altered wound healing, skin cancer outcomes and contact hypersensitivity. Understanding how 
these functions are modulated could be used for therapeutic treatments to combat undesired 
outcomes such as chronic wounds and skin cancer. Although many studies have described the 
different populations of macrophages within the skin and detailing their developmental origin, 
their respective implications in clinically relevant situations of injury have not been fully 
explored.  
 
Hypotheses: 
Skin wound macrophages can be altered from proinflammatory to anti-
inflammatory/pro-healing by inhibiting certain proinflammatory cytokines including IL-17, 
IL-23, IL-33 and the NLRP3 inflammasome. 
 
UVB irradiation on neonates will alter resident macrophage populations and induce a 
long-term immune suppression, identifiable by delayed-type contact hypersensitivity 
experiments, and the immunosuppression can be modulated by the depletion of macrophages 
at the time of the UV exposure. 
 
Aims: 
To identify the effects of macrophages on long-term immunosuppression, either local or 
systemic from neonatal UV irradiation followed by contact hypersensitivity experiments at 8 
weeks of age, with or without macrophage depletion at the time of UV irradiation. 
I will aim to demonstrate that neonatal UV irradiation induces long-term systemic 
immunosuppression, although depletion of macrophages around the time of UV irradiation can 
prevent this long-term immunosuppression.  
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To identify changes in resident skin macrophages following trauma from UV irradiation 
I aim to analyse skin-resident macrophage following UV exposure over time and draw 
comparisons between the populations using flow cytometic analysis 
 
To modulate macrophage activity in acute and chronic wounds through targeting of early 
inflammatory events. 
I aim to use genetically modified mice with deficiencies in leptin, IL-23 subunits, IL-
12 subunits and the ST2 receptor. These mice will be wounded and used to identify 
inflammation modulated by macrophages, as well as treatment with antibodies and small 
molecules against inflammatory targets such as IL-17, IL-23 and the NLRP3 inflammasome.  
 
To determine how skin-resident macrophages renew/repopulate under homeostasis compared 
to after injury such as UV irradiation or wound healing 
I aim to use genetically modified mice expressing a multicolour fluorescent construct 
which will be used to lineage trace resident or recruited macrophages using bone marrow 
transplants and/or skin grafts. These mice will then be exposed to either wounding or UV 
irradiation to determine the clonality of resident skin macrophages, if they derive from bone 
marrow progenitors or self-renew in situ.  
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Significance: 
Macrophages are one of the most plastic cells in the body, with the ability to both 
protect and damage local systems. They can identify and kill tumour cells, but can supplement 
and grow them too. They can prevent bacteria from colonising a wound, but can also prevent 
the wound from closing. The ability to change the polarisation of macrophages in vivo would 
have profound clinical applications, where in the skin they could prevent cancer growth and 
promote wound closure. Further research needs to be performed to identify key signalling 
molecules which allow preferential polarisation. 
UV exposure is one of the leading causes of skin cancer. Understanding how the 
immune system is modified and what can be attempted in order to restore its function to a pre-
irradiated state would have significant outcomes in the future of skin cancer treatment or 
possibly even prevention. We have evidence that macrophages are able to modulate an immune 
suppression after UV, so further studies may reveal the mechanism by which this occurs, and 
possible methods to replicate this mechanism without the systemic depletion of macrophages, 
which by itself is not a clinically suitable form of treatment. 
Chronic wounds are a major burden both physically and financially, with an estimated 
400,000 Australians with a chronic wound at any given time (Association 2012). The 
modulation or treatment of these wounds has had limited success (Han and Ceilley 2017), with 
each individual case currently requiring specialised, individual treatment. As macrophages are 
the main immune cell required for the control of wound closure, the ability to manually switch 
them from an inflammatory state to a pro-angiogenic state would greatly improve wound 
outcomes. Early research has identified inflammatory factors such as IL-17 which can be 
targeted through the use of antibodies, small molecules or siRNA, in order to improve wound 
closure. Further research would allow the identification of more molecules, opening up more 
targets for the therapeutic treatment of chronic wounds. 
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Chapter 2 - Materials and Methods 
 
Mice 
Mice were housed at the University of Queensland Centre for Clinical Research 
(UQCCR), Herston Medical Research Centre (HMRC), the Translational Research Institute 
(TRI) and Pharmacy Australia Centre for Excellence (PACE) animal facilities and were treated 
in accordance with institutional ethics approvals and guidelines for the care of experimenta l 
animals. The following mice were housed in the respective locations under the attached ethics 
approvals. 
 
Table 1. List of animal strains used under ethics UQCCR/424/12/NHMRC (Pre-2015) and 
UQCCR/460/15/STARTUP (Post-2015) 
Mouse Strain Strain Name  Mouse Strain Strain Name 
C57Bl/6J C57Bl/6 or WT  LepOb Ob/Ob 
IL-12p35-/- P35 KO  Heterozygous LepOb Ob/+ 
IL-23p19-/- P19 KO  LepOb IL-17-/- Ob/Ob x IL-17-/- 
IL-12p40-/- P40 KO  LepOb IL-17+/- Ob/Ob x IL-17+/- 
IL-17-/- IL-17 KO  C57Bl/6J Tg(CAG-
Brainbow1.0)3Eggn 
CAGGSBOW 
BALB/c BALB/c or WT  B6. Lyz2tm1(Cre)lfo LysM-Cre 
Il1rl1-/- ST2 KO  LysM-Cre x 
CAGGSBOW 
Macbow 
 
Animal handling and techniques 
Clodronate depletion and UVB irradiation 
C57Bl/6J neonates from the University of Queensland, Centre for Clinical Research 
had daily injections subcutaneously and intra-peritoneal with 100μL either PBS-containing 
liposomes or Clodronate-containing liposomes (clodronateliposomes.org, The Netherlands) 
from postnatal day 1 (P1) until P5. Litters were randomised to receive either a single burning 
dose of broad-spectrum (280-315nm) UVB irradiation (Phillips TL100W 12RS UVB lamps), 
total UVB at 0.8KJ/m2 per minute and erythemal UVB at 0.21KJ/m2 per minute for a duration 
of 10 minutes. This dose and regimen was selected based on previous experiments performed 
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in the lab on melanoma induction in genetically modified mice, where a minimum erythemal 
dose (MED) was observed based on the presence of erythema or not.  
Contact Hypersensitivity 
At 8 weeks, mice were anaesthetized with 2% isofluorane in 100% oxygen, then had 
abdominal fur shaved using electric clippers and were then immediately sensitized with 100μL 
of 5% Oxazolone (4-Ethoxymethylene-2-phenyl-2-oxazolin-5-one, Sigma-Aldrich, MO, 
USA) in a 4:1 Acetone/Corn Oil (Sigma-Aldrich, MO, USA) solution, topically applied. One 
week later, mouse ears were challenged with 20μL vehicle on the left ear (control) and 2% 
oxazolone in acetone/corn oil on the right ear. 24 hours post challenge, ear thickness was 
measured using digital Vernier callipers (Mitutoyo, Japan) down to the nearest tenth of a mm. 
The difference in thickness between the left ear and right ear was calculated to determine level 
of inflammation. This follows a protocol paper for UV-mediated CHS immunosuppression, 
with a modification for oxazolone instead of TNCB. (Bruhs and Schwarz 2017) 
Wounding 
Mice were anaesthetized in a chamber containing 1.5% Isoflurane in 100% oxygen. 
Back skin was shaved with electric clippers, and depilatory cream (Veet® Reckitt Benckiser, 
Slough, UK) was applied for 2 mins. Veet and remaining hair was scraped off using the 
supplied rubber scraper, and back skin was sterilized using 10% Povidone/Iodine solution 
(Pfizer, NY, USA). Four 6mm wounds were generated using a sterile punch biopsy tool (Stiefel 
Laboratories, NC, USA). Wounds were full thickness (to the panniculus carnosus muscle) and 
not covered with bandaging or gauze. Mice were given 1mg/ml children’s Panadol post-
wounding for analgesia via oral solution. Mice were culled at required time-points post-
wounding as required, which usually consisted of day-3 (D3) post-wounding to study the 
kinetics of inflammation, D4/D5 to study the proliferative phase and D7 to study wound closure 
in WT mice, or to study the shift in inflammation in obese mice. 
Antibody injections 
Mice were wounded as per the above protocol. Immediately after wounding, anti-
mouse-IL-17A, IL-23p19 and Isotype-matched control antibodies (eBioscience, Cat no. 16-
7173, 16-7232, 16-4301, 16-4714 respectively) were intradermally injected in PBS into the 
peri-wound area, at a final dose of 30µg/mouse, as previously reported (Rodero, Hodgson et 
al. 2013). This was applied daily into the wounds up to D3 post-wounding. 
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Small molecule delivery 
Mice were wounded as per above protocol. MCC950 was supplied by the Institute for 
Molecular Bioscience, University of Queensland, Australia. MCC950 was first applied 
topically at a dose of 1mg/day in ice-cold 30% F-127 Pluronic gel (Sigma-Aldrich, MO, USA) 
dissolved in PBS. The second experiment used MCC950 taken orally at a dose of 0.3mg/ml in 
drinking water ad libitum giving a dose of approximately 20mg/kg/day. 
Macroscopic wound imaging 
Imaging was performed using a Xenogen IVIS Spectrum live imaging system 
(PerkinElmer, MA, USA). Mice were anaesthetized in 1.5% Isofluorane in 100% O2 before 
being placed into the imaging chamber dorsal side up. Images were acquired using the 
following parameters: Exposure: Auto; F/Stop: 8; Binning: small; Field of view: D. Wound 
images were analysed using ImageJ software (NIH, MD, USA). 
 
Flow Cytometry 
Mice were culled at required time points; wounds at D3-7, neonates for skin at P5 and 
P10, adults for skin at P21, P42 and P60. Back skin, whole wounds, left and right cervical 
lymph nodes, inguinal lymph nodes and spleen were harvested. Alternatively for the 
comparison of skin with and without UV only, whole back skin was shaved and depilated using 
Veet cream for adult mice for skin harvesting at P21, P42 and P60. The entire dorsal surface 
was removed, and hypodermis was scraped off using a razor blade. The skin was sliced into 
1mm3 sections and placed in 10ml HBBS + 307ul Liberase TL (5mg/mL) (Sigma Aldrich, MO, 
USA) + 20ul DNAseI (10mg/mL) (Sigma Aldrich, MO, USA) in an orbital shaker at 37oC for 
2 hours. A serological pipette was used to separate aggregates every 30 mins. Cells were 
filtered through a 70um cell strainer and washed with Phosphate buffered saline, 0.5% bovine 
serum albumin, 2μM Ethylenediaminetetraacetic acid (FACS) buffer. Red blood cells were 
lysed in ACK lysis buffer. Wounds were resuspended in 4ml FACS buffer and layered on 2ml 
of Histopaque-1083 at 25oC and spun at 400g for 30 mins. Cells were stained with the following 
antibodies listed in Table 2. Cells were fixed and permeabilized using BD-biosciences FoxP3 
staining buffer kit if any intracellular staining was required. The fixing step was performed 
overnight at 4oC and intracellular staining performed the following day. All flow cytometry 
samples were analysed using a Beckman Coulter Cytoflex S. Post-acquisition analysis was 
performed using FlowJo X.  
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Table 2. List of conjugated flow cytometry antibodies 
Antibody Source Dilution 
CCR2-APC [475301] R&D Systems 1/200 
CD3-PE [17A2] BioLegend 1/200 
CD3ε-Pacific blue [500A2] BD Biosciences 1/200 
CD4-PE-Texas Red [RM4-5] Invitrogen 1/200 
CD8α-PerCP/Cy5.5 [53-6.7] BD Biosciences 1/200 
CD11b-PerCP/Cy5.5 [M1/70] BioLegend 1/200 
CD11c-PE/Cy7 [N418] BioLegend 1/200 
CD25-PE [PC61] BD Biosciences 1/200 
CD45-BV650 [30-F11] BioLegend 1/800 
CD64-BV421 [X54-5/7.1] BioLegend 1/200 
CD115-BV605 [AFS98] BioLegend 1/400 
CD206-AlexaFluor700 [C068C2] BioLegend 1/100 
FoxP3-AlexaFluor647 [MF-14] BioLegend 1/100 
Fixable viability stain 510  BD Biosciences 1/500 
Ly6c-APC/Cy7 [AL-21] BD Biosciences 1/200 
Ly6g-PE [1A8] BioLegend 1/200 
MHCII (I-A/I-E)-FITC [M5/114.15.2] BioLegend 1/100 
IL-17A-AlexaFluor647 [TC11-18H10.1] BioLegend 1/100 
IFN-FITC [XMG1.2] BioLegend 1/100 
TCR-PE [GL3] BioLegend 1/200 
CD16/32 (FC-Block) Unconjugated BD Biosciences 1/100 
 
Histology 
Tissue collection 
Mice were culled dependant on the experiment; for wounds, mice were culled between 
D3-D14 post-wounding, for contact hypersensitivity, mice were culled at P5, to test clodronate 
efficacy, P16 to test repopulation following clodronate depletion, and 9 weeks after birth and 
after the contact hypersensitivity experiment was concluded, for measuring the macrophage 
populations in the skin over the first two hair follicle cycles, mice were culled at P0, P4, P10, 
P16, P22, P30, P42 and P60. Whole back skin was shaved and Veet cream was applied for 2 
mins to depilate the skin for adult mice at 9 weeks and at all the time points over the first two 
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hair follicle cycles. Skin was washed and pat dry with paper towel. Scissors were used to 
remove the whole back skin. Skin was cut into 2-3mm strips for embedding. Left and right ears 
were removed using scissors and halved base-to-tip, one piece for embedding. 
Wounds were removed, with care taken to prevent detachment of the underlying 
granulation tissue. Wounds were butterflied from anterior to posterior, and embedded cut side 
down.  
Paraffin-embedded sections 
Tissues were fixed in 4% paraformaldehyde at 4oC for 24 hours. Tissues were processed 
at the Translational Research Institute histology facility for paraffin embedding, sectioning and 
H&E staining.  
Formalin-fixed frozen sections 
Tissues were fixed for 2 hours at 25oC in 4% paraformaldehyde for fixation of the 
tissue, then cryoprotected by immersion in multiple gradients of sucrose solutions ranging from 
10% to 30% overnight, or until tissue sank. Tissue was embedded in OCT (Sakura tissue-tek) 
and 8μm sections were cut using a Leica CM1950 cryostat or a ThermoFisher HM525NX 
cryostat at -20oC by myself. Sections were mounted on Superfrost™ Plus microscope slides 
(Thermo Fisher Scientific, MA, USA). 
Immunofluorescence 
Paraffin sections were dewaxed in De-Solv-It citrus cleaner as a xylene alternative, then 
rehydrated in ethanol gradients; 100%, 95%, 70% followed by dH2O. Antigen retrieval was 
performed using a Carezyme I: Trypsin antigen retrieval kit (Biocare Medical). Slides were 
blocked using 5% Normal Donkey Serum (NDS), 1% Bovine Serum Albumin (BSA) in 0.1% 
Tween-20 PBS for 20 mins at 25oC. Primary antibodies were used at the following 
concentrations in table 1. Antibodies were diluted in blocking solution at 4oC overnight. 
Secondary antibodies were as listed in Table 4, diluted in 3% BSA, 0.1% Tween-20 PBS and 
incubated for 1 hour at 25oC. Slides were counterstained with DAPI and imaged on a Zeiss 
LSM710, Olympus FV1200 or Olympus FV3000. 
 
Table 3. Primary antibodies used for immunofluorescence 
Antibody Source Dilution 
Rat anti-F4/80 [Cl:A3-1] Serotec 1/200 
Rabbit anti-iNOS [polyclonal] Abcam 1/100 
Goat anti-MRC1(CD206) [polyclonal] R&D 1/200 
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Rabbit anti-LYVE1 [polyclonal] Abcam 1/200 
Rabbit anti-IL-17A [polyclonal] Proteintech 1/100 
Rabbit anti-Keratin14 [polyclonal] Covance 1/1000 
Rat anti-CD31 [MEC 13.3] BD Biosciences 1/200 
Rabbit anti-αSMA [polyclonal] Abcam 1/100 
 
Table 4. List of Secondary antibodies used for immunofluorence 
Antibody Source Dilution 
Goat anti-Rat IgG [H+L] Alexa® 568 Invitrogen 1/500 
Goat anti-Rabbit IgG [H+L] Alexa® 488 Invitrogen 1/500 
Goat anti-Rat IgG [H+L] Alexa® 647 Invitrogen 1/500 
Donkey anti-Goat IgG [H+L] Alexa® 647 Invitrogen 1/500 
Donkey anti-Rat IgG [H+L] Alexa® 488 Invitrogen 1/500 
Donkey anti-Rabbit IgG [H+L] Alexa® 568 Invitrogen  1/500 
 
Microscopy 
Fluorescent Microscopy 
Samples prepared with fluorescent probes/dyes were imaged using a Zeiss Axio 
Microscope with a mercury lamp and filter sets for FITC, dsRed, Cy5 and DAPI, connected to 
a computer running Zeiss Zen software. Settings were set individually dependant on brightness 
intensity of each batch of samples and magnification. Overview images were acquired at 40x 
and field of view (FOV) images were acquired at 400x. An Olympus BX68 upright motorized 
microscope was also used for fluorescent probes and dyes, as well as picosirius red staining 
using cross-polarized light. Images were acquired using the RGB-colour camera at 400x 
magnification and 100x magnification respectively. Images were analysed using ImageJ 
software, cell surface area was calculated using thresholding to identify positively labelled 
cells, and area of the cells per image was calculated. The cell counter tool was used to manually 
count positive cells per field of view, which was then standardized to per 1mm2. 
 
Confocal Microscopy 
Samples with fluorescent probes, dyes and/or tissues with a fluorescent reporter model 
were imaged using one of four confocal microscopes, a Zeiss LSM510 meta, a Zeiss LSM710, 
an Olympus FV1200 or an Olympus FV3000. Multispectral acquisition was performed in a 
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minimum of 2 phases to minimise fluorescent overlap, while also minimising the time taken 
for each acquisition, most commonly DAPI and Alexa568 (Phase 1) and Alexa488 and 
Alexa647 (Phase 2). Rainbow mice were imaged with the following channels as pre-set 
channels on the Zeiss LSM710; DAPI, mCFP, dTomato, YFP and Alexa647, using 3 phases. 
For more specific settings, please see chapter 7, methods, microscopy. The FV3000 used a 
10ND filter on the laser side to reduce laser intensity and 4 high sensitivity detectors (HSDs) 
were equipped with GaAsP photomultipler tubes (PMTs), giving high signal to noise ratios 
with minimal sample bleaching. Images were acquired at 400x, 630x or 1000x and sample 
analysis was standardised to 1mm2 to compensate for magnification and field of view 
differences. All images were analysed using ImageJ software as per analysis methods listed in 
the previous paragraph on fluorescent microscopy. 
 
Gene expression analysis 
RNA extraction 
Wounds, ears and lymph nodes were snap frozen by immersion in liquid nitrogen. The 
sample was ground into a powder with liquid nitrogen in a mortar and pestle, then immersed 
in . RNA extraction was performed using a QIAGEN RNeasy Micro Kit (Qiagen, Limburg, 
Netherlands). The powder was transferred into an Eppendorf tube containing 350µl Qiagen 
buffer RLTTM lysis buffer with the addition of 10µl β-mercaptoethanol (Sigma-Aldrich, MO, 
USA) per 1ml RLTTM. 350µl 70% ethanol was added to precipitate the RNA, and 700µl of the 
mixture was added to the RNeasy MinEluteTM spin column. Sample was centrifuged for 15s at 
10000g and flow-through was discarded. 350µl of RW1TM wash buffer was added to the 
column and spun for 15s at 10000g. Flow through was discarded. 10µl DNaseI was added to 
70µl buffer RDDTM DNA buffer and was added to each sample and incubated for 15 mins at 
25oC. 350µl RW1TM was added after 15 mins, and sample was centrifuged at 10000g for 15s, 
and flow through discarded. 500µl buffer RPETM wash buffer was added and sample was spun 
at 10000g for 15s, flow through discarded. 500µl 80% ethanol was added to the column, and 
centrifuged for 2 min at 10000g, and the collection tube was discarded. The spin column was 
transferred into a new 1.5ml collection tube and 14µl RNase-free water was added. The tube 
was spun at 10000g for 1 min to elute the RNA. RNA quality and quantity were determined 
using a nanodrop ND-1000 (Thermo Fisher Scientific, MA, USA). Acceptable quality was 
assumed with an A260/A280 value between 1.8-2.2, indicating little protein contamination. 
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Samples were not run on a bioanalyzer as these were not used for sequencing and was therefore 
deemed unnecessary. 
 
cDNA synthesis 
Extracted RNA was converted into cDNA with the use of a commercially available 
Tetro cDNA Synthesis Kit (Bioline, London, UK). A master mix was made up of the reagents 
listed in table 5. 8µl of master mix was transferred to each tube of 1µg RNA, and ultrapure 
water was used to top up each tube to 20µl. Samples were incubated in a thermal cycler, with 
the protocol at 45oC for 30min, then 85oC for 5 mins, then 4oC indefinitely. Samples were 
diluted 1:4 in ultrapure H2O then stored at -20oC until qPCR. 
 
Table 5. Tetro cDNA Synthesis per tube 
Reagent Volume 
Primer: Oligo (dT)18 1µl 
10mM dNTP mix 1µl 
5x RT buffer 4µl 
RiboSafe RNase Inhibitor 1µl 
Tetro Reverse Transcriptase (200u/µl) 1µl 
Sample RNA nµl 
RNase-free water  To 20µl 
 
Quantitative PCR 
Quantitative polymerase chain reaction (qPCR) was performed on cDNA synthesized 
from RNA extracted from tissue samples as previously described. Assays were performed with 
SYBR® Green (Applied Biosystems, CA, USA) or Taqman primers (Thermo Fisher Scientific , 
MA, USA). Primers and their corresponding sequences are listed in Table 6. All samples were 
prepared in 96 well plates, at 20µl reaction per well. The qPCR master mix is as listed in Table 
7. A StepOnePlus™ real-time PCR system (Applied Biosystems, CA, USA) was used for 
analysis. Cycling conditions were left as standard for Delta Delta CT analysis: 95oC for ten 
minutes; 40 cycles of 95oC for 15 seconds and 60oC for one minute; and 25oC for two minutes. 
Analysis was performed using Delta Delta CT analysis to calculate fold change per gene 
normalised to housekeeping genes (18S or HPRT). This was then averaged per treatment 
group, and expression level was compared between groups.  
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Table 6. Primers used in qPCR analysis 
Gene Sequence 
18S F:5’GTAACCCGTTGAACCCCATT3’ 
R:5’CCATCCAATCGGTAGTAGCG3’ 
IL-12p35 F:5’CACCCTTGCCCTCCTAAACC 3’ 
R:5’CACCTGGCAGGTCCAGAGA 3’ 
TNFalpha F:5’CACGTCGTAGCAAACCACCAAGTGGA3’ 
R: 5’ TGGGAGTAGACAAGGTACAACCC 3’ 
TGF-beta F: 5’ CACCGGAGAGCCCTGGATA 3’ 
R: 5’ TGTACAGCTGCCGCACACA 3’ 
Col1alpha2 F: 5’ GCCACCATTGATAGTCTCTCC 3’ 
R: 5’ CACCCCAGCGAAGAACTCATA 3’ 
iNOS F: 5’ CGA AAC GCT TCA CTT CCA A 3’  
R: 5’ TGA GCC TAT ATT GCT GTG GCT 3’ 
Arg1 F: 5’ AAC ACG GCA GTG GCT TTA ACC 3’  
R: 5’ GGT TTT CAT GTG GCG CAT TC 3’ 
IL-17A  Purchased: Assay ID: Mm00439618_m1  
HPRT  Purchased: Assay ID: Mm01545399_m1 
  
Table 7. qPCR components per well 
Reagent Volume 
10x SYBR Green 10µl 
Forward and Reverse Primers (10µM) 1:1 ratio 2µl 
Ultrapure H2O 5µl 
cDNA Template 3µl 
Statistical Analyses 
All statistics were performed using GraphPad Prism 7 (Graphpad software, CA, USA). 
Non-parametric data was analysed using a Mann-Whitney test, and parametric data was 
analysed using either a T-test (1v1), one-way analysis of variance (ANOVA) or two-way 
ANOVA (comparing more than 2 groups) with a post-hoc Tuckey’s or Dunnett’s test 
dependant on type of analysis required. Data was considered significant with a P-value of less 
than 0.05.   
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Chapter 3 - The role of Interleukin-23 and Interleukin-17 on chronic wound healing 
and macrophage polarisation 
An adaptation of a paper published in Federation of American Societies for Experimenta l 
Biology [FASEB], Dec 2017 DOI: 10.1096/fj.201700773R 
 
 
Interleukin-23 regulates interleukin-17 expression in wounds, and its inhibition 
accelerates diabetic wound healing through the alteration of macrophage polarisation 
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Abbreviations 
IL- Interleukin- 
D‘x’ Day ‘X’ after wounding 
BSA Bovine Serum Albumin 
EDTA Ethylenediaminetetraacetic acid 
iNOS Induced nitric oxide synthase 
LYVE1 Lymphatic Vessel Endothelial Hyaluronic Acid Receptor 1 
CD206 Also known as mannose receptor (MRC1) 
MMP Matrix metalloproteinase 
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Abstract 
Introduction: Inflammation is a critical phase in the healing of skin wounds. Excessive 
inflammation and inflammatory macrophages are known to cause impaired wound closure and 
outcome. This prompted us to test the role of IL-23 in IL-17 expression, and in modulat ing 
wound inflammation and macrophage polarisation.  
Methods: Four 6mm full thickness wounds were created on the dorsal surface of 
multiple genetically modified mouse models. Obese, diabetic mouse wounds were treated with 
anti-IL-17A, anti-IL-23 or isotype matched antibodies.  
Results: IL-23 but not IL-12 deficient mice displayed significantly reduced IL-17 
expression in wounds. This was rescued by delivery of recombinant IL-23. IL-23 and IL-17 
deficient mice showed a significant increase in non-inflammatory macrophages. Obese diabetic 
mice treated with anti-IL-17A and anti-IL-23p19 blocking antibodies had significantly 
improved wound re-epithelialisation. Similarly IL-17-/- obese mice had accelerated wound 
closure, resulting in reduced iNOS expression and inflammatory macrophages while 
maintaining pro-healing CD206 and Lyve 1 expressing macrophages.  
Conclusion: This study highlights the importance of the IL-17 pathway in wound 
closure offering new possibilities of therapeutic intervention in chronic wounds. 
 
Key Words 
Chronic wound healing; antibody therapy; inflammation 
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Introduction 
Non-healing chronic wounds are a prevalent, increasing global issue, due to the rise in 
the incidence of diabetes, obesity and an ageing population. Normal skin wound healing is a 
complex process triggering overlapping phases of inflammation, proliferation and remodelling. 
More recent studies have highlighted the importance and dominant role of alternative ly 
activated macrophages in resolving inflammation and driving re-epithelialisation, collagen 
production and deposition during the proliferation and remodelling phases (1-5). On the 
contrary, inflammatory macrophages have been demonstrated as a causal factor in the onset of 
ulcers in humans due to venous insufficiency or diabetes (6, 7). In these chronic ulcers, 
excessive inflammation has been shown to result in increased protease degradation of growth 
factors and extracellular matrix components, as well as a reduction of the sensitivity of 
epidermal cells to growth factors such as insulin growth factor 1 (IGF1) (8). It is therefore 
tempting to speculate that modulation of the inflammatory phase may strongly impact on 
wound healing success. 
However, modulation of inflammation has proven difficult because recruited 
macrophages are heterogeneous in function. Studies that non-selectively abrogate macrophage 
populations or affect molecules important in their recruitment significantly delay wound 
healing (9-11). Recent studies by us and others, have closely examined the kinetics of different 
populations of monocyte/macrophages infiltrating the wound bed. Pro-inflammato ry 
macrophages characterised by CCR2 or Ly6cHi expression in mice, or CCR2- CD14++ CD16+ 
in humans infiltrate the skin concomitantly to neutrophils (4, 12). These macrophages often 
described as M1, cause excessive inflammation by producing TNFα, which increases fibrosis 
and scarring (13). M1 macrophages also synthesize nitric oxide (NO) as part of their 
cytotoxic/cytostatic function against pathogens, primarily through inducible nitric oxide 
synthase (iNOS). This inflammatory wave is rapidly followed by Ly6cLo MHC class IIHi 
macrophages reported to express CD163, CD206, LYVE-1, and many other typical markers of 
alternatively activated macrophages, often described as M2. These have a leading role in 
immune regulation and are associated with tissue repair (14, 15). There is still discrepancy as 
to which inflammatory cytokines are essential for wound healing and closure, and which are 
detrimental, such as TNFα (16, 17). It is therefore important to find interventions that target 
the former inflammatory M1 macrophages without affecting the latter, pro-repair M2 
macrophages.   
We have previously identified that the cytokine IL-17 plays a key role in the shift from 
pro-inflammatory to pro-repair macrophages in the wound (12). In the present study, we 
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decided to investigate modulation of IL-17 production by IL-23 and their comparative effects 
on wound healing associated macrophage polarization.  
 
Materials and Methods 
Mice 
All mice were bred on a C57B/6J background, with gene knockouts of IL-17-/-, IL23P19-
/-, IL-12P35 -/- and IL12/23P40-/- being bred at Herston Medical Research Centre. Ob/Ob, Ob/Ob 
IL-17-/- and Ob/Ob IL-17+/- mice were bred from the same parent lines. Mice were wounded 
after 6 months of aging, to promote the chronic wound healing phenotype. Equal numbers of 
males and females were used. All mice were treated in accordance with institutional ethics 
approvals and guidelines for the care of experimental animals.  
Experimental Procedures 
Wounding was performed as per previous literature (18). Mice were anaesthetized 
under isoflurane gas inhalation at 2% in 100% O2. Mice were shaved, had remaining hair 
removed via depilatory cream (Veet), and the area of wounding was cleaned using 10% 
Povidone-Iodine solution. 4x 6mm full-thickness wounds were created on the dorsal surface of 
each mouse using a 6mm punch biopsy. Mice were given 10uL children’s Panadol once daily 
until they no longer showed signs of discomfort. 
Antibody injection: 
Mice were wounded as per the above protocol. Immediately after wounding, anti-
mouse-IL-17A, IL-23p19 and Isotype-matched control antibodies (eBioscience, Cat no. 16-
7173, 16-7232, 16-4714, 16-4301 respectively) were intradermally injected in PBS into the 
peri-wound area, at a final dose of 25µg/mouse, as previously reported. This was applied daily 
into the wounds up to D3 post-wounding.  
Recombinant IL-23 injection: 
 Recombinant IL-23 (eBioscience, Cat no. 14-8231) was injected into P19-/- mice at D0-
2 at a dose of 62.5ng in 125l per wound. Mice were then harvested at D3 post-wounding and 
wounds were collected for RNA and histology. 
Immunofluorescence Staining (Frozen sections): 
Paraformaldehyde-fixed frozen sections were used for IF. 
Slides were rehydrated in PBS + 0.1% tween-20 (PBST). Primary antibodies were 
diluted in the blocking solution (LYVE-1, MRC1, F4/80=1:200; iNOS, IL-17=1:100) and left 
to bind at 4oC overnight. Secondary antibodies (Alexa488-Goat anti-Rabbit, Alexa568-Goat 
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anti-Rat, Alexa488-Donkey anti-Rat, Alexa568-Donkey anti-Rabbit & Alexa647-Donkey anti-
Goat) were diluted in blocking solution at a ratio of 1:500 and left to incubate at room 
temperature for 1 hour. Slides were counterstained with DAPI (300nM) and mounted with 
Dako fluorescent mounting media (Agilent Technologies).  
Immunofluorescence Image Analysis 
Images were analysed using ImageJ software.  
F4/80, iNOS, IL-17, LYVE-1 and MRC-1 stains were analysed by counting the number 
cells positively labelled by their respective antibodies per micrograph. Three images per 
section in the granulation tissue were taken at 40X or 60X magnification, and the image was 
standardized to remove background florescence so only positive cells were identified using 
ZEN Black edition (Carl Zeiss). 
Multicolour Flow Cytometry: 
Wounds were minced and washed through a 70m cell strainer using PBS + 0.5% w/v 
Bovine Serum Albumin (BSA) + 2µM Ethylenediaminetetraacetic acid (EDTA) (Referred to 
as PBE from hereon). The cell suspension was layered on Histopaque®-1083 (Sigma-Aldrich) 
to collect the mononuclear cell layer. Cells were blocked with anti-CD16/32 Fc-block and 
FVS510 live/dead marker (BD Biosciences) for 10-mins before cell surface staining. Cells 
were then stained with MHCII-FITC, CD11b-Per-CP Cy5.5, Ly6c-Apc-Cy7 (Biolegend) and 
NK1.1-PE and Ly6g-PE (BD-Biosciences). Concentrations were 1:200, for all except MHCII 
at 1:100, and FVS510 at 1:500. Incubation was at 4oC for 40mins. Gating strategy is depicted 
in Figure 3. 
A Beckman-Coulter Gallios™ Flow cytometer was used for sample acquisition and 
analysis was completed using Kaluza® software (Beckman Coulter Inc).  
Xenogen live imaging: 
Mice were imaged on the day of wounding and several timepoints up to 14 days post-
wounding. Images were analysed using ImageJ software, where the circumference of each 
wound was individually measured, and the total area was noted. The wounds were tracked 
throughout the two weeks, and the wound size was calculated as a percentage of the init ia l 
wound size.  
Statistical Analysis: 
All statistical analyses were performed using Graphpad Prism 6. For antibody vs 
control tests, an unpaired T-test was used. For WT vs IL-12/23KO vs IL-17KO mice, and 
Obese Isotype vs IL-23Ab and IL-17Ab groups, an ordinary ANOVA was used to identify 
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significant differences between the means of multiple groups. If the ANOVA was significant, 
a post-hoc Dunnett test was used to identify the significant differences between the WT (as 
control) and experimental groups. Brown-Forsythe and Bartlett’s tests were used to determine 
differences between standard deviations. Results were considered significant if the P-value was 
less than 0.05. Results are displayed as the mean and standard deviation. *P<0.05, **P<0.01, 
***P<0.001 
 
Results 
IL-23 deficiency impairs IL-17 production in the wound 
Since IL-23 is known to tightly regulate IL-17 expression in T-cells, we examined mice 
deficient in IL-23 subunits, IL-23p19-/- (P19-/-) or IL-12/23p40-/- (P40-/-). An IL-12p35-/- (P35-/-) 
knockout model was also used as a control to determine if the P40 subunit deficient mice had 
a phenotype related to an IL-12 or IL-23 dependent mechanism. We also used an IL-17-/- mouse 
to determine if the IL-23 knockouts were as effective as the IL-17 knockout. All knockout 
strains were compared to WT mice on the shared C57Bl/6 genetic background. We used 
immunofluorescent staining against IL-17A to count the number of cells producing IL-17 in 
wild-type and knockout wounds at day 3 (D3) post-wounding. All evaluation was performed 
blinded to the murine genotype. In control IL-17-/- wounds, no staining could be observed. We 
observed significantly reduced IL-17 producing cells in IL-23 subunit knockout mice, but not 
in P35-/- compared to control (Figure 1a,b). Furthermore, IL-17 expression could be 
significantly recovered by the addition of recombinant IL-23 via injection directly into the 
wound of P19-/- mice, and was identified at both a protein level using IF (Figure 1c) and RNA 
level using qPCR (Figure 1d). 
There is some discrepancy about the source of IL-17 produced in the skin, with reports 
showing that macrophages, neutrophils, γδT-cells and Th17 cells are able to express IL-17 (12, 
19, 20). Using a reporter mouse model, we labelled any cell that has expressed the promoter 
for IL-17A with YFP. Flow cytometric analysis revealed that the exclusive population marked 
with YFP was the CD3ε/Ly6g/NK1.1 dump channel positive, CD11b- population, indicat ing 
the only cells expressing IL-17A in skin wounds are non-myeloid cells expressing CD3ε and/or 
NK1.1 which identifies T or natural killer cells (Supplementary Figure 1a-c). Further flow 
cytometric analysis revealed that the majority of T-cells expressing IL-17 are γδT-cells, with a 
significantly increased population in old Ob/Ob mice (6 months) compared to young Ob/Ob (8 
weeks) or WT mice (Figure 2a). We also compared the differences in T-cell populations 
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between aged obese, young obese and wild-type mice. We found significantly more 
inflammatory T-cells in obese mouse wounds compared to WT, with a greater number of 
gamma-delta T-cells, and CD4+ Th1 and Th17 cells found in obese mice compared to WT 
(Figure 2b,c). What was interesting to note was the significantly increased number of IL-17 
expressing γδT-cells in aged obese mice compared to young obese mice, indicating that the 
chronic wounds of aged, obese mice express more IL-17 than the non-chronic wounds of young 
obese mice (Figure 2d). However, there was no significant differences in the % of IL-17 
expressing cells (Figure 2e).  
 
IL-23p19 deficiency reduces neutrophil infiltration and promotes alternatively-activated 
macrophage polarization. 
We next investigated changes in leukocyte infiltration into the wounds over time, using 
flow cytometry. CD11b+Ly6g- cells were defined as macrophages, while CD11b+Ly6g+ cells 
were defined as neutrophils. The macrophage population was further separated into 4 
categories based on Ly6c and MHCII expression (Figure 3a). We have previously analysed 
these populations based on gene expression studies on FACS sorted populations (12) which 
revealed that; Ly6clo MHCIIhi macrophages are associated with a pro-healing phenotype, while 
Ly6chi MHCIIlo were pro-inflammatory. Total cell count analysis revealed a significant 
impairment in D2-neutrophil recruitment in both IL-12 and IL-23 subunit knockout groups, 
that correlated with a reduced wound associated macrophage (WAM) counts in the IL-12 
subunit knockouts (Figures 3b,c). However, by D4 this difference was no longer significant. 
Analysis of WAMs showed a significantly increased population of Ly6clo MHCIIhi WAM in 
the P19-/- group compared to control, at both D2 and D4 post wounding recapitulating our 
previous observations for IL-17-/- mice (Figure 3c) (12).  
Macrophage polarisation was further confirmed using immunofluorescence. 
Macrophage phenotypes were identified based on their cell surface markers at D3 post-
wounding. The combination of F4/80 and iNOS was used to define the inflammato ry 
population (Figures 4a-b) and F4/80, LYVE-1 and CD206 was used to identify the non-
inflammatory ‘pro-healing’ population of macrophages (Figure 4c-f). Quantification on stained 
wound sections revealed a significant decrease in inflammatory macrophages across IL-17-/-, 
P19-/- and P35-/- strains, although not in P40-/- (Figure 4g). The IL-17-/- and the IL-23 subunit 
knockout groups showed a significant increase in LYVE-1 expressing pro-healing 
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macrophages compared to wild-type (WT) mice (Figure 4h). Only the IL-17-/- wounds showed 
a significant increase in CD206 expression compared to WT wounds (Figure 4i).  
 
Inhibition of IL-17 and IL-23p19 in a chronic wound healing model improves wound closure  
After identifying a change in macrophage polarization, but without affecting wound 
closure (Supplementary figure 5), we wanted to determine if an improved wound closure 
phenotype could be identified under conditions of chronic wounds. We wounded obese diabetic 
mice deficient in leptin (ob/ob) that display a delay in wound healing, and injected either 
recombinant anti-IL-23p19, anti-IL-17A or isotype-matched control antibodies into the 
wounds daily for three days. Macroscopic measurements of the wounds over 14 days revealed 
significant improvements in wound closure in the antibody treated mice compared to isotype 
treated controls (Figure 5a,b). Isotype control-treated diabetic mice did not display any level 
of healing over the first 14 days clearly reflecting the course of a chronic diabetic wound. Both 
anti-IL-17 and anti-IL23 treatment significantly improved wound closure and no difference 
could be observed between these different regimen. Wounds were harvested at D4 and D14, 
and stained for macrophage populations. We observed an increased percentage of pro-healing 
macrophages through IF staining, however total cell numbers of LYVE1+ macrophages 
remained the same suggesting a reduction in inflammatory macrophages (Figure 5c-f).  
To confirm these observations and the specificity of the effect of anti-IL-17 antibodies 
we next used a knockout model of IL-17 on obese mice (ob/ob IL-17-/-) compared to a 
heterozygous littermate control (ob/ob IL-17+/-), we found improved wound closure 
macroscopically (Supplementary Figure 2a), and reduced iNOS+ cells in the granulation tissue 
(Supplementary figure 2b-d).  
 
Discussion 
Wound inflammation is an important phase of healing. It is a fine balance, as both 
defective and excessive inflammation result in delayed healing. This is in part related to the 
dual role of macrophages as effectors of cellular immunity but also as drivers of tissue repair. 
The molecular determinants of this macrophage polarisation in the context of wound healing 
are still to be fully understood. IL-23 but not IL-12 deficiency resulted in a marked reduction 
of IL-17 production. IL-17 as well as IL-23 inhibition or deficiency significantly impacted on 
macrophage polarisation. In both cases, a significant shift in the proportion of M1/M2 
macrophage populations could be observed. However, whether this was due to modulation of 
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polarization, impaired recruitment or altered survival of specific populations will need further 
investigation. Finally, this change in macrophage polarisation was associated with reduced 
inflammation in wounds in normal and obese diabetic mice with reduced iNOS expression and 
reduced neutrophil recruitment. This modulation of inflammation by IL-17 or IL-23 blocking 
antibodies or by IL-17 deficiency resulted in accelerated wound closure in obese diabetic mice.  
The ability of IL-17 to control iNOS expression, could be the leading mechanisms 
behind the increased rate of wound closure. Previously demonstrating that IL-17 knockout 
reduces the number of inflammatory macrophages, we believe that inhibiting IL-17 changes 
the inflammatory phenotype of macrophages, which globally reduces the inflammation in the 
wound, specifically through the reduction in nitric oxide synthesis. Similar to IL-17 deficiency, 
a reduction in iNOS-positive macrophages was also observed in both IL-12 and IL-23 
knockouts compared to WT. IL-12 is an inflammatory cytokine whose expression is also 
known to strongly correlate with iNOS expression in M1 macrophages. This effect might be 
through the induction of IFNγ, which in turn activates iNOS expression in macrophages. A 
potential explanation for the differences identified between the IL-12 and IL-23 deficient 
animals might reside in the significant global reduction in macrophage numbers in P35 -/- mice 
observed in our study. This large and significant decrease in macrophage numbers might 
replicate the phenotype observed upon macrophage depletion delaying wound healing (9). 
Finally, IL-17 and TNFα are reported to sustain neutrophil recruitment. The detrimental effects 
of neutrophils have also been previously reported (19), where neutrophil-depleted mice had a 
significant improvement in acute wound closure. Both IL-23 and IL-17 deficiency resulted in 
reduced neutrophil numbers. 
Ob/Ob mice have a point mutation invalidating the leptin gene, leading to excessive 
consumption of food from a young age. These mice develop chronic obesity and display 
delayed wound healing associated with an increased percentage of inflammato ry 
monocytes/macrophages and a delayed switch towards alternatively activated macrophages 
during the healing process (Goren, Muller et al. 2006, Rodero, Hodgson et al. 2013). This 
mouse strain has been recognized as one of the most reliable models of diabetic wound healing, 
due to increased lipid deposition from excessive, chronic caloric intake and associated chronic 
low-grade inflammation mimicking human phenotypes of type-2 diabetes (Goren, Muller et al. 
2006, Seitz, Schurmann et al. 2010, Pereira and Alvarez-Leite 2014). Ob/Ob mice are known 
to have prolonged inflammation compared to WT mice and imbalances in wound proteases 
and their inhibitors (Schurmann, Goren et al. 2014, Gao, Nguyen et al. 2015). In accordance 
with our findings, previous studies have reported better wound outcomes when blocking TNFα 
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in Ob/Ob mice (17). Part of that effect was through better insulin/IGF-1 receptor signalling in 
keratinocytes. Whether IL-17 improves the healing through additional/independent ways 
compared to TNFα inhibition remains to be elucidated. Although Ob/Ob mice are the most 
reliable animal model of diabetic wound healing, it is incredibly difficult to replicate true 
chronic wounds in animal models due to genetic differences, as well as experimental conditions 
(Ansell, Holden et al. 2012). Some of the major differences between murine and human chronic 
wounds is the mechanism of wound closure in murine skin (contraction), the immune system 
where mice have different resident immune populations such as dendritic epidermal T-cells, 
and of course the method of wound formation, which is artificially induced in animal models 
and which heal, whereas a true chronic wound will not heal at all. Whether these differences 
prevent a direct translational effect still remains to be elucidated, although evidence suggests 
that despite more than 1000 papers published on different wound therapies in animal models, 
only one (human platelet-derived growth factor subunit bb (PDGFbb)) is now approved and 
used in a clinical setting for human therapy (Ansell, Holden et al. 2012).  
In summary, our study further clarifies the importance of IL-23 and IL-17 as major 
determinants of macrophage polarisation in skin wounds. Their modulation resulting in 
improved healing constitutes a potential therapeutic option of chronic wounds harbouring 
excessive inflammation. In particular, targeting these cytokines did not alter macrophage 
recruitment globally to the extent of delaying wound closure as observed for IL-12. The current 
development of anti-IL-17 and anti-IL23 (p19 subunit) targeted therapy in inflammato ry 
disorders could represent a novel opportunity for the molecular therapy of chronic wounds. 
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Figure 1: IL-17 expression in skin wounds 
(a) Representative photomicrographs of IL-17A (green) stained using immunofluorescent 
probes on C57Bl/6 (WT) IL-17-/-, P19-/-, P35-/- and P40-/- wounds. Scale bar = 50µm. (b) Bar 
graph histogram representing the number of IL-17A producing cells in the granulation tissue 
from the different strains per high-powered field (HPF). ****P<0.0001, *P<0.05 N=4 mice. 
(c) Representative photomicrograph of IL-17 expressing cells (green) in P19-/- mice treated 
with PBS (control) or recombinant IL-23 (rIL-23). (d) Relative RNA expression of IL-17A 
from P19-/- murine wounds treated with rIL-23 compared to control. Scale bars = 50µm. 
*P<0.05 N=3 mice. Error bars represent mean±SD. 
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Figure 2: IL-17 expression from T-cells in skin wounds 
(a) Representative flow cytometry plots of T-cell analysis from skin wounds. Cells were gated 
on CD45+ and Live (not shown), before being further identified by CD3+ and ɣδ TCR+/- 
expression. CD3+ ɣδ TCR- cells were further gated on CD8 and CD4, and CD3+ CD4+ cells 
were gated on IFNɣ for Th1 and IL-17A to identify Th17 cells. ɣδ TCR+ cells were also gated 
on IL-17A expression. (b) Absolute count of Th1 cells (CD3+CD4+IFNɣ+) between WT 
(C57Bl/6), young Ob/Ob mice and old Ob/Ob mice. (c) Absolute count of Th17 cells between 
groups. (d) Absolute count of IL-17A expressing ɣδ T-Cells between groups. (e) Percentage 
of IL-17A expressing ɣδ T-Cells between groups. * P<0.05 compared to Young Ob/Ob group. 
+ P<0.05 compared to WT group. ++ P<0.01 compared to WT group. Unlabeled = not 
significant between any groups. N=3-4 mice per group. Error bars represent mean±SD.  
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Figure 3: Macrophage polarisation in knockout mice using flow cytometric analysis  
Flow cytometry analysis of wound infiltrates collected at D2 and D4. (a) Wound Associated 
Macrophage (WAM) population was identified as CD11b+Ly6g-, and neutrophils as 
CD11b+Ly6g+. WAM were further analysed based on Ly6c and MHCII cell surface 
expression. Representative plot charts for the different IL-12/23 subunit knockout strains 
compared to WT. (b) Total cell counts of wound-associated macrophages at D2 and D4. (c) 
Total cell counts of neutrophils in the wound at D2 and D4. (d-g) Histograms of the different 
macrophage populations based on Ly6c and MHCII expression, at D2 and D4 post-wounding. 
*P<0.05, **P<0.01 N=3-7 mice from 2 independent experiments. No * = Not significant. Error 
bars represent mean±SD.  
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Figure 4: Macrophage polarisation in knockout mice using immunofluorescence  
Representative photomicrographs of cell surface markers to identify macrophage phenotype. 
(a) iNOS (Red) (b) F4/80 (Green) (c) LYVE1 (Red) (d) F4/80 (Green) (e) CD206 (Purple) (f) 
Merged of LYVE1, F4/80 and CD206. Scale bar = 50µm. Histograms of the percentage of cells 
expressing both F4/80 and (g) iNOS (h) LYVE-1 or (i) CD206 among all F4/80 positive cells. 
N=3 to 7 mice from 2 independent experiments depending on strain and time point. 
*P<0.05;**P<0.01. Error bars represent Mean±SD. 
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Figure 5: IL-17 and IL-23 inhibition accelerate diabetic wound healing 
(a) Macroscopic measurement of wound closure in ob/ob mice treated with either isotype 
control IgG, anti-IL-17 antibody or anti-IL-23 antibody. (b) Representative photographs from 
wounds showing wound size at D14 post-wounding. Yellow dotted lines indicate edge of an 
open wound. (c) Photomicrographs of immunofluorescent staining of skin wounds from treated 
and untreated mice at D4 for F4/80 (green) and LYVE1 (red) and merged. DAPI for nuclear 
staining is blue. Top is isotype control, middle is anti-IL-17A and lower is anti-IL-23A treated 
wounds. Scale bar = 50µm (d) Histogram of number of F4/80+ cells per high powered field 
(HPF). (e) Histogram of percent of LYVE1+ F4/80+ cells reported to total F4/80+ cells per 
HPF. (f) Total number of LYVE1+ F4/80+ cells per HPF. N=4-10 mice, 4 wounds per mouse 
depending on time point from 2 independent experiments. *P<0.05 
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Supplementary Figure 1: Lineage tracing of IL-17A expressing cells  
(a) Representative flow cytometry plots for gating strategy used for leukocyte identification. 
Cells were gated based on forward and side scatter, then selected for singlets. Dead cells were 
excluded, and live cells were sorted based on CD11b and a Ly6g, NK1.1 and CD3 dump 
channel. CD11b+Exc- were defined as macrophages, CD11b+Exc+ were defined as 
neutrophils/NK cells and CD11b-Exc+ were defined as T-cells. (b) Mouse wounds from IL-
17-Cre x RosaYFP cells were sorted into the three aforementioned populations and gated on 
YFP+ cells. Only the T-cell population has a significant number of YFP+ cells. (c) A YFP- 
control mouse was used to define the gating of YFP+ cells and identify false positive staining.  
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Supplementary Figure 2: Obese mice deficient in IL-17 have improved initial wound 
healing and reduced inflammatory macrophages  
(a) Line graph showing the rate of macroscopic wound closure between Ob/Ob x IL-17-/- and 
Ob/Ob x IL-17+/- mice. (b) Representative photomicrographs of F4/80 and iNOS staining in 
Ob/Ob x IL-17-/- and Ob/Ob x IL-17+/- mouse wounds at D3. (c) Histogram of total F4/80+ 
cells per high powered field (HPF). (d) Histogram of iNOS+ macrophages per HPF. 
***P=<0.001, N=5 mice per group, Scale bar = 50µm 
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Supplementary Figure 3: RNA expression analysis on Ob/Ob antibody-treated wounds  
Bar graph histograms of relative fold change of RNA expression between IL-17Ab, IL-23Ab 
and Isotype Ab treated obese mouse wounds at D5. Expression was normalised against isotype 
antibody treated (control) wounds. The following targets were: (a) IL-12p35 (b) IL-6 (c) TNFα 
(d) TGF-β (e) Col1a2. **P<0.001 n = 3 mice per group, 2 wounds per mouse 
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Supplementary Figure 4: IL-17 and IL-23 does not affect fibrosis and scarring  
(a) Representative photomicrograph of alpha smooth muscle staining (green) and DAPI 
counterstain (blue). Scale bar = 200μm. (b) Bar graph histogram comparing area per 
photomicrograph expressing αSMA+ cells. (c) Representative images of the different treatment 
groups using picrosirius red staining under cross-polarised light. N=3 mice per group. 
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Supplementary Figure 5: Rate of wound healing in IL-23p19, IL-12p35 and IL-12/23p40 
compared to WT mice  
(a) Rate of wound healing for mice deficient in IL-23p19 vs WT (b) Rate of wound healing for 
mice deficient in IL-12p35 vs WT (c) Rate of wound healing for mice deficient in IL-12/23p40 
vs WT. No significant differences.  
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Chapter 4 - The role of Interleukin-33 receptor; ST2 on acute wound healing 
Chapter published in Experimental Dermatology, Jan 2016. DOI: 10.1111/exd.12833 
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Abstract: 
Skin wound healing is a complex multistep process involving multiple cell types 
including keratinocytes, fibroblasts, endothelial and immune cells, mainly from the myelo id 
lineage. Despite evidence that the abundant alarmin IL-33 affects the biology of endothelia l 
cells and macrophages, the role of this molecule and its receptor ST2 remains unclear. Here, 
we studied the effect of ST2 invalidation on acute skin wound closure, angiogenesis and 
inflammatory status. ST2-/- mice had delayed wound closure compared to BALB/C controls. 
Increased inflammation in the wound was found in ST2-/- compared to control, with an 
increased number of neutrophils and a shift in macrophage polarization toward a pro-
inflammatory phenotype. ST2-/- mice displayed reduced angiogenesis in the granulation tissue 
at D5 post-wounding. There was an increase in the collagen I/III ratio in the ST2-/- compared 
to control mice. Our results indicate that ST2 receptor affects several aspects of the wound 
healing including macrophage polarization and control of the wound inflammation. 
 
Background: 
Wound healing consists of multiple consecutive, overlapping phases of inflammation, 
proliferation and remodelling. Acute wounds initiate an early inflammatory response, 
implicated in altering the subsequent phases of healing (Mirza, DiPietro et al. 2009, Rodero 
and Khosrotehrani 2010). However, the effects of inflammation on wound closure rate and 
regeneration quality remain obscure. PU1 KO mice (deficient in myeloid lineage) and 
neutrophil-depleted mice have improved wound healing  (Dovi, He et al. 2003, Oboki, 
Ohno et al. 2010), while depletion of macrophages results in delayed healing (Rodero, Legrand 
et al. 2013). The initial triggers of inflammation upon injury are still enigmatic. Interleukin-33 
(IL-33), by its alarmin-like function could be implicated in the initiation of inflammation as 
other members of the IL-1 family (Haraldsen, Balogh et al. 2009). Increased expression at the 
RNA and protein levels after wounding support an important role for IL-33 in skin wound 
healing (Yin, Li et al. 2013). IL-33 upon synthesis is stored in the nucleus where it has 
regulatory activities over NFkB transcriptional activity. When released extracellularly it binds 
to its receptor ST2 (Choi, Choi et al. 2009, Haraldsen, Balogh et al. 2009). ST2 exists in two 
isoforms, a membrane-bound receptor (ST2L) or a soluble form acting as a decoy receptor 
(sST2). Here we used ST2-/- mice to assess if the action of IL-33 during wound healing was 
through the interaction with its receptor ST2 or related to its nuclear transcriptional activity. 
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Questions addressed: 
Does the genetic ablation of ST2 result in altered skin wound inflammation, 
angiogenesis and overall closure? 
 
Experimental design: 
Four full-thickness skin wounds were performed on T1/ST2-deficient mice (ST2-/-) 
created on a BALB/C background (Brint, Xu et al. 2004) and wild-type (WT) (BALB/C) 
controls. Wounds were imaged daily and collected at 4, 5, 7 or 14-days post-wounding. Wound 
closure was measured by standardized digital photographs and kertain-14 staining. Neutrophil 
and macrophage subset infiltration of the granulation tissue was evaluated by flow cytometry, 
and angiogenesis was evaluated by CD31 immunofluorescence. Collagen content was assessed 
by pico-sirius red staining (see supplementary methods).  
 
Results: 
ST2 genetic ablation impairs skin wound closure, angiogenesis and remodeling. 
Wound closure analysis revealed no observable macroscopic differences in wound 
surface between the Balb/C controls and ST2-/- mice (Figure 1A-B). However, analysis of 
wound cross-sections using keratin-14 staining at D5 post injury identified significantly 
improved re-epidermisation of the wound surface in WT mice (Figure 1 C-D).  
ST2 is highly expressed in endothelial cells (Choi, Choi et al. 2009) prompting us to 
analyse wound angiogenesis. Wound sections at D5, the peak of angiogenesis, were stained 
using the pan-endothelial marker CD31. ST2-/- mice displayed a significant, 45% reduction in 
the area of CD31 staining within the granulation tissue (WT: 11.2+/-5.7%; ST2: 7.0 +/-3.8%, 
p=0.018) (Figure 1E-G).  
Multiple links have been identified in the literature between inflammation and collagen 
deposition and scar formation (Rodero and Khosrotehrani 2010, Nucera, Biziato et al. 2011, 
Madsen, Leonard et al. 2013). Therefore, we stained fully closed D14 wounds with pico-sirius 
red identifying the different collagen fibers by their birefringence under polarized light  
(Junqueira, Bignolas et al. 1979, Cuttle, Nataatmadja et al. 2005). We observed a marked 
increase in thick type I collagen fibers, and a decrease in the thinner type III collagen in ST2-
/- wounds (figure 1H-J). 
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ST2 deficiency affects macrophage and neutrophil recruitment and differentiation 
Macrophage polarization has been reported to change during the healing in normal 
wounds (Rodero and Khosrotehrani 2010, Rodero, Hodgson et al. 2013). We harvested wounds 
at D4, a time point when the majority of the shift in wound macrophage polarization occurs 
from pro-inflammatory to pro-repair (Rodero, Hodgson et al. 2013), and analysed macrophage 
populations (CD11b+Ly6g-/low). No difference was found in global macrophage numbers, 
however the proportion of pro-inflammatory, Ly6chiMHCIIlo macrophages was significantly 
increased in ST2-/- mice compared to control (Figure 2A-E). In concordance with lack of 
transition from inflammatory to pro-repair macrophages, neutrophils (CD11b+Ly6G+), also 
represented a significantly higher proportion of myeloid cells in ST2-/- mice (Figure 2F). 
Conclusions: 
Our preliminary results suggest that ST2 receptor signalling improves wound closure 
and promotes angiogenesis while preventing or delaying fibrosis and scarring. The downstream 
signalling of the receptor complex of ST2L has been reported to involve MyD88 (Macedo, 
Pinhal-Enfield et al. 2007). Our findings recapitulate similar observations of MyD88 deficient 
mice that demonstrated slower healing with reduced levels of Ly6clo MHCIIhi pro-repair 
macrophages compared to control (Macedo, Pinhal-Enfield et al. 2007). It is therefore expected 
that the effects of the ST2 receptor on skin wound healing are conducted through canonica l 
signalling. 
IL-33 signalling through ST2L promotes T-helper 2 (Th2) responses, via the promotion 
of Th2 cytokines such as IL-4, IL-5 and IL-13 (Schmitz, Owyang et al. 2005). ST2 could also 
be activated by IL-1β, with much lower affinity (Reikerstorfer, Holz et al. 1995). This shift is 
not only limited to T-cell responses, as macrophages have also been noted to adjust their 
responses based on ST2 expression, notably in sST2 (Jetten, Verbruggen et al. 2014). sST2 is 
reported to act as a decoy receptor for IL-33, also with the ability to inhibit macrophage-
dependant inflammation (Trajkovic, Sweet et al. 2004). This is most likely through IL-33-
induced production of IL-4 and IL-13, which are polarizing agents for M2a differentiation in 
vitro (Martinez, Sica et al. 2008). Whether the observed effects of ST2 invalidation on wound 
closure, angiogenesis and fibrosis are exclusively the consequence of these inflammato ry 
changes could not be addressed here. 
Fetal wound healing is generally considered the ideal model of wound closure, with 
multiple studies demonstrating little to no inflammation (Larson, Longaker et al. 2010). In 
addition, a higher ratio of type III to type I fibres upon fetal wound healing, is associated with 
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minimal to no scar formation (Cheng, Yan-hua et al. 2013). We found that with the increased 
inflammation in our ST2-/- mice, we had decreased type III collagen deposition, and increased 
type I collagen in the wound, indicating a worse scarring outcome. However, the short course 
of our observations (14 days) makes it difficult to draw conclusions on the long term 
remodelling of the wound in this model. 
In conclusion, we believe that ST2 receptor promotes the transition from inflammato ry 
to non-inflammatory macrophages during wound healing, supporting epidermal closure, 
wound angiogenesis and reduced scarring.  
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Figure 1: Stages 
of wound healing: (a) 
Wound closure was 
measured by 
standardized imaging 
using a Xenogen CCD 
camera. (b) Wounds 
were photographed every 
day and wound are was 
measured as a percentage 
of wound size on D0. (c) 
Re-epidermization was 
measured using keratin-
14 staining and closure 
was assessed by the neo-
epidermal length from 
the last hair follic le 
(LHF) to the epithelia l 
edge (EE). Scale bar = 
1mm (d) There was 
significantly less neo-
epidermis in the ST2-/- 
mice compared to WT. 
N=7 mice, 4 wounds per mouse from two independent experiments.  (e) A representative image 
of CD31 staining. Angiogenesis was measured using CD31 staining to label endothelial cells 
(red). Green was used as an open channel. Scale bar = 50µm (f) CD31 staining was measured 
in relative surface area of the high-powered field in the centre of the granulation tissue. There 
was a significant reduction in CD31 positive area in ST2-/- compared to control. (g) Total 
number of CD31+ vessels were counted per wound section. Representative images of pico-
sirius red staining on Balb/C (h) and ST2-/- (i) D14 wounds under polarized light. Scale bar = 
1mm (j) There was a significant difference found in collagen fibre types between WT and ST2-
/- wounds. N=4-7 mice, 4 wounds per mouse from 2 independent experiments. 
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Figure 2: Flow cytometry on wound leukocyte population: (a, c) Macrophages were gated 
as CD11bhi, Ly6gNeg-lo. Neutrophils were gated as CD11bhi Ly6ghi. (b, d) Macrophages were 
further analysed for Ly6c and MHCII expression. Macrophages were analysed as a percentage 
of total leukocytes, and subpopulations were also measured as a percentage. (e) Analysis 
revealed a significant difference between WT and ST2-/- wounds in Ly6c+MHCII-  
macrophages. (f) There were no significant differences between macrophage numbers, but 
there was a significant increase in the neutrophil numbers in ST2-/- mice. N= 5-6 mice, 4 
wounds per mouse.  
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Supplementary Materials and Methods  
Mice  
WT and ST2 deficient mice Balb/C were use in this study. Mice were wounded 
between 8-12 weeks of age, with equal numbers of males and females. All mice were treated 
in accordance with institutional ethics approvals and guidelines for the care of experimental 
animals.  
 
Wounding:  
Mice were anaesthetized using 2% isoflurane (Bomac, Australia) in O2 for 5 minutes. 
The dorsal skin was shaved using an electric razor, and depilatory cream (Veet, Reckitt 
Benckiser) was applied for 60 seconds. Once the majority of dorsal hair had been removed, 
70% ethanol was applied for 5 minutes. Four full-thickness wounds were generated using a 
6mm punch biopsy (Stiefel Laboratories, Research Triangle Park, NC).  
 
Flow Cytometry:  
Mice were sacrificed on days 2, 3 and 4 post-wounding via CO2 asphyxiation, and the 
back skin was removed. Each wound was trimmed to remove excess subcutaneous tissue, and 
the wounds were excised from the surrounding skin. All four wounds were briefly minced 
using scissors, and washed through a 70nm cell strainer using PBS + 0.5% w/v Bovine 
Serum Albumin (BSA) + 2μM Ethylenediaminetetraacetic acid (EDTA) (PBE). The cell 
suspension was added to Histopaque®-1083 (Sigma-Aldrich Inc, Steinheim, Germany) and 
centrifuged for 30mins at room-temperature. The leukocyte cell layer was collected and 
resuspended in PBE. The cells were stained with MHCII-Fitc, CD11b-Per-CP Cy5.5 and 
Ly6c-PacB (Biolegend, San Diego, CA) and NK1.1-PE, Ly6g-PE (BD-Biosciences, Franklin 
Lakes, NJ). Concentrations were 1:50, for all except MHCII which were at 1:100. Incubation 
was at 4oC for 40mins.  
A Beckman-Coulter Gallios™ Flow cytometer was used for sample acquisition and 
analysis was completed using Kaluza® software (Beckman Coulter Inc, Brea, CA). 
Leukocyte first discriminated based on CD11b and Ly6g staining to identify macrophage  
and neutrophils populations. The macrophage population was further sorted based on Ly6c 
and MHCII marker expression.  
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Immunofluorescence Staining (Frozen sections):  
Mice were sacrificed on day 5 post-wounding via CO2 asphyxiation, and the back 
skin was removed. Each wound was excised from surrounding skin with 1-2mm clearance 
around each wound. Wounds were fixed in 4% paraformaldehyde for 2 hours, and then left in 
20% sucrose solution overnight. The wounds were blocked in Tissue Tek® O.C.T™ (Sakura 
Finetek, Tokyo, Japan) and frozen at -80oC until sectioned.  
Sectioning was completed on a HM550 Cryostat (Thermo Fisher Scientific, Waltham, 
MA) at -20oC. Sections were cut at 6μm and picked up on Superfrost® Plus Slides (Thermo 
Fisher Scientific, Waltham, MA) and stored at -20oC until use.  
Prior to staining, sections were circled around using a wax-based Dako pen to form a 
hydrophobic barrier. Slides were then re-hydrated in 1X phosphate buffered saline (PBS) + 
0.1% Tween 20 (PBST), then permeablized in PBS + 0.5% Triton-X (PBTX) for 10 mins. 
Sections were blocked using PBST + 1% BSA + 10% Normal Goat Serum (NGS) at room 
temperature (RT) for 30 mins. Primary antibodies were diluted in the blocking solution 
(K14=1:1000; CD31=1:200) and left to bind at 4oC overnight. Secondary antibodies 
(Alexa488-Goat anti-Rabbit & Alexa568-Goat anti-Rat) were diluted in blocking solution at 
a ratio of 1:500 and left to bind at RT for 40 mins. Slides were washed with PBS T between 
each step for 3x5mins. Slides were counterstained and mounted with Prolong® Gold with 
Dapi (Life Technologies, Carlsbad, CA). Imaging was performed using a Zeiss Axio 
Microscope.  
 
Immunofluorescence Image Analysis  
Images were analysed using ImageJ (National Institute of Health) software. Wound 
closure was measured using keratin-14 (K14) staining, where the distance between the two 
last hair follicles adjacent to the wound was measured across the wound open gap, and the 
distance between the leading edges of the keratinocytes was also measured. The difference in 
wound closure was calculated, and converted into a percentage of the initial wound size.  
CD31 was analysed by calculating the total area covered per 40X image. Cells were 
identified by adjusting the threshold of fluorescence emitted so only positively labelled cells 
were measured, using ImageJ software.  
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Sirius Red Staining and Analysis 
Mice were sacrificed on day 14 post-wounding via CO2 asphyxiation, and the back 
skin was removed. Each wound was excised from surrounding skin with 1-2mm clearance 
around each wound. Wounds were fixed in 4% paraformaldehyde overnight, then sent for 
paraffin processing and embedding at the Translational Research Institute, QLD.  
Sections were cut at 6μm on Superfrost Plus slides, and heated at 72oC for 10 mins. 
Slides were dewaxed and rehydrated in xylene and gradients of alcohol to water. Slides were 
stained in pico-sirius red for 1 hour, then washed with two changes of acidified water. Slides 
were counter-stained with Mayer’s haematoxylin, differentiated in 1% HCl and blued in 
scotts solution. Slides were then dehydrated and cleared, then mounted with DPX mountant 
(Sigma-Aldrich Inc, Steinheim, Germany). 
 
Statistical Analysis:  
All statistical analyses were performed using Graphpad Prism 6. Data were analyse 
using non-parametric Mann-Whitney test or qui scare test. Results were considered 
significant if the P-value was less than 0.05.  
 
Supplemental Figures 
 
Supplemental Figure 1: Representative staining of haematoxylin and eosin in wounds at D5 
post-wounding of (A) Balb/C and (B) ST2-/-. There is no significantly altered wound 
formation, although the granulation tissue (red arrow) is larger and more densely packed with 
infiltrate in the ST2-/- compared to control. We can also see the WT wound has improved 
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healing compared to ST2-/- as identified by the wound margin distance (between black 
arrows). Scale bar = 0.5mm 
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Chapter 5 - The effect of the small molecule inhibitor; MCC950 on wound healing 
Chapter accepted for publication in The International Journal of Molecular Sciences, 16 Oct 
2018. DOI: 10.3390/ijms19113289 
 
Abstract 
The incidence of chronic wounds is escalating, and the associated healing process is especially 
problematic in an aging population with increased morbidity. Targeting increased 
inflammation in chronic wounds is a promising but challenging therapeutic strategy. Indeed, 
inflammation and especially macrophages are required for wound healing. As the NLRP3 
inflammasome has been implicated with various other inflammatory diseases, here we used 
MCC950, a selective NLRP3 small molecule inhibitor on murine models of both acute and 
chronic wounds respectively. This molecule, while tested for other inflammatory conditions 
has never been investigated to reduce topical inflammation driving chronic wounds. We found 
there were no significant differences when the treatment was applied either topically or orally, 
in wild-type C57Bl/6 mice, and even impaired wound healing in obese mice. The treatment 
was also unable to improve re-epithelialisation, or angiogenesis, both required for the closure 
of wounds. We are inclined to believe that MCC950 may inhibit the closure of chronic wounds 
and does not alter wound-associated macrophage polarisation. 
 Introduction 
In the ever-growing human population, chronic wounds are a significant issue and are 
associated with comorbidities such as an obesity, diabetes and aging. Varying interventions 
have been trialled in order to induce wound closure, such as negative pressure, hyperbaric 
oxygen, growth factor supplementation and acellular scaffold therapies, all with varying 
success due to the large heterogeneity in chronic wounds (Frykberg and Banks 2015). Despite 
these varying methods, data from the centres for disease control and prevention (CDC) 
identified that there were still 5 lower-extremity amputations per 1000 people with diabetes 
(Translation 2017). With a 5-year post-operative mortality rate of 50%, new methods of 
treating chronic wounds need to be further explored. 
Current literature indicates that the majority of these chronic ulcers and wounds develop 
due to impaired vascularisation, with increased recruitment of inflammatory leukocytes such 
as inflammatory macrophages (Mckelvey, Xue et al. 2012). Under normal healing conditions, 
early recruited monocytes differentiate into inflammatory macrophages, which then switch 
their phenotype into a pro-healing, anti-inflammatory macrophage, identified through the 
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difference in surface expression and functions (Brancato and Albina 2011). However, current 
literature has described the prolonged accumulation of inflammatory macrophages due to 
haemostasis and iron overloading, which then initiates an inflammatory phenotype in the lower 
limbs of chronic venous leg ulcer patients (Sindrilaru, Peters et al. 2011). Multiple other studies 
have identified that interventions which are able to change the polarisation state of 
macrophages from inflammatory to non-inflammatory/pro-healing are able to significantly 
improve wound closure (Ferrante and Leibovich 2012). However, if the intervention results in 
a depletion of macrophages, this will result in deleterious outcomes (Goren, Allmann et al. 
2009).  
Previous reports have highlighted the importance of inflammasomes as mediators of 
inflammation in macrophages, especially in the context of chronic diseases (Guo, Callaway et 
al. 2015). The nod-like receptor family protein 3 (NLRP3) inflammasome is the most well 
characterised inflammasome, and its formation is triggered by a diverse number of pathogen-
associated molecular patterns (PAMPS) as well as danger-associated molecular patterns 
(DAMPS), both of which would be present in wounds. When triggered NLRP3 protein binds 
to the adaptor protein ASC and subsequently Caspase-1. Once formed this NLRP3 
inflammasome complex activates caspase-1 which initiates proteolytic cleavage of pro-IL-1β 
and pro-IL-18 into functional pyrogenic cytokines IL-1β and IL-18. A small molecule inhibito r 
termed MCC950 has been published as a potent and selective NLRP3 inflammasome inhibito r 
(Coll, Robertson et al. 2015). We used this molecule to test whether MCC950 was able to 
improve wound closure in obese, diabetic mice. These ob/ob mice replicate a phenotype simila r 
to human patients, with delayed wound healing and chronic wounds (Seitz, Schurmann et al. 
2010). Although they are obese, they do not develop a diabetic phenotype (Giesbertz, Padberg 
et al. 2015). As we have initially found no significant results with the use of MCC950 in wound 
healing, this paper has been presented as a short communication. 
 
Results 
Topical treatment of MCC950 was insufficient to promote wound closure in WT and obese 
mice 
C57Bl/6J mice were treated topically with MCC950 [1mg/dose] in 30% pluronic gel, 
daily from D0 to D4 post-wounding. There was no significant difference in wound surface 
found between MCC950 and gel alone (control) groups (Figure 1a,b). As C57Bl/6J mice are 
known as a naturally fast-healing strain, we thought we might find more of a difference in 
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models of delayed wound healing. We therefore used Ob/Ob mice older than 6 months, as these 
display a chronic wound healing phenotype. Unexpectedly, topical MCC950 significantly 
impaired wound closure compared to control (Figure 1c,d) when measured macroscopically. 
However, upon further examination of the wounds using keratin-14 immunostaining to 
measure wound re-epithelialisation at D5, there was no significant difference found between 
groups (Figure 1e,f). 
 
MCC950 does not alter wound-associated macrophage polarisation 
 As IL-1  is a pro-inflammatory cytokine associated with the inflammasome, we 
decided to next investigate the effect of MCC950 administration on macrophage polarisat ion 
in wounds. Using the Ob/Ob mouse wounds at D5 from the previous experiments, we used 
immunofluorescent staining against macrophages (F4/80) with co-staining against 
proinflammatory M1 (iNOS+) or pro-wound healing associated M2 (MRC1+) macrophages 
between groups at D5 (Figures 3a-f). We found no significant differences in either macrophage 
numbers nor in polarisation for either M1 or M2 between treated groups.  
 
Oral treatment of MCC950 was insufficient to promote wound closure in obese mice 
We next decided to investigate a systemic, rather than local treatment of MCC950, as 
this method has been previously described to induce sufficient NLRP3 inhib ition in cases of 
experimental autoimmune encephalomyelitis (Coll, Robertson et al. 2015). We therefore added 
MCC950 into the drinking water of obese mice, at a concentration of 0.3mg/ml to take ad 
libitum, repeating our previous data showing efficacy of MCC950 to inhibit NLRP3 activation 
and subsequent IL-1  production at 20mg/kg (Coll, Robertson et al. 2015). We measured 
wound closure both macroscopically and histologically. Macroscopically, we found no 
significant difference between treated and untreated groups (Figure 3a,b). We also didn’t find 
any significant differences histologically, as all wounds were completely covered with an 
epidermis by D14 measured with keratin-14 staining (Figure 3c). As angiogenesis is a major 
step in wound healing, we next looked at CD31+ vessel coverage in wound granulation tissue. 
There were no significant differences between MCC950 treated mice vs. control in 
angiogenesis at D14 (Figure 3d).  
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Discussion 
Wound healing is a delicate balance of inflammation and growth factors, each essentia l 
at specific phases of the healing process. Indeed, many previous studies have identified the 
ablation of specific leukocyte populations such as neutrophils as beneficial for wound healing 
(Dovi, He et al. 2003), whereas the ablation of macrophages from wounds results in impaired 
closure (van Amerongen, Harmsen et al. 2007, Li, Li et al. 2013). While macrophages have 
been described as ‘essential’ for effective wound healing, their presence is mostly required for 
their pro-wound healing and remodelling properties, rather than their early inflammato ry 
functions (Mirza, DiPietro et al. 2009). Therefore, current research has focused on inhibit ing 
the inflammatory phase without compromising the pro-healing properties of these cells.   
As the inflammasome is a key player in the induction of inflammation and associated 
with many inflammatory disorders (Guo, Callaway et al. 2015), we expected MCC950 to 
improve wound closure, in the context of chronic wounds by preventing excess inflammation. 
However, we failed to observe any significant change in wound healing at all, with impairment 
of wound healing in one of our treatment groups, although failed to observe any significant 
effects through histological experiments indicating that the macroscopic observation may have 
just been an artefact due to slightly improved wound contraction. Macrophages are a key player 
in the regulation of wound healing, where having an increased inflammatory profile from 
diabetes in theory should impair wound healing. This impaired wound healing is observed 
when comparing WT mice to Ob/Ob mice, where WT mice heal within 7 days and Ob/Ob mice 
take up to 2 weeks to heal wounds of the same size (Rodero, Hodgson et al. 2013). MCC950 
has been previously described to have no effect on obesity or diabetes in a model of db/db 
diabetic mice (Kammoun, Allen et al. 2018). Therefore, to study the effects of inflammasome-
driven inflammation in chronic wound healing, the db/db model seemed ideal to test the effects 
of MCC950 on diabetic wounds, without affecting the diabetic phenotype itself. In these 
experiments, we used ob/ob mice which have a deficiency in the leptin protein, rather than a 
deficiency in the leptin receptor of the db/db mice used in the previous study. These mice have 
different genetic backgrounds, and while the db/db mice develop a strong obese and diabetic 
phenotype, the ob/ob mice are more resistant the to the diabetic phenotype with only mild 
hyperglycemia (Giesbertz, Padberg et al. 2015).  
Recently, in accordance with our findings, NLRP3 knockout mice have been described 
to have impaired wound healing (Weinheimer-Haus, Mirza et al. 2015, Ito, Kanbe et al. 2018), 
albeit not in a chronic wound healing model. Although, Lee, Kim (Lee, Kim et al. 2013) 
identified that monocyte-derived macrophages from diabetic patients expressed higher levels 
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of NLRP3 and its associated inflammatory cytokines, inhibition of this pathway may seem too 
deleterious for the process of healing. Alternatively, the reduction of NLRP3-induced 
inflammation is not significant compared to other proinflammatory cytokines, such as TNF, 
IL-6 or iNOS, present in chronic wounds (Zhao, Liang et al. 2016). Chronic wounds are a 
complex, multifactorial disease with many different facets regarding inflammation, presence 
of growth factors, venous insufficiency and vascularisation. This may be why we did not 
observe any significant differences in mice treated with MCC950 because NLRP3 inhibit ion 
alone was insufficient to reduce overall inflammation in the chronic wounds. 
NLRP3 has also been described as important for angiogenesis, in tumour models 
(Voronov, Carmi et al. 2014) and in matrigel plugs (Carmi, Voronov et al. 2009). As 
angiogenesis is a critical part of wound healing, especially in chronic wounds (Bauer, Bauer et 
al. 2005) we aimed to identify if we could recapitulate the results found in previously published 
papers. What we observed was a trend toward reduced angiogenesis in our mice at D14 
wounds, however this difference was not significant. Further studies investigating long-term 
effects on endothelial-to-mesenchymal transition (EndMT) could also be useful in studying 
long-term scar formation due to the reduction in NLRP3-associated inflammation (Patel, Baz 
et al. 2018). 
The rising cost of chronic wound treatments and therapies is a massive economic strain 
on healthcare systems. The development of easy to manufacture small molecules as an 
alternative to expensive antibody therapies is a new avenue which aims to lessen the burden of 
rising healthcare costs. While this novel, cost-effective small molecule inhibitor MCC950 has 
shown efficacy in the treatment of other inflammatory conditions, unfortunately, in this case it 
appears inhibiting the NLRP3 inflammasome using the small molecule MCC950 does not 
significantly affect wound closure. This may simply be due to the reason that the NLRP3 
inflammasome itself does not play a significant role in macrophage polarisation in a chronic 
wound healing model. 
 
Materials and Methods  
Mice 
All mice were bred on a C57B/6J background. C57Bl/6J and Ob/Ob mice were 
wounded after 6 months of aging, to promote the chronic wound healing phenotype. Equal 
numbers of males and females were used. All mice were treated in accordance with institutiona l 
ethics approvals and guidelines for the care of experimental animals.  
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Experimental Procedures 
Mice were wounded as per previous literature (Lee, Rodero et al. 2018). Mice were 
shaved and had Veet depilatory cream applied to remove excess hair. Four 6mm full-thickness 
wounds were created using a 6mm punch biopsy and wounds were left to heal without 
bandaging or covering. MCC950 was supplied by the Institute for Molecular Bioscience, 
University of Queensland, Australia. MCC950 was first applied topically at a dose of 1 mg/day 
in 30% F-127 Pluronic gel dissolved in PBS. The second experiment used MCC950 taken 
orally at a dose of 0.3 mg/ml in drinking water ad libitum giving a dose of approximately 20 
mg/kg/day, in replication of previous experiments performed and published (Kammoun, Allen 
et al. 2018). 
Wounds were photographed every second day using standardized xenogen live imaging 
CCD system. Wound images were analysed using ImageJ software where the edge of the 
wound was traced and measured as an area, and was calculated as a percentage of the origina l 
wound area. Wounds were calculated as a percentage of wound size based on D0 wounds. 
Histology – Frozen Sections 
Wounds were harvested at D5, D7 and D14 post-wounding. Wounds were fixed in 4% 
paraformaldehyde for 2 hours, and cryoprotected in gradients of sucrose up to 30% in PBS 
until the tissue sank. Wounds were sectioned through their centre and embedded cut side down 
in OCT on an isopentane/dry ice mix. Frozen section slides were cut at 8 µm on superfrost plus 
slides and stored at -30 ˚C until use.  
Histology – Paraffin Section 
Wounds were harvested at D14 post-wounding. Wounds were fixed in 4% 
paraformaldehyde for 24 hours at 4 ˚C. Wounds were sectioned through the centre, then 
dehydrated and paraffin embedded in a Leica HistoCore Pearl tissue processor for 12 hours. 
Sections were cut at 4 µm on superfrost plus slides. 
Immunofluorescence 
Frozen section slides were rehydrated in PBS-Tween 20 0.1% (PBS-T) for 5 mins. 
Slides were blocked in 10% normal goat serum, 1% bovine serum albumin and PBS-T for 15 
mins at room temperature. Primary antibodies were diluted in blocking solution respective ly, 
Keratin-14 1:1000, CD31 1:200, F4/80 1:200, iNOS 1:100, LYVE-1 1:200 and incubated 
overnight at 4 ˚C. Secondary antibodies were a combination of Alexafluor-A488, A568 or 
A647 1:500 dilution in 3% BSA and PBS-T. Slides were counterstained with DAPI and imaged 
on a Zeiss LSM510 Meta.   
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Figure 1. MCC950 inhibits wound closure in diabetic mice when administered topically 
(a) Comparing topically applied MCC950 vs control, there is no significant difference in the 
rate of wound closure. (b) Representative photographs of wound closure on C57Bl/6 mice. 
(c) Comparing topical administration of MCC950 vs control on obese mice with chronic 
wounds, the control mice had improved wound healing at D5 compared to MCC950. (d) 
Representative photographs of wound closure on Ob/Ob mice. (e) Histogram comparing re-
epithelialisation between MCC950 and controls in Ob/Ob mice at D5 using Keratin-14 
staining. (f) Representative photomicrograph showing epithelial migration stained with 
keratin-14 (Red) over the wound bed, stained with DAPI (Blue). The last hair follicle before 
the opening of the wound (green arrows) are used to determine to how far the epithelium has 
migrated along the wound bed (white arrows). N.s.=Not significant. N=5 mice per group.  
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Figure 2. MCC950 does not alter macrophage polarisation in wounds  
(a) Representative photomicrograph of macrophages stained with F4/80 (green), (b) iNOS to 
stain for M1 macrophages (red), (c) MRC1 to stain for M2 macrophages (purple), (d) A 
merged image of all antibodies plus DAPI for nuclear staining (blue). (e) No significant 
difference between M1 macrophage percentage for either control or treated group. (f) No 
significant difference between M2 macrophages from either group. Error bars = SD. 
N.s.=Not significant. Scale bar = 100m.  
 75 
 
Figure 3. Oral administration of MCC950 does not significantly improve chronic wound 
healing 
(a) Comparing orally administered MCC950 to control, there was no significant difference in 
the rate of macroscopic wound healing. (b) Representative photographs of wound closure on 
Ob/Ob mice. (c) Histogram comparing wound re-epithelialisation at D14 between groups, 
using Keratin-14 immunofluorescent staining. (d) Histogram comparing endothelial area 
between groups at D14 using CD31 immunofluorescent staining. 
 
  
 76 
Author Contributions: J.L and K.K conceived and designed the experiments; J.L. performed 
the experiments; J.L and K.K. analysed the data; A.R and M.C contributed 
reagents/materials/analysis tools and reviewed the manuscript; J.L. wrote the paper. 
Conflicts of Interest: MAC currently holds a fractional Professorial Research Fellow 
appointment at the University of Queensland with his remaining time as CEO of Inflazome 
Ltd. a company headquartered in Dublin, Ireland that is developing drugs to address clinica l 
unmet needs in inflammatory disease by targeting the inflammasome.  
 
  
 77 
Chapter 6 - Clodronate liposome-induced macrophage depletion prevents UVR-induced 
immunosuppression 
 
Abstract 
Ultraviolet irradiation- induced immunosuppression creates a permissive environment 
for skin tumour growth. Previous research has identified, using mice, the roles of Langerhans 
cells in systemic immune suppression, through their lymph node migration and activation of 
IL-10 secreting regulatory T-cells. However, experiments performed in our lab also identified 
a myeloid population affected by clodronate depletion in the response to UV and subsequent 
melanoma formation. We used C57Bl/6 mice to aim to identify if myeloid cell populations 
may be required for the modulation of UV-dependent immunosuppression, and which specific 
populations. We also aimed to find the long-term effects of UV irradiation on neonatal skin-
resident myeloid populations. We found clodronate liposome-induced myeloid cell depletion 
during a burning dose of UV irradiation as a neonate could prevent long-term local 
immunosuppression measured with delayed-type contact hypersensitivity. We also found a 
change in resident dermal macrophage populations due to a single burning dose of UV could 
be identified more than a month following UV irradiation. This data opens up a new avenue of 
research that demonstrate not only the importance of Langerhans cells in UV irradiation, but 
of the dermal compartment of myeloid cells as well, and possible methods for modulating the 
immune response to UV. 
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Introduction 
Melanoma is the most fatal form of skin cancer, and the 4th most common cancer in 
Australia (Australian Institute of Health and Welfare, 2018). Known to be driven by both 
genetics and environmental exposure, it is evident that some factors may be more important 
than others. Previous studies have investigated the genetics of hereditary melanoma, 
identifying mutations in CDKN2A or CDK4 as the most common factor in melanoma patients 
(Soura, Eliades et al. 2016). Mouse models have been developed to study melanoma with 
mutations in the CDK4 gene (CDK4R24C/R24C) with an associated NRAS mutation (Tyr-
NRASQ61K) which increases their sensitivity to UV exposure and subsequent melanoma 
formation (Hacker, Muller et al. 2006, Wurm, Lin et al. 2012). This mouse model has been 
extensively used by multiple research institutes in Brisbane, Australia, which has uncovered a 
link between neonatal exposure and melanoma formation in these mice (Wurm, Lin et al. 2012, 
Rodero, Handoko et al. 2014). Interestingly, neonatal mice developed melanomas from a single 
burning dose of UV much earlier than mice which were not irradiated, but also earlier than 
mice which were irradiated as adults. The link between neonatal UV exposure and melanoma 
formation is unknown, and thus requires further investigation. (Hacker, Irwin et al. 2005).  
In order to study the effects of phagocytic macrophages in the response to UV, we used 
clodronate, also known as clodronic acid which is encapsulated by a bilipid membrane capsule 
known as a liposome. The liposome is phagocytosed by macrophages which then degrade the 
bilipid membrane, releasing the stored clodronate. Clodronate then builds up in the macrophage 
to a toxic threshold, inducing apoptosis. Free clodronate (non-encapsulated) is reported to have 
no effect on the host and is easily passed through the renal system (van Rooijen, Sanders et al. 
1996, van Rooijen and Hendrikx 2010). Importantly, while other cells such as antigen-
presenting dendritic cells and neutrophils are also known as professional phagocytes, the 
clodronate liposomes are too large for these cells to ingest and thus has no effect on these cell 
types (Claassen, Van Rooijen et al. 1990).  
As there are many different myeloid populations present depending on the organ of 
residence, we based our myeloid analysis off Tamoutounour et al. (2013) and their study on 
the origins and functional specialization of macrophages and dendritic cells, specifically in the 
skin. They identified 6 CD11b+ monocyte/dendritic cell/macrophage populations; CD11b+ 
Dendritic cells (CD11b+ DC), Monocytes (A1), Monocyte-derived DCs (A2,A3) and resident 
macrophages (A4, A5). There is also a classical DC population which is CD11b-, 
CD11c+MHCII+Ly6c-CSF1R-. The final population we were partially able to define are 
Langerhans cells, which we classified as CD11b+CD11c+MHCII+Ly6c-CSF1R+, as classica l 
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DCs do not express CSF1R (Table 1). While further DC populations exist such as plasmacyto id 
DCs (pDC), CD8+ DC and various other subtypes of classical DCs such as CD1c+ and 
CD141+ DCs, many of these types are lymphoid in origin and/or circulating and were 
overlooked in these preliminary experiments. 
Most skin cancers are highly antigenic (Kripke 1974), and when implanted into a host 
with an effective immune system, they are rapidly destroyed. Animals exposed to UV are also 
unable to induce a contact hypersensitivity (CHS) response, a typical T-cell mediated delayed 
hypersensitivity reaction against haptens such as oxazolone or DNFB (Reeve, Allanson et al. 
2012, Prasad and Katiyar 2013, Nunomura, Ohtsubo-Yoshioka et al. 2015). Previous reports 
have found that monocytes, dendritic cells or macrophages are capable of inducing 
immunosuppression following UV irradiation, either through IL-10 secretion or IL-12 
inhibition (Schmitt and Ullrich 2000, Toichi, Lu et al. 2008). We aimed to discover whether 
the depletion of macrophages at the time of UV irradiation was sufficient to prevent 
immunosuppression via a depletion using clodronate liposomes.  
 
Methods 
Mice 
All mice were bred on a C57Bl/6J background.  A minimum age of 8-week-old mice 
were used for breeding. All mice were treated in accordance with institutional ethics approvals 
and guidelines for the care of experimental animals. 
Clodronate depletion and UVB irradiation 
Neonates had daily injections both subcutaneously and intra-peritoneal with 100μL 
total (50 μL per site) of either PBS liposomes or Clodronate liposomes from postnatal day 1 
(P1) until P5. This dose is based on the recommended amount from the manufacturer based off 
animal weight (Clodronateliposomes.com). Litters were randomised to receive either a single 
burning dose of broad-spectrum UVB irradiation (Phillips TL100W 12RS UVB lamps), total 
UVB at 0.8KJ/m2 per minute (emission from the source) and erythemal UVB (emission as read 
from the site of animal placement) at 0.21KJ/m2 per minute for a duration of 10 minutes.  
Contact Hypersensitivity 
At 8 weeks, mice had abdominal fur shaved and were sensitized with 150μL of 5% 
Oxazolone (4-Ethoxymethylene-2-phenyl-2-oxazolin-5-one, Sigma Aldrich) in a 4:1 
Acetone/Corn Oil solution, topically applied. One week later, mouse ears were challenged with 
20μL vehicle on the left ear (control) and 2% oxazolone in acetone/corn oil on the right ear. 24 
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hours post challenge, ear thickness was measured using digital Vernier callipers. The difference 
in thickness between the left ear and right ear was calculated to determine level of 
inflammation.  
Flow Cytometry – T-cells 
Mice were culled 24 hours post-challenge, left and right thoracic lymph nodes, inguina l 
lymph nodes and spleen were harvested. Organs were pressed through a 70um cell strainer in 
2mL FACS buffer (Phosphate buffered saline, 0.5% bovine serum albumin, 2μM 
Ethylenediaminetetraacetic acid) to obtain a single cell suspension. Cells were stained for the 
following: CD3ε-Pacific blue, CD4-PE-Texas Red, CD8α-PerCP-Cy5.5, CD25-PE, FoxP3-
Alexa647, Fixable viability stain 510. Cells were fixed and permeabilized using BD-
biosciences FoxP3 staining buffer kit.  
Flow Cytometry – Myeloid cells 
Mice were culled at required time points from each treatment group. Whole back skin 
was shaved and depilated using Veet cream. The entire dorsal surface was removed, and 
hypodermis was scraped off using a razor blade. The skin was sliced into 1mm3 sections and 
placed in 10ml HBBS + 307ul Liberase TL (5mg/mL) + 20ul DNAseI (10mg/mL) in an orbital 
shaker at 37oC for 2 hours. A serological pipette was used to separate aggregates every 30 mins. 
Cells were filtered through a 70um cell strainer and washed with FACS buffer. Cells were 
stained with: CD64-BV421, FVS510, CD115-BV605, CD45-BV650, MHCII-FITC, CD11b-
PerCP/Cy5.5, Ly6g-PE, CD3-PE, CD4-PETR, CD11c-PE/Cy7, CCR2-APC, CD206-AF700, 
Ly6c-APC/Cy7.  
All flow cytometry samples were analysed using a Beckman Coulter Cytoflex S. Post-
acquisition analysis was performed using FlowJo X.  
Histology 
Paraffin-embedded sections 
Mice were culled 72 hours post-challenge and back skin and ears were collected. 
Tissues were fixed in 4% paraformaldehyde at 4 degrees Celsius for 24 hours. Tissues were 
processed at the Translational Research Institute histology facility for paraffin embedding, 
sectioning and H&E staining.  
Formalin-fixed frozen sections 
Fresh tissues were harvested from mice at previously specified time-points. Tissues 
were fixed for 2 hours at RT in 4% paraformaldehyde, then cryoprotected in gradient sucrose 
solutions from 15% to 30% overnight, or until tissue sank. Tissue was embedded in OCT 
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(Sakura tissue-tek) and 8μm sections were cut using a Leica CM1950 cryostat or a 
ThermoFisher HM525NX cryostat at -20oC.  
 
Immunofluorescence 
Paraffin sections were dewaxed in De-Solv-It citrus cleaner as a xylene alternative, then 
rehydrated in ethanol gradients; 100%, 95%, 70% followed by dH2O. Antigen retrieval was 
performed using a Carezyme I: Trypsin antigen retrieval kit (Biocare Medical). Slides were 
blocked using 5% Normal Donkey Serum (NDS), 1% Bovine Serum Albumin (BSA) in 0.1% 
Tween-20 PBS for 20 mins at RT. Primary antibodies used were Serotec Rat-anti-F4/80 and 
R&D Goat-anti-MMR at a 1:200 dilution and Abcam Rabbit-anti-iNOS at a 1:100 dilution in 
blocking solution at 4oC overnight. Secondary antibodies were Donkey anti-Rat Alexafluor-
488, Donkey anti-Rabbit Alexafluor-568, Donkey anti-Goat Alexafluor-647 all at 1:500 
dilution in 3% BSA, 0.1% Tween-20 PBS for 1 hour at RT. Slides were counterstained with 
DAPI and imaged on a Zeiss LSM710, Olympus FV1200 or Olympus FV3000. 
 
Results 
Clodronate liposomes reduces the number of F4/80+ cells in the skin and spleen temporarily 
We first aimed to validate the reduction of F4/80+ cells in the skin, which have been 
commonly associated as a macrophage marker, although A1-A5 cells are known to also 
express F4/80, as are Langerhans cells (Tamoutounour, Guilliams et al. 2013). We found a 
significant reduction in F4/80+ cells in the skin, although there was not a total depletion 
present (Figure 1a-c). There was also an observable depletion in the spleen of mice, although 
this was not quantified (Figure 1d,e).  
 
Macrophage depletion prevents UVB-induced long-term immunosuppression in delayed-type 
contact hypersensitivity 
We first tested whether broad-band UVB irradiation was sufficient to induce 
immunosuppression. A single burning dose of UVB was delivered 4 days after birth (P4) as 
shown in figure 2a. Mice were separated into four groups, UVB irradiated or not, and treated 
with control liposomes (PBS-filled liposomes) or clodronate containing liposomes. We found 
control liposome injected mice that were UVB irradiated displayed reduced ear swelling after 
contact hypersensitivity testing 8 weeks later, indicating a level of immune suppression. 
(P<0.05, Figure 2b). Importantly however, Clodronate treated mice could mount an equivalent 
immune response to CHS compared to unirradiated mice, indicating that clodronate depletion 
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of a myeloid population during UVB is able to protect the mouse from long-term 
immunosuppression.  
 
Clodronate depletion reduces the number of skin-resident macrophages 
We next aimed to identify the effects of clodronate on the myeloid populations of 
immune cells in the skin immediately following clodronate depletion and UV irradiation. 
Neonates had 4 days of clodronate injections both subcutaneously and intraperitoneally as per 
manufacturer instructions to deplete skin-resident and circulating macrophages (Figure 3).  
Neonates then received a burning dose of UV irradiation, and skin was analysed using flow 
cytometry 24h following UV at postnatal day 5 (P5). Clodronate was effective at depleting 
global myeloid populations (CD11b+Ly6g-CD3-) both with the presence and in the absence of 
UV and CD11b populations were decreased in both PBS and Clodronate treated mice following 
UV, most likely due to migration of LC and DC to the lymph nodes (Figure 4a). Total 
monocyte-derived cells (CCR2+) and total resident (CD64+) macrophages were both affected 
by clodronate depletion (Figure 4b,c). However monocytes alone (A1), were not significantly 
affected by clodronate (Figure 4d) but the remaining moDC populations (A2-A3) were both  
depleted by clodronate (Figure 4e,f). Both resident macrophage populations (A4-A5) were 
significantly depleted by clodronate as expected (Figure g,h). Of note, neutrophil numbers were 
significantly increased 24h after UV in PBS-treated groups as expected, however there was 
impaired neutrophil recruitment to the skin in clodronate treated groups after UV irradiat ion 
(Figure 4i). Neutrophil numbers were not significantly different in clodronate-treated mice in 
the absence of UV, suggesting that clodronate does not directly affect neutrophil numbers , 
rather the cells depleted by clodronate have an effect on neutrophil recruitment. The 
CD11b+CD11c+MHCII+ DC population also appeared by be sightly depleted by clodronate 
unexpectedly, although this difference was not statistically significant (Figure 4j). 
Clodronate depletion did not affect the number of Langerhans cells, classical dendritic 
cells or T-cells (Figure 4k-n). It is worth noting the cDC population was reduced in numbers 
immediately post-UV but was not affected by clodronate depletion (Figure 4l), most likely due 
to lymph node migration. These results have been summarised in Table 2. 
 
A single burning dose of UVB at a neonatal age induces a shift in resident myeloid populations 
We next decided to investigate the effects of UV alone on the skin over longer time 
points than just the P5 skin previously analysed with and without UV. Previous studies have 
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shown that resident macrophages in the skin have a different embryological origin and derive 
from the yolk sac rather than the bone marrow (Davies, Jenkins et al. 2013). This prompted us 
to ask whether changes observed through UV irradiation would result in long term alterations 
of macrophage populations in the skin. We have previously reported that after 7 days, the 
numbers of macrophages and neutrophils return to normal levels after a sunburn of UV 
(Rodero, Handoko et al. 2014). We therefore aimed to evaluate the long-term changes in 
myeloid population in mouse skin following a burning dose of UVB at P4. For preliminary 
experiments, we used immunofluorescent staining against F4/80 to stain macrophages and 
other F4/80+ cells such as Langerhans cells and P1-P3 moDC subsets. We found an increased 
number of F4/80+ cells consistently throughout later timepoints, finally regressing at P42 
(Figure 5a,d,e). We also analysed the M1 vs M2 expression of F4/80+ cells using 
immunofluorescence, although only on homeostatic skin. We observed a general increase in 
inflammatory macrophages (iNOS) over time (Figure 5b,f). There were no significant 
differences found in MRC1+ macrophages (Figure 5c,g). 
 
We then used flow cytometry for increased specificity in identifying the changing cell 
populations observed using immunofluorescence in the skin. A representative flow cytometry 
plot for the full population dissemination is provided, with fluorescent minus one (FMO) 
controls for every colour (Figure 6, Figure 7). We found an issue with our CCR2 staining, 
where cross contamination from other colours were spilling over into the CCR2 channel, which 
could not be corrected with compensation. However after careful analysis on the CCR2 vs 
CD64 populations and subsequence Ly6c/MHCII populations, we determined as CD64 was 
effective in pulling out the resident A4,A5 populations the effect of CCR2 contamination was 
not a serious effect. We compared UV irradiated vs. non-UV irradiated at the following time 
points; P10, 16 and 42. We first looked at recruited (CCR2+CD64-) subpopulations and 
observed a significant increase in the percent of A1 and A2 moDC subsets at P10 after UV 
irradiation (Figure 8a,b). By P16 however, the A1 and A2 populations had returned to baseline 
compared to non-irradiated skin, and while there are differences in the homeostatic baseline 
for non-UV-irradiated skin at P42 compared to P16, there were no differences between P42 
UV irradiated vs. non-irradiated skin. We also found a significantly decreased expression of 
the mannose receptor 1 (CD206) in the A1-A3 populations following UV irradiation, which is 
associated with a more inflammatory phenotype (Figure 8c).   
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We next compared resident CCR2- populations.  Interestingly, there were no significant 
differences between resident populations at P10 nor P16, however at P42, there was a 
significant increase in Ly6cloMHCIIlo and a correlated reduction in Ly6cloMHCIIhi (Figure 8d).  
We also compared neutrophils (Ly6g+CD11b+), and classical DC populations (CD11b-
CD11c+MHCII+) and found no significant differences between UV+ and UV- skin at any of 
the time points. (Figure 9a,b).  
 
Regulatory T-cells suppress CHS-mediated inflammation 
We finally aimed to identify if the clodronate depletion was directly affecting the 
impaired immunosuppression due to altered moDC and resident macrophage recruitment, or if 
it was an indirect effect caused by altered Treg recruitment and proliferation. Previous studies 
have reported that T-regs are a key cell type responsible for UV induced immunosuppress ion 
through an IL-10-dependent mechanism (Simkin, Tao et al. 2000). We therefore performed 
flow cytometry on the ear draining cervical lymph nodes from the left (unchallenged) or right 
(challenged) ear, 24 hours post-CHS challenge in 8-week old mice that were either irradiated 
with a single burning dose of UVB at P4 or not irradiated at all, and that had received clodronate 
depletion or not at the same time. In the draining lymph node, on the challenged side, neonatal 
UVB irradiation resulted in significantly higher levels of regulatory T cells 
(FoxP3+CD25+CD4+) and a reduction in other CD4+ T cells (CD4+FoxP3-) at 8 weeks of age 
(Figure 10a,b). Similar observations could be made on the contralateral non-challenged ear 
suggesting that this was a systemic effect (Figure 9c). There were no significant changes in 
CD8+ T cells. Upon clodronate depletion at birth in animals receiving sunburn UVB 
irradiation, the levels of regulatory T cells and effector CD4+ cells in the challenged side 
reached levels observed in unirradiated controls (Fig 10c). This was only observed on the 
challenged side and did not seem to affect regulatory T cell levels in the left unchallenged ear 
suggesting that the clodronate-induced cell depletion may be altering the local regulatory 
response contributing to UVB induced long term immunosuppression. Interestingly, we do not 
observe a systemic immune suppression, as distal lymph nodes collected from the inguina l 
region had no significant differences in any T-cell populations including Tregs (Figure 10d).  
 
Discussion 
Ultraviolet irradiation is the leading cause of skin cancer. In particular, in melanoma 
intermittent burning exposure during childhood is a significant risk factor (Kulichova, Danova 
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et al. 2014). Beyond its carcinogenic and proliferative effects UV is also known to induce long 
term immunosuppression. In this study, we show that this long-term cutaneous 
immunosuppression may be influenced by resident macrophage and monocyte-derived DC 
populations. Depletion of this population prior to UV irradiation prevented the long-term 
immunosuppressive effects, at least at local levels. A single dose of erythemal UV irradiat ion 
elicited a local immunosuppressive effect through the development of Tregs, as observed via 
delayed-type contact hypersensitivity testing, however our results are not consistent with 
previous reports which demonstrate a total systemic immune suppression (Simkin, Tao et al. 
2000, Hart, Grimbaldeston et al. 2001, Schwarz 2005).  
In addition, the importance of regulatory T cells in this immunosuppression and the 
possibility of transfer of the immunosuppressive response to secondary recipients has been well 
characterised. In our study, we indeed identified a systemic increase in Tregs in UV irradiated 
mice. Interestingly though, Clodronate depletion at the time of irradiation only affected Treg 
numbers in the challenged site. The unchallenged ear draining lymph node maintained 
increased number of Tregs after UV irradiation. This suggests that macrophage depletion does 
not affect the initial and systemic establishment of immunosuppression. However, it affected 
the cutaneous response to inflammation. We speculate that CD64+ macrophages are 
responsible for blocking Treg activity at the sensitization phase, as previous studies have 
identified that the depletion of Tregs at the sensitization phase results in a marked increase in 
inflammation, whereas at elicitation, the inhibition of Tregs has no immediate effect on 
inflammation (Lehtimäki, Savinko et al. 2012). However further functional studies will need 
to be performed to support this hypothesis. 
 
While Tamoutounour et al. found CD11b+ dermal DCs upregulated Aldh1a2 which 
codes for aldehyde dehydrogenase, associated with Treg-inducing capacity, this population 
was not directly affected by clodronate. They also found neither A4 or A5 macrophages were 
able to present antigen to stimulate T-cells, whereas we believe the simulation of Tregs due to 
UV irradiation may be induced by P4 macrophages, as these were a population identified to be 
significantly depleted by clodronate. What is interesting is they identified an increase in IL-10 
production by A2, A3, A4 and A5 cell populations compared to CD11b dermal DCs during 
their transciptomic analysis, which may be the key as to why their depletion prevents this long-
term immunosuppression. However, these are all still assumptions as we have not performed 
functional studies to assert this yet. We also had trouble distinguishing our CCR2 staining on 
our flow cytometry due to colour compensation. While CCR2 may have been compromised, 
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we still believe we were able to successfully pull out the populations described based on the 
Ly6c/MHCII plots pulling out the A1-A5 populations.  
Immediately following UV irradiation, we observe an influx of A1 monocytes which 
has been described in previous literature (Zaidi, Davis et al. 2011, Handoko, Rodero et al. 
2013). At P10, we observe the progression from A1 monocytes toward the differentiated, 
A2/A3 moDCs. The number of these recruited cells have mostly returned to normal levels by 
P16, as there are no significant differences at P42 in the A1-A3 populations. However, we 
speculate that there may be a shift in the resident macrophage population where some of these 
recruited CCR2+ cells lose their CCR2 surface expression and become the new resident 
macrophages, which has been identified previously (Phillips, Lutz et al. 2005). Infiltrat ing 
inflammatory CCR2+ cells have also been described as the leading cell type associated with 
tumour associated macrophages (TAMs) with their ability to induce an immunosuppress ive 
environment to promote tumour growth (Franklin, Liao et al. 2014). An alternative explanation 
is the increased proliferation and self-renewal of CD64+ resident macrophages which are 
derived from the yolk-sac or liver during foetal development, rather than bone marrow 
monocyte-derived (Gomez Perdiguero, Klapproth et al. 2015). Due to the vast heterogeneity 
of macrophages, multiple reports have stated immunosuppressive functions for a variety of 
resident macrophages from different organs (Mantovani, Biswas et al. 2013, Davies and Taylor 
2015). We also found a prolonged inflammatory profile in A1-A3 recruited moDCs. These 
cells may be the key APCs involved in the priming of the Tregs found in the contact 
hypersensitivity tests. Indeed, a recent study identified that in humans, inflammato ry 
monocytes recruited to the skin following UV irradiation differentiated into DC to replace 
Langerhans cell depletion/migration which occurs following UV irradiation (Achachi, 
Vocanson et al. 2015). Those cells were notably able to prime T-cells and induce alloantigenic 
immune responses. 
 
This project is still in its early phases, as there are still many avenues to explore from 
the data collected and shown in this early manuscript. We still don’t specifically know which 
mechanisms the resident macrophages act by to induce/prevent immunosuppression, or if there 
is an indirect effect due to other immune cell populations. I believe that this is still a project 
that can be continued by another colleague, possibly looking at the genetic differences between 
macrophage populations comparing UV irradiated vs. non-irradiated and depleted vs. not 
depleted. We already have hypotheses on further targets to test, such as CTLA-4 which is 
involved in CD80/CD86 binding and the subsequent downregulation of immune responses. 
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Other unpublished data includes the damage of reticular lymph nodes due to clodronate 
depletion, which releases a high number of lymphocytes into the circulating bloodstream. 
These all could be further studied; however, we believe that this was beyond the scopes of what 
I aimed to achieve in my PhD.  
 
Years of evolution have created redundancies within all living organisms. With two 
copies of every gene, multiple signalling pathways which achieve the same end result, it also 
stands to reason that multiple cell types would be responsible for eliciting immunosuppress ive 
effects. My results identify a possible mechanism for the inhibition of local immune 
suppression driven by monocyte-derived DCs and resident macrophages. The validity of our 
model needs to be verified, as we were unable to mount a systemic immune suppression in our 
model, which may be due to the long time period (7 weeks) elapsed since the single burning 
dose of UV. If so, we may have demonstrated a local immune suppression driven by myelo id 
cells can supersede a systemic immune suppression. I hypothesize that UV-exposed moDC and 
resident macrophage populations induce Tregs from naïve CD4 T-cells in a local manner. 
Futher experiments will be required to test this hypothesis formed from this preliminary data 
set presented in this chapter.  
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Figure 1: Clodronate depletion on F4/80+ cells in the skin and spleen 
A representative photomicrograph of P4 skin stained with DAPI, a nuclear counterstain 
(blue) and F4/80 (green) to identify macropahges. (a) PBS lipsome treated skin. (b) 
Clodronate liposome treated skin. (c) A histogram showing cell counts of F4/80 per high 
powered field (HPF) between groups. ****=P<0.0001 (d,e) Spleen of treated mice showing a 
reduction in splenic macrophages.  
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Figure 2: Schematic for delayed-type contact hypersensitivity 
(a) Timeline schematic showing the days of injection with liposomes (P1-P5), UV irradiat ion 
at D4, and the study on long-term effects with delayed-type contact hypersensitivity at 8 weeks 
of age. (b) Bar histogram showing the difference in ear thickness between the left and right 
ears of mice 24 hours following second application of oxazolone. ***P<0.001, *P<0.05, N=7-
14 mice dependant on group, from two independent experiments. 
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Figure 3: Liposome injection diagram 
A direct copy of the injection diagrams from Liposoma, indicating systemic depletion of 
macrophages through intraperitoneal injection and local depletion of macrophages through 
subcutaneous route. Copyright Liposoma BVTM The Netherlands. 
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Figure 4: Myeloid total counts in P5 neonates 
Histogram plots of total cell counts of specific immune cell populations found in the skin, 
comparing (left to right) PBS liposome injected, no UV irradiation, PBS liposome injected, 
UV radiated, Clodronate liposome injected, no UV irradiation and Clodronate liposome 
injected, UV radiated. (a) CD11b+Ly6g- myeloid cells (b) Monocyte-derived (A1-A3) (c) 
Resident macropahges (A4/A5) (d) A1 monocyte population (e) A2 Monocyte-derived DC 
population (f) A3 MoDC population (g) Resident macrophage A4 population (h) Resident 
macrophage A5 population (i ) Neutrophils (j) CD11b+ DCs (k) Langerhans Cells (l) Classical 
DC population (m) T-cell population (n) CD4 T-cells *P<0.05, **P<0.01. N=3 mice per group.   
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Figure 5: The Effect of UV on macrophage populations over time 
Representative immunofluorescence photomicrographs of skin stained with DAPI (Nuclear 
counterstain) and (a) F4/80 (green), (b) iNOS (red) (c) MRC1 (blue) and (d) Merged. (e) Bar 
graph representing total count of F4/80 per m2 at different time points following unirrated 
skin (black bars) or a single burning dose of UV at P4 (grey bars). (f) A histogram representing 
homeostatic skin macrophage production of iNOS and (g) MRC1 to identify M1 vs M2 
macrophages. *P<0.05, n=4-7 mice per group dependant on time point. Scale bar = 100m. 
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Figure 6: Disseminating  subsets in the skin myeloid populations 
(a) Representative flow cytometry panel from back skin identifying myeloid cell populations. 
Cells were gated on CD45+ and dead cells excluded (Not shown), then gated on CD11b-
Ly6g/CD3- (red box) (a). They were further sorted based on CD11c and MHCII, and CD11chi 
MHCIIhi cells were defined as classical DCs (b). CD11b+ Ly6g/CD3- cells (blue box) (c). 
Cells were then sorted into two populations, Ly6c-CD64- (purple box) (g) and Ly6c+/-
CD64+/- (yellow box) (d). The yellow box cells were then sorted based on CCR2 and CD64 
expression, where CD64+CCR2- were defined as A4,A5 macrophages (green box) (e), and the 
remainder were sorted as A1,A2,A3 monocyte-derived DCs (brown box) (f). Meanwhile, 
Ly6c-CD64- cells were further sorted on CD11c and MHCII (dark blue box) and separated into 
CD115 low and hi to delineate CD11b+DCs and Langerhans cells (h). 
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Figure 7: Fluorescence minus one flow cytometry plots for figure 6 
Fluorescence minus one control graphs, indicating negative gating for expected populations. 
CCR2 FMO indicates some CCR2 staining was caused by fluorescence from other channels.  
However, as the CD64 staining was effective, the populations were still able to be dissemina ted 
with only a small amount of gating error and thus population contamination from A1-3 into 
A4,5 and vice versa. 
  
 97 
Figure 8: Resident myeloid populations in the skin at P10, P16 and P42 
(a) Representative flow cytometry plots of A1-A5 populations in P10 and P16 skin. (b) 
Comparison of the percent of CD11b+ CCR2+ A1-A3 moDC populations in the skin between 
UV exposed (black) and unexposed (grey) skin. (c) Comparison of the percent of CD206 
expression in A1-A3 populations between UV exposed and unexposed skin in P10 and P16 
mice. (d) Comparison of the percent of CD11b+ CD64+ A4,A5 resident macrophage 
populations in the skin between UV exposed (black) and unexposed (grey) skin. 
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Figure 9: Non-macrophage myeloid cell counts in skin 
(a) Bar graph histogram representing total neutrophil numbers at P10 and P16, UV exposed or 
unexposed conditions. (b) Bar graph histogram representing total cDC numbers at P10 and 
P16, under UV exposed or unexposed conditions. N=4-7 mice per group dependant on time 
point. N.s = Not significant. 
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Figure 10: Regulatory T-cell flow cytometry panel and results 
(a) A representative flow cytometry panel identifying T-cells and their subpopulations. Lymph 
node cells were first gated on live and CD45+, then gated on CD3+ only. CD3+ cells were 
divided into CD8+ and CD4+, and CD4+ cells were further sorted into Treg based on 
CD25+FoxP3+ expression. (b) Bar graph comparing right ear draining lymph node T-cell 
populations between groups.  (c) Bar graph comparing left ear draining lymph node T-cell 
populations between groups. (d) Bar graph comparing distal inguinal lymph node T-cell 
populations between groups. *P<0.05, **P<0.01, ***P<0.001 compared to PBS UV+ group. 
N=5-7 mice per group. 
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Chapter 7 - A multicolour lineage tracing mouse model to study the kinetics of 
macrophage recruitment and proliferation  
 
Abstract 
The origins of resident macrophages are a highly contested debate, with usually one or 
more sources attributed per organ. The skin is believed to be initially supplied by yolk-sac 
progenitors and foetal liver progenitors. It is also believed that in adults, resident skin 
macrophages are renewed by bone-marrow derived monocytes. This study attempted to use a 
multicolour lineage tracing model of bone marrow macrophages to determine the kinetics of 
resident macrophages under homeostasis compared to after injury such as wounding or UV 
irradiation.  
 
Introduction 
The origin and differentiation of myeloid cells has been studied extensively, with more 
recent studies indicating that there is substantial diversity and heterogeneity between 
circulating monocytes, monocyte-derived macrophages and tissue resident macrophages 
within different tissues (Gomez Perdiguero, Klapproth et al. 2015, Minutti, Knipper et al. 2017, 
Munro and Hughes 2017). Even within tissue resident macrophages, the origin and function 
depend on the organ of residence, and even within different compartments of the organ itself 
(Gordon and Plüddemann 2017). Gene expression studies utilizing FACS-sorted cell 
populations and microarray RNA analysis aimed to elucidate the difference between organ 
specific macrophages, and to delineate the difference between dendritic cells and macrophages 
(Gautier, Shay et al. 2012, Miller, Brown et al. 2012). However, what these experiments are 
unable to do is define the mechanism of repopulation within tissues after development. 
Previous reports have identified that macrophages are able to be resupplied by monocytes, and 
other tissue resident macrophages are able to self-renew (Davies, Jenkins et al. 2013).  
The skin is an organ with some controversy about the origin and specialisations of 
macrophages within the different layers. The most well-known of the skin resident 
macrophages are Langerhans cells (LC), which are epidermal dendritic cells/macrophages. LC 
express traits of both macrophages and dendritic cells, as like tissue macrophages, they are 
colony stimulating factor 1 receptor (CSF1R) dependent, are yolk-sac derived and can also 
develop from foetal liver monocytes (Chorro and Geissmann 2010). However, unlike other 
tissue macrophages, they migrate to lymph nodes upon stimulation for antigen presenting, like 
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dendritic cells. This was confirmed with a gene expression study which identified LC as an 
intermediate between classical DCs and macrophages, as their gene expression did not cluster 
with either population (Gautier, Shay et al. 2012).  
Dermal macrophages are a lesser well-understood population of resident macrophages. 
These cells consist of a heterogeneous population of foetal liver-derived and bone marrow-
derived macrophages, with current literature indicating that approximately 15-25% of resident 
macrophages are derived and replenished from monocyte precursors under homeostasis 
(Tamoutounour, Guilliams et al. 2013).  
Inflammatory events where high numbers of monocytic infiltration occur are also 
believed to significantly alter the resident macrophage populations in the skin, such as UV 
irradiation, exposure to a hypersensitivity agent or wounding (Davies, Jenkins et al. 2013). It 
is not yet known if or how these macrophages repopulate the skin, nor the differences between 
these cells compared to the yolk-sac or foetal liver-derived counterparts.  
In an attempt to answer these questions, we aimed to use a reporter mouse model based 
on the brainbow-1.0 construct which gives us multicolour lineage tracing to identify cells 
expressing the LysM promoter, commonly associated with macrophages. We termed this 
LysM-Cre x Rainbow3 genetically modified mouse ‘Macbow’. The LysM-Cre was 
constitutively active, so that anytime the cell expresses Lysozyme C-2 (Lyz2), there is 
activation of the Cre and recombination would occur. The Rainbow3 mouse strain contains the  
Brainbow 1.0 cassette (encoding lox2272-flanked dTomato, lox2272/loxP-flanked mCerulean, 
and EYFP fluorescent proteins) placed under the control of a CAG (cytomegalovirus (CMV) 
early enhancer element and chicken beta-actin) promotor (Figure 1). Each cell contains two 
Brainbow1.0 constructs, allowing 6 possible colour combinations following recombination; 
red, yellow, blue, orange, white and pink. This would allow us to identify any Lyz2 expressing 
cells with a random colour, and trace its progeny. The purpose of this would be to identify 
if/how many times a LysM-expressing macrophage is able to self-renew.  
The aim was to observe both resident macrophage populations in the skin over time, 
and observe the percentage of these cells expressing Lyz2. We would then compare this to skin 
that had been exposed to inflammatory events, in this model we used skin wounding. We 
hypothesized that we would observe an increased population of cells expressing fluorescent 
proteins (XFP) remaining in the dermis following inflammation, compared to non-inflamed 
dermis. We also hypothesized that we would observe clustering of cells expressing single 
colours, indicative of self-renewal capacity. Unfortunately, due to the technical limitations of 
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this mouse model, we were unable to acquire adequate results from the preliminary 
experiments which led to early termination of this project. 
Methods 
Mice 
Macbow mice were generated on a C57Bl/6J background. Two genetic strains of mice 
were bred to produce the Macbow mouse model. The first is a LysM-Cre mouse, which has a 
Cre recombinase inserted into the first coding ATG of the lysozyme 2 gene, inducing Cre 
expression under the control of Lyz2 promoter/enhancer elements. The second strain is a CAG-
Brainbow1.0 (CAGGSBOW) mice carrying two copies of the brainbow1.0 construct, also 
identified as Rainbow3. This gives a possible colour combination of 6 colours randomly 
following Cre recombination for any cell expressing the LysM promoter. The Cre promoter 
was constitutively expressed. All mice were treated in accordance with institutional ethics 
approvals and guidelines for the care of experimental animals.  
 
Wounding 
Mice used were aged between 8-12 weeks old. Dorsal skin was shaved, and remaining 
hair removed using Veet depilation cream.  Skin was cleaned with a 10% Povidone/Iod ine 
solution, and 4 full-thickness wounds were created using a 6mm punch biopsy. Mice were 
given 1mg/ml children’s paracetamol for analgesia as needed, from Day 0 (D0) of wounding 
to D3-4. 
Histology/Immunofluorescence 
Unwounded mouse skin was harvested between 8-12 weeks of age, and mice who were 
wounded had their wounds harvested at D1 and D4 post-wounding. Tissue was fixed in 4% 
paraformaldehyde for 2 hours, then immersed in increasing gradients of sucrose (10%-30%) at 
4oC overnight for cryoprotection. Tissues were embedded in OCT and stored at -80oC. Sections 
were cut at 8µm using a thermofisher cryostat at -20oC, and mounted on superfrost plus glass 
slides. Slides were stored at -20oC until use. 
Sections were blocked in 10% normal goat serum, 1% bovine serum albumin and 0.1% 
Tween-20 in PBS (blocking solution) for 15 mins at room temperature (RT). Sections were 
stained with Rat anti-F4/80 (Serotec) at a 1:200 dilution in blocking solution overnight at 4oC. 
Secondary primary antibody used was an Alexafluor-A647 1:500 dilution in PBST for 1 hour 
at RT. Slides were counterstained in DAPI.  
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Microscopy 
Imaging was performed on a Zeiss LSM710 confocal microscope. Settings were as 
follows: Sequential acquisition, average line 16, 20x objective: DAPI – Diode 405nm 4%, 
450nm-521nm bandpasss, MBS T80/R20 splitter Cerulean – Argon 458nm 28%, 463-560nm 
bandpass, filter on, YFP – Argon 514nm 5%, 512-570nm bandpass, tdTomato – DPSS 561nm 
5%, 570-674nm bandpass, MBS 458/514 A647 – Neon/Helium 633nm 15%, 637-702nm 
bandpass. 
 
Results  
We first wanted to determine how many skin resident macrophages are controlled under 
the LysM-Cre promoter. We therefore used immunofluorescent imaging, staining for F4/80+ 
cells within the skin, and identifying the ratio of double XFP+F4/80+ cells to total F4/80+ cells. 
We found there was a 28%±4.99% rate of LysM promoted F4/80+ cells (Figure 2a,b). At this 
timepoint, we did not observe any clustering of any specific coloured cells. We also observed 
a few cells fluorescent for all 3 colours (red arrow). 
 
We next decided to investigate the rate of recombination in wounds. We looked at 
wounds harvested from 1 and 4 days post wounding (D1, D4 respectively). At D1, there was a 
massive recruitment of XFP+ cells, many of them surprisingly negative for F4/80 (Figure 3a,b). 
At D4, the majority of XFP+ cells were also F4/80+ (Figure 3c,d). We also observed a 
considerable number of Rainbow+ cells that were negative for F4/80 (Red arrows, figure 3e).  
 
Discussion 
The development of the different types of brainbow cassettes were revolutionary in 
their function, where they were first used to resolve individual components of neural circuits 
(Livet, Weissman et al. 2007). The insertion of multiple copies (16 or more) of the brainbow1.0 
transcript could identify more than 100 colours, allowing identification of individual neurons 
throughout the brain with more than 98% resolution of individual neurons. As our model only 
used 2 copies of the transgene, 6 colours were not enough to resolve individual macrophages 
in the skin, and therefore unable to identify any self-renewal from differentiated adult 
macrophages.  
Another issue we had is with the LysM-Cre transgene. The Cre chosen is constitutive ly 
active, so unlike other inducible forms of Cre, for example CreER, which are only activated 
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upon stimulation of the estrogen receptor, this Cre will induce recombination every time Lyz2 
is expressed. This means that the colour of the cell can change multiple times in its life, making 
cell tracking nearly impossible, and identifying daughter cells also impossible. Lyz2 expression 
is also highly varied, with some resident macrophages expressing Lyz2, but not all or none.  
LysM-Cre mice have also been reported to label neutrophils, with roughly 70% of neutrophils 
in spleen, blood and bone marrow expressing LysM (Abram, Roberge et al. 2014). Neutrophils 
are the first immune cell recruited into the wound bed following wounding and constitute 50% 
of all cells in the granulation tissue 24 hours post-wounding (Su and Richmond 2015). This 
made specific identification of monocyte-derived macrophages nearly impossible without 
further staining and prevented the identification of any possible colour clustering that may have 
occurred at this stage. 
While these limitations prevented successful demonstration of the aims of this project, 
several methods could be used in future studies which might achieve the original aims of this 
project. The first would be an inducible form of Cre, preferably not using the Lyz2 promoter 
but something either specific for monocyte-derived or resident. These have been identified as 
CCR2 or CD64 respectively, although there are no transgenic mice for CD64 developed at the 
time of writing, and no CCR2Cre available either. These would allow for specific identificat ion 
of monocyte-derived macrophages, as well as their role in replacing resident dermal 
macrophages, with fate tracking and multicolour flow cytometry determining if it is possible 
for these cells to lose their CCR2 markers and gain CD64 expression over time.  
The second modification would be with the rainbow model. We used a brainbow1.0 
construct, although since the initial development, there are now new models such as the 
brainbow3.x constructs which express XFPs that are brighter, more photostable (less prone to 
bleaching), and fixable (Cai, Cohen et al. 2013). These also have no endogenous fluorescence 
without the presence of Cre, and each XFP is antigenically distinct from the others, so 
antibodies can be used to label the respective XFP if necessary. There are also transgenic lines 
which contain multiple copies of the gene allowing a possible combination of more than 100 
distinct colours. Experiments would include bone marrow transplantation from CCR2CreER x 
eYFP into WT mice to determine the rate of replacement of dermal macrophages by bone 
marrow-derived monocytes, and their localisation in the skin using histological methods. Skin 
from CD64CreER x Brainbow3.2 mice would allow for identification of self-renewal, providing 
there are enough distinct colours available to allow for the identification of clustered clones of 
macrophages. Induction of macrophage expansion may be required, with the presence of 
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inflammatory effectors, such as contact allergens like DNFB and oxazolone, or irradiation such 
as UV light.  
As technology progresses, we have more techniques available to us to investigate the 
less-well understood cell types such as macrophages. While these experiments were not 
successful in completing the aims set out, we now have some insight as to what models may 
be better suited for these types of experiments in the future. The macrophage is an incredib ly 
heterogeneous cell type, with different origins, distinct functions and its plasticity to change 
from different phenotypes dependant on the situation or location. There is still much to be 
discovered, and as technology progresses, the future will provide the adequate tools required 
to do so. 
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Figure 1: Adaptation of the diagram of the rainbow 1.0 construct model (Roy, Neufeld et al. 
2014) reprinted with permission from the original author. The possible recombination 
results from two copies of the construct per cell. 
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Figure 2: Representative photomicrograph of Macbow skin stained with DAPI and F4/80 to 
label macrophages.  
A representative photomicrograph of Macbow skin and the respective colours of: (a) DAPI (b) 
tdTomato (c) YFP (d) Cerulean (e) F4/80-Alexa647 (f) All of the previous colours merged. Red 
arrow indicates a single cell. Scale bar = 50m.  
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Figure 3: Representative photomicrographs of Macbow mouse skin wounds 
(a) Representative Day 1 Macbow wound expressing only XFPs (b) The same 
photomicrograph except labelled with F4/80 as well (green) (c) Representative D4 wound 
expressing only XFPs (d) The same photomicrograph except labelling F4/80 (green) (e) A 
representative photomicrograph of D4 wound of cells expressing XFP’s which are not 
labelled with F4/80 (red arrows). Scale bar = 100m.  
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Chapter 8 - Discussion 
 
Why study macrophages? 
The role of macrophages is vast, from their strong phagocytic and anti-microb ia l 
functions through to their growth factor secreting and proliferative functions. Studying these 
cells for their specific purposes only increases in complexity as these cells are highly plastic 
and are known to switch between these differing functions and phenotypes dependant of the 
local environment. This thesis has aimed at uncovering the role of macrophages in specific 
conditions of skin wound healing and UV irradiation in neonates.  
The heterogeneity and plasticity of macrophages establishes them as complex cells 
which are very difficult to study in vivo. Arising from different embryonic origins, with 
differing gene expression dependant on the organ or residence and even between differ ing 
compartments, it is clear that not all macrophages are made equal. Dermal macrophages are a 
population which are constantly overlooked and underexplored, as the most commonly studied 
‘skin-resident’ macrophage is the Langerhans cell. However, more research is being performed 
uncovering the origins and mechanisms of the specialisation of dermal macrophages and 
dendritic cells, both of which can be derived from monocytes. Furthermore, the differentiat ion 
between resident and recruited macrophages is also being demystified, with the use of gene 
expression studies and functional testing (Gautier, Shay et al. 2012, Schulz, Gomez Perdiguero 
et al. 2012).  
The interplay between immune cell populations is also constantly overlooked. The most 
common link between the adaptive and innate immune system is between dendritic cells with 
their antigen presenting functions and T-cells. However, the work presented in this thesis has 
clearly identified relationships not just between DC and T-cells, but between macrophages and 
T-cells as described in conditions of wound healing (IL-17 producing T-cells on macrophage 
polarisation, chapter 3) and UV-induced immunosuppression (Resident macrophages on 
regulatory T-cell function, chapter 5). Another established link is between resident perivascula r 
macrophages and their recruitment on neutrophils, found in chapter 5 and also previous ly 
described (Abtin, Jain et al. 2014).  
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Summary and interpretation of findings 
Wound healing 
Chronic skin wounds are an increasing burden on the public healthcare system, with 
suboptimal treatments and expensive surgeries required for complex cases. An aging 
population and the growing incidence of obese/diabetic patients have established a substantia l 
need for more effective therapies. The primary problem was the lack of an effective model for 
chronic wound healing. Previous papers have used leptin-deficient mice and rats as models for 
chronic wound healing, however our research found that these mice did not properly replicate 
the clinical development of chronic wounds. We therefore used mice that were aged older than 
6 months, which we found had a consistent chronic wound phenotype, where wounds created 
would not always spontaneously heal, and if there was healing, it was at a reduced rate 
compared to young ob/ob mice.  
  
IL-17 is a relatively new cytokine which has been associated with many different 
inflammatory diseases. The strong anti-microbial activity of IL-17 and its production by γδT-
cells has been evolutionary beneficial when there were less sterile conditions and the barrier 
such as the skin or gut was broken. On the other hand, when there is an absence of any 
microbes, excessive inflammatory cytokine production including IL-17 has been found to be 
leading causes of inflammatory conditions such as psoriasis and inflammatory bowel disease, 
as well as non-barrier diseases such as rheumatoid arthritis and multiple sclerosis (Buckland 
2014, Campa, Mansouri et al. 2016).  
Obese patients are at higher risk for complications due to an increased inflammato ry 
profile throughout their body (Xu, Barnes et al. 2003). As IL-17 has been previously implica ted 
with inflammatory skin diseases such as psoriasis, we aimed to target IL-17 in our chronic 
wound healing model, due to its excessive inflammatory profile, as well as its upstream 
regulator, IL-23. Neither IL-17 or IL-23 had been researched as a chronic wound healing 
therapy at the time of commencement, and as such was a novel therapy which may be utilized 
for the treatment of chronic wounds. The rapid recruitment and infiltration of monocytes and 
macrophages into skin wounds make them the most abundant immune cell in wounds. Their 
response to inflammatory signals can prevent them from progressing into a pro-wound healing 
and angiogenic phenotype, which makes them preferential targets for the treatment of chronic 
wounds. Indeed, our findings demonstrate that the inflammatory nature of IL-17 in wounds 
impairs the rate of wound healing in subjects with excessive or prolonged inflammation, such 
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as those with obesity and diabetes. We also demonstrated that the presence of IL-17 in wounds 
is increased in older mice compared to younger mice, most likely due to the chronic 
inflammation found in obesity. Although significant differences were found in our model, the 
translational ability for mouse-to-human research, especially in such a heterogeneous model of 
chronic wound healing, means it is unlikely we will observe any significant effects from the 
use of this as a therapy. The role of IL-17 as an antimicrobial cytokine increases the risk of 
infection in patients with chronic wounds where bacterial biofilms are abundant. This may 
prove more of a burden than benefit in terms of macrophage polarisation and the reduction of 
a pathogen fighting capacity which isn’t present in our specific-pathogen free mouse models. 
Despite this, the next stage of this project is a clinical trial funded by Eli Lily which will observe 
the efficacy of phase I approved IL-17 antibodies currently used for the treatment of psoriasis .  
 
IL-33 can function both as a cytokine by binding to the receptor ST2 or can operate as 
an alarmin where it controls NFkB signalling in the nucleus. As the receptor ST2 can be 
membrane bound (ST2L) or in a soluble, free floating decoy receptor (sST2), we can deduce 
that ST2 is important to regulate IL-33 signalling. Because IL-33 has a multitude of functions, 
we genetically knocked out ST2 in mice and wounded them to determine if IL-33 signalling 
was through its nuclear transcription functions, or as a cytokine.  
In our model, we found ST2 signalling was important for wound inflammation, as ST2-
/- mice had prolonged inflammation compared to controls, as well as reduced angiogenesis and 
a worse scar outcome. Our data indicates that the increased neutrophil and inflammato ry 
macrophage recruitment are the leading causes for the changes in wound phenotype. This work 
overall suggests that IL-33 signalling through ST2 is important for normal wound healing.  
Unfortunately, the clinical use of this research is limited. Since the first paper published the 
dual-function of IL-33 acting as a transcription factor, there has been a significant lack of 
further evidence to suggest this actually occurs (Cayrol and Girard 2018). Furthermore, the 
addition of exogenous IL-33 to wounds has been studied extensively, and no current therapies 
for human translation are in progress, indicating that either no one is interested, and/or it does 
not work Yin, 2013 #79}(Molofsky, Savage et al. 2015, He, Yin et al. 2017). 
 
The NLRP3 inflammasome, while implicated in multiple inflammatory diseases, does 
not appear to contribute to chronic wound healing. We found that in some cases of normal 
wound healing, the topical application of the NLRP3 inflammasome inhibitor MCC950 
actually impaired wound closure at a macroscopic level, although further histologica l 
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examination revealed no changes in epithelial migration. From these results, we can assume 
that other factors are involved in the excessive inflammatory response found in chronic 
wounds, at least under controlled conditions, with no pathogenic bacterial infections. This may 
vary under different microbial conditions; however, this remains to be studied. Another 
explanation could revolve around the fact that macrophages are essential for adult wound 
healing, and non-specific therapies which impair macrophage recruitment have been 
implicated with delayed wound healing (Gallucci, Simeonova et al. 2000, Goren, Allmann et 
al. 2009). My current theory is that only therapies which shift macrophage polarisation from 
inflammatory (M1) to pro-healing (M2) without a reduction in macrophages are able to 
improve wound healing. Of course, another other possibility is that MCC950 was not 
biologically active and had no effect as the mechanism was not directly tested in our model. 
This was an unfortunate oversight, with the lack of IL-1  and proIL-1  analysis. However due 
to the stability, and well-described previous mechanisms of action and efficacy through the 
given oral administration route, we believe there would have been an effect. Seeing as DMSO 
has been reported as a non-specific inhibitor for NLRP3 (Ahn, Kim et al. 2014) and DMSO 
has had no reported effects on the improvement of wound closure (Goldblum, Alvarez et al. 
1983), nor as a vehicle (control) for the addition of other therapies (Altavilla, Saitta et al. 2001, 
Kawanabe, Kawakami et al. 2007, Walker, Rossini et al. 2013) we can deduce that targeting 
the NLRP3 inflammasome is not beneficial for wound healing. 
 
Experimental models of wound healing vs. Clinical presentation 
 Skin wound healing is an incredibly complex model to study, as the interplay between 
the local environmental factors, the vast number and types of cells present including immune 
cells, skin cells and even the presence of commensal/pathogenic bacteria all vary between 
experiments and models. However, as much as we try to minimise the differences between 
methods of wounding and studying the kinetics of healing, the differences between a murine 
model and humans are diverse. The first difference is the method of wounding; I physically 
induce a wound on an area of the mouse where there is good vascular flow and venous return, 
whereas in humans with chronic wounds, the wound is almost always on the lower limbs in an 
area with poor vascularisation and venous return. This is an unavoidable aspect of research, as 
the presence of ‘naturally forming’ chronic wounds on obese mice first appear around the anus, 
subject to dragging on the cage floor and subsequent infection, which classifies them for 
immediate euthanasia under our ethics guidelines, leaving us unable to test our therapies on 
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these chronic wounds. We therefore select the back because of its ease of access for the 
application of therapies, is less prone to scraping and reopening of the wounds which can affect 
results aiming to measure wound closure, and is less prone to infection as it does not rub along 
the floor where the faecal matter also resides.  
There are also many cellular differences between mice and humans. While both mice 
and humans have the same composition of layers in the skin, human skin has a much thicker 
epidermis, and humans lack the presence of dendritic epidermal T-cells (DETC) which was 
identified as a key player in IL-17-mediated inflammation in chapter 3. While this might seem 
like a massive caveat, other models of IL-17-induced skin inflammation such as psoriasis has 
been well translated from mouse models into humans with incredible efficacy (Frieder, 
Kivelevitch et al. 2018). Differences are also found between the localisation of IL-33 
expression between humans and mice. In mice, IL-33 is found in high quantities in the skin 
under homeostasis, but upon inflammation, detectable IL-33 is lost. The converse is found in 
humans, where IL-33 in homeostatic skin is low/absent but is induced by the presence of IFN-
induced inflammation (Sundnes, Pietka et al. 2015). This affects the ability of the results shown 
in chapter 5 of this thesis to be clinically useful, although the significance of this research is 
low.  
Issues between preclinical studies in mice and the actual effect in humans have always 
plagued the transition to clinical practice. The most well-known example of this was the 
TGN1412 tragedy, where a superagonist for CD28 was successfully used in mice and 
chimpanzees for the treatment of B-cell lymphoma or other autoimmune diseases. When a dose 
of TGN1412 less than 1/500th of a ‘no observed adverse effect’ in monkeys was administe red 
to 6 healthy volunteers, all of the patients suffered a massive cytokine storm resulting in 
multiple organ failure, immune depletion and were left maimed for life. This was despite 
testing in mice, rats, cynomolgus and rhesus monkeys (St Clair 2008). Overall, the differences 
between mice and humans are significant, with the possibility of a successful therapy identified 
in mouse models being useless or even detrimental, however the benefits for using animal 
models such as genetically modified mice significantly outweigh the issues surrounding them. 
 
UV irradiation and immunosuppression 
We first aimed to observe the effects of ultraviolet irradiation on the resident 
macrophage population. As there is a significantly increased recruitment of monocytes and 
monocyte-derived macrophages into the inflamed dermis, we wanted to identify if the UV-
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irradiation induced a shift in resident macrophages within the skin, and the long-term effects 
of these new resident macrophages. Clodronate depletion seemed to primarily affect skin-
resident macrophages, as there was still robust recruitment of monocytes and monocyte -
derived macrophages/dendritic cells following UVR, regardless of clodronate depletion. We 
also noted there was a significant decrease in the number of Tregs present in draining lymph 
nodes in the ear treated with its CHS agent, in UV irradiated mice, although this interestingly 
was not a systemic event and could be prevented by the depletion of macrophages via 
clodronate liposomes at the period of the UV insult.  
We believe there is a long-term change in the resident macrophages, as our data showed 
a decrease in the expression of CD206 on all populations of skin-resident macrophages after a 
burning dose of UV. Our results suggest a significant long-term change in the CCR2-Ly6c-
MHCII-/+ populations, and that some, if not all of these populations may be responsible for 
modulating inflammation in delayed-type contact hypersensitivity. We also found no 
significant difference in CD11b-CD11c+MHCII+ classical dendritic cells, in any of the 
conditions. While there are obviously many more dendritic cell populations, all the flow 
cytometry statistics came from a 13-antibody panel consisting of live/dead, CD45, CD3, CD4, 
CD11b, CD11c, Ly6g, Ly6c, MHCII, CCR2, CD64, CD206 and CD115. The mice used had 
to be bred and used on call, as the neonates were required for all of these experiments. 
Clodronate liposomes only last 1 month, and had to be ordered from Europe. With 4 
experimental groups to compare, all of these factors severely limited the amount of data that 
could be collected from the number of mice and the remaining time that I had. Despite this, the 
results found here implicate some form of signalling between macrophages, moDCs, 
neutrophils and T-cells. There is a possibility CD64+ vascular-resident macrophages are 
involved in the emigration of neutrophils into the skin, which is then able to mount a second 
inflammatory wave of CCR2+ monocytes which then differentiate into M2 macrophages. In 
order to investigate the roles of the recruited neutrophils, further experiments will utilize the 
anti-neutrophil Gr-1 antibody which has been established as a neutrophil-specific depleting 
antibody (Weber, Nemeth et al. 2015). 
Of course, this work is still very preliminary, with many avenues yet to be investigated. 
The populations of macrophages in question are still not completely characterized, with several 
subpopulations of CCR2/CD64 yet to be defined which were found in mice less than 7 days 
old, which were not present in adult skin. Cell sorting these populations and performing an 
RNAseq would help define these populations, and may lead to an insight as to what happens 
to these populations in adulthood, where they are no longer identifiable or present. They may 
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even be the basis of the resident skin macrophages, with different populations migrating to 
different compartments based on their expression. The work here has formed the base of a 
novel method for the discovery of myeloid cells in the skin, and although much more work is 
required, it could open up a new avenue of research for skin-resident myeloid cells and their 
origin and mechanism of self-renewal. 
 
Future directions 
Although UV irradiation and wounding are two distinct types of injury, they both 
follow very similar processes, which critically involve macrophages. The initial injury is 
followed by a rapid, robust recruitment of neutrophils within 24 hours, followed by the slow 
influx of inflammatory, then non-inflammatory macrophages from 3-7 days following init ia l 
injury. My lab is still interested in the link between these two conditions, and one experiment 
proposed at the close of my PhD, is attempting to identify if the preceding stages to UV 
immunosuppression is caused by this inflammatory myeloid recruitment. This would entail 
performing a large full thickness skin wound on the flank of neonatal mice, allowing them to 
heal up to 8 weeks of age, and identify if there is any sign of immunosuppressive effect. If 
there were no signs of immunosuppression, this would indicate that UV-driven inflammation 
is distinctly different to other types of stress and injury, and the mechanisms behind why and 
how would rather interesting to differentiate.  
The discovery of methods to modulate macrophage populations under these conditions 
will not only be able to develop treatments for these two injuries, they could have the potential 
to be used in various other diseases which rely on macrophage polarisation and phenotypes 
such as rheumatoid arthritis and inflammatory bowel disease, both of which current literature 
is using anti-IL-17 therapies for the treatment of inflammation (Fitzpatrick 2013, Fischer, 
Hueber et al. 2014). 
Specific investigation of each of the following aspects of UV irradiation and wound 
healing will be described in the following sections. 
 
Wound healing 
We find that IL-17 and IL-23 antibody therapy is indeed effective for the reduction in 
wound inflammation, and also wound closure. However, these studies were investigating the 
effects of single cytokines and cytokine subunits. I propose future studies possibly targeting 
combination therapies, for example bi-specific antibodies such as the anti-TNF and anti-IL-
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17 antibody which is currently used for the treatment of rheumatoid arthritis (Fischer, Hueber 
et al. 2014). This would be tested in mouse models initially. 
As there are some human IL-17 antibodies (brodalumab, ixekizumab, and 
secukinumab) and IL-23 antibodies (briakinumab, guselkumab, tildrakizumab, and 
ustekinumab) either clinically available or in late stage clinical trials (Campa, Mansouri et al. 
2016), the next stage of this work is to utilize these antibodies which have already passed stage 
I safety clinical trials, and test their efficiency in human chronic wounds. This project has 
already been started in conjunction with Eli Lily. 
While we found the deletion of ST2 receptor from mice was detrimental to wound 
healing, we do not have sufficient evidence that the addition of IL-33 or its signalling wound 
improve wound closure, nor do we believe the results are significant enough to have clinica l 
relevance. 
Along similar thoughts, the MCC950 study results were insufficient for us to 
investigate this molecule any further, as while it is a potent NLRP3 inhibitor which has strong 
potential in the amelioration of other inflammatory diseases (Coll, Robertson et al. 2015), it 
does not appear to have a significant effect in wound healing.  
 
UV irradiation and immunosuppression 
Previous studies have looked at the relationship between Langerhans cells and Tregs, 
both of which have been vastly studied in their effects on delayed-type contact hypersensitivity 
and UV immunosuppression, with little focus on any other type of myeloid cell. This project 
aimed to identify if other myeloid cell types such as macrophages have an effect on long-term 
immunosuppression mediated by UV-irradiation.  
While these experiments are still preliminary, the results suggest that the relationship 
between T-cells and myeloid cells extends beyond just T-Cell/dendritic cell signalling. 
Following our experiments, we now hypothesize that the resident macrophages in the skin are 
required for neutrophil recruitment following UV-irradiation, which may in itself play a part 
in UV-induced immunosuppression. As mentioned above, further studies will need to be 
performed on neutrophil-specific depletion at the time of UV-irradiation, such as the use of Gr-
1 antibodies to determine if immunosuppression is caused by the strong recruitment of 
inflammatory neutrophils at 24h post-UV.  
An alternative hypothesis could be the macrophages themselves secrete inflammato ry 
molecules which produce an increased number of circulating Tregs. One cell currently 
 117 
described in previous literature as an important mediator for delayed-type contact 
hypersensitivity is the Langerhans cell. It’s a skin-resident APC, with an intermedia te 
phenotype between dendritic cells and macrophages. It is currently believed to be depleted with 
the application of clodronate liposomes, however we unfortunately did not look for these cells 
in our flow cytometry panels. Indeed, current literature is divided between the purpose of 
Langerhans cells in UV-mediated immunosuppression, with some studies claiming they are 
essential for UVB-induced immunosuppression (Cruz, P., 1992; Schwarz et al., 2010) and 
others saying they are not required at all (Wang et al., 2009). Further experiments will need to 
be performed to identify the underlying effects of resident macrophages and Langerhans cells 
in UV-mediated immunosuppression. The difficulty with studying Langerhans cells is due to 
how robust they are. Radioresistant, localised to a completely avascular layer of the skin, and 
with no unique antigens known at this point in time. Previous studies which have studied LC 
depletion have inadvertently depleted langerin+ dermal dendritic cells as well (Kaplan, Jenison 
et al. 2005, Igyarto, Jenison et al. 2009). However, a paper published in 2005 used a method 
of Langerhans cell depletion via the use of a bacterial artificial chromosome (BAC) inserted 
into Langerhans cells, expressing human langerin driving diptheria toxin (Kaplan, Jenison et 
al. 2005). They demonstrated their model was specific for Langerhans cell depletion, and that 
Langerhans cells were essential for the regulation of contact hypersensitivity. The use of this 
model may be handy in order to study the effects of a LC-specific depletion before UV 
irradiation, and the following effects on contact hypersensitivity.  
Many experiments are yet to follow on this project, including gene expression studies 
on the depleted resident populations identified within our flow cytometric analysis, aiming to 
identify differential genes expressed upon UV-radiated skin vs. unexposed skin. 
 
Methods of macrophage differentiation and self-renewal 
There is still much to be discovered about the means of macrophage self-renewal 
following injury. Unfortunately, due to the limitations with the model used, I was unable to 
uncover any answers myself. The LysM-Cre mice, while sufficient for previous studies on 
macrophages, were unable to be used in our model to identify resident macrophages. This was 
in part due to the ‘leaky’ Cre with multiple triple-positive cells labelled, and non-specific 
labelling of neutrophils as well as macrophages. The future studies will therefore use recently 
developed CCR2-Cre and CD64-Cre mice in future experiments (Willenborg, Lucas et al. 
2012). In addition, further development of new brainbow constructs for mice with more colours 
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and brighter, more stable flurophores will hopefully be utilised in this lab in the future, to assist 
in the resolution the questions which were not answered in this thesis. To decrease the difficulty 
of multicolour fluorescent expression in these mice, if I were to continue this project, I would 
use a single Rosa-YFP mouse model. This would be crossed with both a CCR2-CreER mouse 
to label the recruited myeloid macrophages/dendritic cells, and also crossed with a CD64-CreER 
mouse to label the resident macrophage populations. The development of a relatively new Dre-
Rox system has been utilized in mouse models, which has the possibility to drive dual gene 
expression based off either Cre-lox recombination and/or Dre-rox induced recombination for 
different expression of promoters within the same mouse (Anastassiadis, Fu et al. 2009). 
Alternatively, the use of CRISPR-Cas9 for targeted genome editing would be a suitable next 
stage of this project, where we would use RNAseq to identify genetic targets based off flow 
cytometric analysis on the resident macrophage populations before and after either depletion 
and repopulation, or following an inflammatory event and studying the new resident 
population. This would allow us to reveal whether CCR2-derived cells are able to express 
CD64 in either homeostatic states or following injury, or if CD64 macrophages can lose their 
resident phenotype and migrate.  
 
Conclusion 
The findings presented in this thesis identify possible methods of macrophage 
polarisation, and their uses in wound healing, as well as the role for macrophages in UV 
irradiation and long-term immunosuppression. We demonstrated the possibility that skin-
resident macrophages can mediate immunosuppression caused by UV irradiation, as well as 
their vital role in chronic wound healing, dependant on their state of polarisation and 
inflammation. We also demonstrated the use of certain antibodies which can be used to switch 
the polarisation state of macrophages in wounds. However, there is still much to be studied, 
such as the specific myeloid populations involved in UV-induced immunosuppression, and 
alternative and/or additional targets for the treatment of chronic wound healing. The research 
published in this thesis is merely a stepping stone for what will likely be the future of 
macrophage-mediated anti-inflammatory therapies. 
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Provisos
The AEC has directed that the Consultant Veterinarian of the Animal Welfare Unit monitor the wounding procedures 
performed in Experiment One of this project.  Please email m.uren@research.uq.edu.au or notify the AWUC on 33652713 
at least 7 - 10 days before monitoring is required.
CVO Monitoring Proviso:
The AEC has directed that the Consultant Veterinarian of the Animal Welfare Unit monitor the first group of animals to 
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notify the AWUC on 52713 at least 7 - 10 days before monitoring is required.
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Mice - genetically modified (DTi ROSA, Mix, Adults, Institutional Breeding Colony)
19 Dec 2013 Modification #18 26 26
31 Dec 2013 Use in 2013 (from 2014 MAR) 0 26
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 26
Mice - genetically modified (DBA/2, Female, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 20 20
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 20
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Mice - genetically modified (F1, Mix, Other, Institutional Breeding Colony)
2 Jul 2014 Modification #21 54 54
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 54
Mice - genetically modified (F2: K14Cre/ER STAT5 lox/lox and K14Cre/ER STAT5lox/+, Mix, Adults, Institutional 
Breeding Colony)
Mice - genetically modified (F1: K14Cre/ER STAT5 lox/+, Mix, Adults, Institutional Breeding Colony)
18 Jul 2013 Modificaiton #11 30 30
31 Dec 2013 Use in 2013 (from 2014 MAR) 0 30
31 Dec 2014 Use in 2014 (from 2015 MAR) -65 -35
1 Jan 2015 Administrative adjustment to zero on 2014 MAR 35 0
Mice - genetically modified (Cdh5 Cre Caggsbow, Mix, Adults, Institutional Breeding Colony)
19 Dec 2013 Modification #18 120 120
31 Dec 2013 Use in 2013 (from 2014 MAR) 0 120
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 120
Mice - genetically modified (Caspase-1-/-, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 50 50
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 50
31 Dec 2013 Use in 2013 (from 2014 MAR) 0 50
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 50
Mice - genetically modified (Cdh5 Cre ROSA YFP, Mix, Adults, Institutional Breeding Colony)
19 Dec 2013 Modification #18 60 60
31 Dec 2013 Use in 2013 (from 2014 MAR) 0 60
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 60
Mice - genetically modified (c-Rel KO, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 50 50
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 50
31 Dec 2013 Use in 2013 (from 2014 MAR) 0 50
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 50
Mice - genetically modified (Col1a2-Luc, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 265 265
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 265
31 Dec 2013 Use in 2013 (from 2014 MAR) -65 200
31 Dec 2014 Use in 2014 (from 2015 MAR) -10 190
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Mice - genetically modified (IL33-/-, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 50 50
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 50
31 Dec 2013 Use in 2013 (from 2014 MAR) -32 18
31 Dec 2014 Use in 2014 (from 2015 MAR) -17 1
Mice - genetically modified (IL1Ra-/-, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 200 200
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 200
31 Dec 2013 Use in 2013 (from 2014 MAR) 0 200
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 200
Mice - genetically modified (K14 ESR: G12 Vras: usp9x, Mix, Adults, Institutional Breeding Colony)
20 Jun 2013 Modification #10 48 48
31 Dec 2013 Use in 2013 (from 2014 MAR) -5 43
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 43
2 Sep 2015 Modification #30 40 83
Mice - genetically modified (K14 ESR/Ptch/RaOP, Mix, Adults, Institutional Breeding Colony)
20 Jun 2013 Modification #8 96 96
31 Dec 2013 Use in 2013 (from 2014 MAR) 0 96
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 96
Mice - genetically modified (IFNg -/-, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 50 50
18 Oct 2012 Initial approval 55 105
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 105
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 105
31 Dec 2013 Use in 2013 (from 2014 MAR) 0 105
31 Dec 2013 Use in 2013 (from 2014 MAR) 0 105
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 105
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 105
18 Jul 2013 Modification #11 120 120
31 Dec 2013 Use in 2013 (from 2014 MAR) 0 120
31 Dec 2014 Use in 2014 (from 2015 MAR) -100 20
Mice - genetically modified (IL-17RA -/-, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 55 55
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 55
31 Dec 2013 Use in 2013 (from 2014 MAR) 0 55
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 55
Mice - genetically modified (IL-17 -/-, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 65 65
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 65
31 Dec 2013 Use in 2013 (from 2014 MAR) -40 25
31 Dec 2014 Use in 2014 (from 2015 MAR) -44 -19
1 Jan 2015 Administrative adjustment to zero on 2014 MAR 19 0
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Mice - genetically modified (mTERT-Cre/ER, Mix, Adults, Institutional Breeding Colony)
3 Sep 2014 Modification #24 46 46
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 46
Mice - genetically modified (MacBow (LysMcre/ER x Caggsbow), Mix, Adults, Institutional Breeding Colony)
6 Aug 2014 Modification #22 220 220
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 220
Mice - genetically modified (mTERT-Cre/ERXCaggsbo (TeloBow), Mix, Adults, Institutional Breeding Colony)
3 Sep 2014 Modification #24 220 220
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 220
Mice - genetically modified (MyD88-/-, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 50 50
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 50
Mice - genetically modified (mTERT-GFP, Mix, Adults, Institutional Breeding Colony)
3 Sep 2014 Modification #24 136 136
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 136
Mice - genetically modified (K14:Ptch EKO, Mix, Adults, Institutional Breeding Colony)
8 Apr 2013 Modification #5 44 44
31 Dec 2013 Use in 2013 (from 2014 MAR) -14 30
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 30
Mice - genetically modified (K14 USP9x, Mix, Adults, Institutional Breeding Colony)
20 Dec 2012 Modification #2 48 48
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 48
31 Dec 2013 Use in 2013 (from 2014 MAR) -22 26
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 26
2 Sep 2015 Modification #30 40 66
Mice - genetically modified (K14-Cre/ER, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 25 25
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 25
18 Jul 2013 Modification #11 6 31
31 Dec 2013 Use in 2013 (from 2014 MAR) -25 6
6 Aug 2014 Modification #23 20 26
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 26
Mice - genetically modified (LysMCre/ER, Mix, Adults, Institutional Breeding Colony)
6 Aug 2014 Modification #22 30 30
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 30
Mice - genetically modified (K14-Cre/PR, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 50 50
31 Dec 2012 Use in 2012 (from 2013 MAR) -48 2
31 Dec 2013 Use in 2013 (from 2014 MAR) -10 -8
1 Jan 2014 Administrative adjustment to zero on 2013 MAR 8 0
31 Dec 2014 Use in 2014 (from 2015 MAR) -9 -9
1 Jan 2015 Administrative adjustment to zero on 2014 MAR 9 0
Page 7 of 12
Mice - genetically modified (p35, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 250 250
31 Dec 2012 Use in 2012 (from 2013 MAR) -65 185
31 Dec 2013 Use in 2013 (from 2014 MAR) -46 139
31 Dec 2014 Use in 2014 (from 2015 MAR) -98 41
Mice - genetically modified (p19, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 250 250
31 Dec 2012 Use in 2012 (from 2013 MAR) -200 50
31 Dec 2013 Use in 2013 (from 2014 MAR) -91 -41
1 Jan 2014 Administrative adjustment to zero on 2013 MAR 41 0
6 Aug 2014 Modification #23 60 60
31 Dec 2014 Use in 2014 (from 2015 MAR) -125 -65
1 Jan 2015 Administrative adjustment to zero on 2014 MAR 65 0
Mice - genetically modified (RaOp, Mix, Adults, Institutional Breeding Colony)
Mice - genetically modified (p40, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 250 250
31 Dec 2012 Use in 2012 (from 2013 MAR) -50 200
31 Dec 2013 Use in 2013 (from 2014 MAR) -62 138
31 Dec 2014 Use in 2014 (from 2015 MAR) -77 61
Mice - genetically modified (ob/ob IL-17 -/-, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 50 50
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 50
31 Dec 2013 Use in 2013 (from 2014 MAR) -47 3
31 Dec 2014 Use in 2014 (from 2015 MAR) -3 0
Mice - genetically modified (ob/+ IL-17 -/-, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 200 200
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 200
31 Dec 2013 Use in 2013 (from 2014 MAR) -176 24
31 Dec 2014 Use in 2014 (from 2015 MAR) -14 10
31 Dec 2013 Use in 2013 (from 2014 MAR) 0 50
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 50
Mice - genetically modified (ob/ob, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 752 752
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 752
31 Dec 2013 Use in 2013 (from 2014 MAR) -20 732
31 Dec 2014 Use in 2014 (from 2015 MAR) -51 681
Mice - genetically modified (ob/+ IL17+/-, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 50 50
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 50
31 Dec 2013 Use in 2013 (from 2014 MAR) -48 2
31 Dec 2014 Use in 2014 (from 2015 MAR) -24 -22
1 Jan 2015 Administrative adjustment to zero on 2014 MAR 22 0
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Mice - genetically modified (RPB-J, Mix, Adults, Institutional Breeding Colony)
19 Dec 2013 Modification #15 10 10
31 Dec 2013 Use in 2013 (from 2014 MAR) 0 10
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 10
Mice - genetically modified (ROSA-EGFP, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 80 80
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 80
31 Dec 2013 Use in 2013 (from 2014 MAR) 0 80
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 80
Mice - genetically modified (Sox 18 Cre, Mix, Adults, Institutional Breeding Colony)
Mice - genetically modified (Skinbow, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 180 180
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 180
2 Sep 2013 Modification #12 15 195
19 Dec 2013 Modification#17 112 307
31 Dec 2013 Use in 2013 (from 2014 MAR) -252 55
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 55
Mice - genetically modified (ROSA YFP, Mix, Adults, Institutional Breeding Colony)
19 Dec 2013 Modification #18 6 6
31 Dec 2013 Use in 2013 (from 2014 MAR) 0 6
31 Dec 2014 Use in 2014 (from 2015 MAR) -6 0
Mice - genetically modified (RaOp x TopFlash, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 160 160
31 Dec 2012 Use in 2012 (from 2013 MAR) -7 153
31 Dec 2013 Use in 2013 (from 2014 MAR) -37 116
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 116
18 Oct 2012 Initial approval 95 95
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 95
31 Dec 2013 Use in 2013 (from 2014 MAR) -76 19
2 Jul 2014 Modification #21 2 21
31 Dec 2014 Use in 2014 (from 2015 MAR) -13 8
Mice - genetically modified (ROSA EYFP, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 30 30
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 30
31 Dec 2013 Use in 2013 (from 2014 MAR) -21 9
31 Dec 2014 Use in 2014 (from 2015 MAR) -70 -61
1 Jan 2015 Administrative adjustment to zero on 2014 MAR 61 0
2 Sep 2015 Modification #33 180 180
Mice - genetically modified (RBP-J / Sox 18 Cre, Mix, Adults, Institutional Breeding Colony)
19 Dec 2013 Modification #16 96 96
31 Dec 2013 Use in 2013 (from 2014 MAR) 0 96
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 96
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Mice - genetically modified (Sox 18 Cre x EYFP, Mix, Adults, Institutional Breeding Colony)
2 Sep 2015 Modification #33 200 200
Mice - genetically modified (Sox 18 Cre x Caggsbow, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 216 216
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 216
31 Dec 2013 Use in 2013 (from 2014 MAR) -110 106
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 106
Mice - genetically modified (Sox 18-Cre x Stat5 lox/lox, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 120 120
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 120
19 Dec 2013 Modification #15 20 140
31 Dec 2013 Use in 2013 (from 2014 MAR) -87 53
31 Dec 2014 Use in 2014 (from 2015 MAR) -140 -87
1 Jan 2015 Administrative adjustment to zero on 2014 MAR 87 0
2 Sep 2015 Modification #33 200 200
Mice - genetically modified (Sox 18 Cre x ROSA YFP, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 288 288
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 288
31 Dec 2013 Use in 2013 (from 2014 MAR) -89 199
31 Dec 2014 Use in 2014 (from 2015 MAR) -77 122
Mice - genetically modified (Sox 18 Cre / DTi ROSA, Mix, Adults, Institutional Breeding Colony)
19 Dec 2013 Modification #18 60 60
31 Dec 2013 Use in 2013 (from 2014 MAR) 0 60
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 60
18 Oct 2012 Initial approval 72 72
31 Dec 2012 Use in 2012 (from 2013 MAR) -12 60
19 Dec 2013 Modification #16 2 62
19 Dec 2013 Modifiation #18 6 68
31 Dec 2013 Use in 2013 (from 2014 MAR) -114 -46
1 Jan 2014 Administrative adjustment to zero on 2013 MAR 46 0
6 Aug 2014 Modification #23 100 100
31 Dec 2014 Use in 2014 (from 2015 MAR) -20 80
Mice - genetically modified (Sox 18 Cre / Stat5 lox/lox / TopFlash, Mix, Adults, Institutional Breeding Colony)
19 Dec 2013 Modification #15 80 80
31 Dec 2013 Use in 2013 (from 2014 MAR) 0 80
31 Dec 2014 Use in 2014 (from 2015 MAR) -110 -30
1 Jan 2015 Administrative adjustment to zero on 2014 MAR 30 0
2 Sep 2015 Modification #33 200 200
Mice - genetically modified (Sox 18 Cre / Ptch / RaOP, Mix, Adults, Institutional Breeding Colony)
9 Jul 2013 Modification #7 96 96
31 Dec 2013 Use in 2013 (from 2014 MAR) -16 80
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 80
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Mice - genetically modified (VECAD Cre (Cdh5 Cre), Mix, Adults, Institutional Breeding Colony)
19 Dec 2013 Modification #18 46 46
31 Dec 2013 Use in 2013 (from 2014 MAR) 0 46
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 46
Mice - Inbred (BALB/c Nude, Female, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 190 190
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 190
8 Apr 2013 Modification #5 24 214
31 Dec 2013 Use in 2013 (from 2014 MAR) -29 185
31 Dec 2014 Use in 2014 (from 2015 MAR) -9 176
1 Jul 2015 Modification #27 30 206
Mice - Inbred (C57BL/6, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 493 493
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 493
31 Dec 2013 Use in 2013 (from 2014 MAR) -82 411
2 Jul 2014 Modification #21 12 423
Mice - genetically modified (TopFlash Stat5 lox/lox, Mix, Adults, Institutional Breeding Colony)
19 Dec 2013 Modification #15 52 52
31 Dec 2013 Use in 2013 (from 2014 MAR) 0 52
31 Dec 2014 Use in 2014 (from 2015 MAR) -96 -44
1 Jan 2015 Administrative adjustment to zero on 2014 MAR 44 0
2 Sep 2015 Modification #33 200 200
Mice - genetically modified (Stat5 lox/lox, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 44 44
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 44
18 Jul 2013 Modification #11 12 56
19 Dec 2013 Modification #15 12 68
31 Dec 2013 Use in 2013 (from 2014 MAR) -11 57
31 Dec 2014 Use in 2014 (from 2015 MAR) -105 -48
1 Jan 2015 Administrative adjustment to zero on 2014 MAR 48 0
2 Sep 2015 Modification #33 200 200
Mice - genetically modified (TopFlash, Mix, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 355 355
31 Dec 2012 Use in 2012 (from 2013 MAR) -100 255
19 Dec 2013 Modification #15 6 261
31 Dec 2013 Use in 2013 (from 2014 MAR) -60 201
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 201
2 Sep 2015 Modification #33 40 241
Mice - genetically modified (TopFlash, Mix, Neonates, Institutional Breeding Colony)
8 Apr 2013 Modification #5 6 6
31 Dec 2013 Use in 2013 (from 2014 MAR) 0 6
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 6
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Please note the animal numbers supplied on this certificate are the total allocated for the approval duration
1. When ordering animals from Animal Breeding Houses
2. For labelling of all animal cages or holding areas.  In addition please include on the label, Chief Investigator's name and 
contact phone number.
3. When you need to communicate with this office about the project.
It is a condition of this approval that all project animal details be made available to Animal House OIC.
(UAEC Ruling 14/12/2001)
The Chief Investigator takes responsibility for ensuring all legislative, regulatory and compliance objectives are satisfied 
for this project.
This certificate supercedes all preceeding certificates for this project (i.e. those certificates dated before 10-Sep-2015)
Please use this Approval Number:
Mice - Inbred (Ly5.1, Female, Adults, Institutional Breeding Colony)
18 Oct 2012 Initial approval 90 90
31 Dec 2012 Use in 2012 (from 2013 MAR) 0 90
31 Dec 2013 Use in 2013 (from 2014 MAR) 0 90
31 Dec 2014 Use in 2014 (from 2015 MAR) 0 90
6 Aug 2014 Modification #22 6 429
31 Dec 2014 Use in 2014 (from 2015 MAR) -9 420
2 Sep 2015 Modification #31 110 530
Cumbrae-Stewart Building
Research Road
Brisbane Qld 4072 Australia
Animal Welfare Unit
UQ Research and Innovation
The University of Queensland
+61 7 336 52925 (Enquiries)
+61 7 334 68710 (Enquiries)
+61 7 336 52713 (Coordinator)
animalwelfare@research.uq.edu.au
uq.edu.au/research
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UQ Research and Innovation
Director, Research Management Office
Nicole Thompson
Animal Ethics Approval Certificate 27-Nov-2015
Please check all details below and inform the Animal Welfare Unit within 10 working days if anything is incorrect.
Activity Details
Chief Investigator: Associate Professor Kiarash Khosrotehrani, UQ Centre for Clinical Research
Title: Macrophages in skin injury-R1
AEC Approval Number: UQCCR/460/15/STARTUP
Previous AEC Number: UQCCR/420/15/STARTUP
Approval Duration: 28-Nov-2015 to 28-Nov-2018
Funding Body: New Staff Research Start up Fund
Group: Molecular Biosciences
Other Staff/Students: Jatin Patel, Bonnie Wong, Sean O'Loughlin, Prudence Donovan, James Lee, Lisa Craig
Summary
Subspecies Strain Class Gender Source Approved Remaining
Mice - genetically 
modified
IL-17 -/- Adults Mix Institutional 
Breeding Colony
40 40
Mice - genetically 
modified
p19 KO Adults Mix Institutional 
Breeding Colony
40 40
Mice - genetically 
modified
IL-12p35-/- Adults Mix Institutional 
Breeding Colony
40 40
Mice - genetically 
modified
IL-12p40-/- Adults Mix Institutional 
Breeding Colony
40 40
Mice - genetically 
modified
Caspase 1-/- Adults Mix Institutional 
Breeding Colony
40 40
Mice - genetically 
modified
MacBow 
(LysMcre/ER x 
Caggsbow)
Juvenile / Weaners 
/ Pouch animal
Mix Institutional 
Breeding Colony
40 40
Mice - genetically 
modified
MacBow 
(LysMcre/ER x 
Caggsbow)
Adults Mix Institutional 
Breeding Colony
360 360
Mice - genetically 
modified
Ob/Ob Adults Mix Institutional 
Breeding Colony
120 120
Mice - genetically 
modified
C57BL/6 Col1a2 Adults Mix Institutional 
Breeding Colony
80 80
Mice - non 
genetically 
modified
C57BL/6 Adults Mix Institutional 
Breeding Colony
230 230
Mice - non 
genetically 
modified
C57BL/6 Juvenile / Weaners 
/ Pouch animal
Mix Institutional 
Breeding Colony
80 80
Location(s): UQCCR
Herston Medical Research Centre
PA Hospital Translational Research Institute (TRI)
Cumbrae-Stewart Building
Research Road
Brisbane Qld 4072 Australia
Animal Welfare Unit
UQ Research and Innovation
The University of Queensland
+61 7 336 52925 (Enquiries)
+61 7 334 68710 (Enquiries)
+61 7 336 52713 (Coordinator)
animalwelfare@research.uq.edu.au
uq.edu.au/research
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Mice - genetically modified (MacBow (LysMcre/ER x Caggsbow), Mix, Adults, Institutional Breeding Colony)
27 Nov 2015 Initial approval 360 360
Mice - genetically modified (IL-17 -/-, Mix, Adults, Institutional Breeding Colony)
27 Nov 2015 Initial approval 40 40
Mice - non genetically modified (C57BL/6, Mix, Juvenile / Weaners / Pouch animal, Institutional Breeding Colony)
27 Nov 2015 Initial approval 80 80
Mice - genetically modified (MacBow (LysMcre/ER x Caggsbow), Mix, Juvenile / Weaners / Pouch animal, 
Institutional Breeding Colony)
27 Nov 2015 Initial approval 40 40
Mice - non genetically modified (C57BL/6, Mix, Adults, Institutional Breeding Colony)
27 Nov 2015 Initial approval 230 230
Mice - genetically modified (p19 KO, Mix, Adults, Institutional Breeding Colony)
27 Nov 2015 Initial approval 40 40
Mice - genetically modified (Ob/Ob, Mix, Adults, Institutional Breeding Colony)
27 Nov 2015 Initial approval 120 120
Mice - genetically modified (C57BL/6 Col1a2, Mix, Adults, Institutional Breeding Colony)
27 Nov 2015 Initial approval 80 80
Mice - genetically modified (IL-12p40-/-, Mix, Adults, Institutional Breeding Colony)
27 Nov 2015 Initial approval 40 40
Mice - genetically modified (IL-12p35-/-, Mix, Adults, Institutional Breeding Colony)
27 Nov 2015 Initial approval 40 40
Mice - genetically modified (Caspase 1-/-, Mix, Adults, Institutional Breeding Colony)
27 Nov 2015 Initial approval 40 40
Description Amount Balance
Approval Details
Permits
Provisos
Sean O'Loughlin and Lisa Craig are listed as participants on this project. According to our records, we have not received a 
response regarding these nomination. These participants cannot work on an approved project until they have confirmed 
involvement via electronic signature or, via email notification being sent to the Animal Welfare Unit Administration 
Officer awu.aec.mbs@research.uq.edu.au. 
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Please note the animal numbers supplied on this certificate are the total allocated for the approval duration
1. When ordering animals from Animal Breeding Houses
2. For labelling of all animal cages or holding areas.  In addition please include on the label, Chief Investigator's name and 
contact phone number.
3. When you need to communicate with this office about the project.
It is a condition of this approval that all project animal details be made available to Animal House OIC.
(UAEC Ruling 14/12/2001)
The Chief Investigator takes responsibility for ensuring all legislative, regulatory and compliance objectives are satisfied 
for this project.
This certificate supercedes all preceeding certificates for this project (i.e. those certificates dated before 27-Nov-2015)
Please use this Approval Number:
Cumbrae-Stewart Building
Research Road
Brisbane Qld 4072 Australia
Animal Welfare Unit
UQ Research and Innovation
The University of Queensland
+61 7 336 52925 (Enquiries)
+61 7 334 68710 (Enquiries)
+61 7 336 52713 (Coordinator)
animalwelfare@research.uq.edu.au
uq.edu.au/research
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